clopidogrel has been researched along with ticagrelor in 1123 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (2.58) | 29.6817 |
| 2010's | 714 (63.58) | 24.3611 |
| 2020's | 380 (33.84) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, SM; Antonsson, T; Bach, P; Björkman, JA; Bylund, R; Giordanetto, F; Österlund, K; van Giezen, JJ; Zachrisson, H; Zetterberg, F | 1 |
| Badorc, A; Barré, G; Besse, A; Boldron, C; Bonnet-Lignon, S; Bono, F; Bordes, MF; Briot, C; Delesque, N; Dol, F; Fossey, V; Gau, B; Hérault, JP; Herbert, JM; Lassalle, G; Meneyrol, J; Millet, L; Nazare, M; Pflieger, AM; Rousseaux, T; Savi, P; Tissandié, S; Yvon, X; Zech, G | 1 |
| Chen, B; Danon, JJ; Kassiou, M; Ma, BB; Montgomery, AP | 1 |
| Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M | 1 |
| Gurbel, PA; Tantry, US | 2 |
| Cattaneo, M | 6 |
| Roe, MT; Steinhubl, S | 1 |
| de Lemos, JA; Wiviott, SD | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF | 1 |
| Angiolillo, DJ | 1 |
| Barker, CM; Price, MJ | 1 |
| Eikelboom, JW; Hirsh, J; Raju, NC | 1 |
| Akram, F; Akram, S; Postuła, M | 1 |
| Husted, S | 2 |
| Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Mitchell, P; Storey, RF | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Makarov, LM; Serebruany, VL | 1 |
| Husted, S; van Giezen, JJ | 1 |
| Armstrong, M; Cannon, CP; Emanuelsson, H; Heptinstall, S; Husted, S; Lawrance, R; Melissa Thornton, S; Storey, RF; Wickens, M | 1 |
| Kumar, A; Roberts, DH | 1 |
| Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H | 1 |
| Schömig, A | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L | 1 |
| Eshaghian, S; Kaul, S; Shah, PK | 1 |
| Antonino, MJ; Bliden, KP; Butler, K; Gesheff, T; Gurbel, PA; Karunakaran, A; Kereiakes, DJ; Ledley, GS; Parris, C; Patil, SB; Purdy, D; Storey, RF; Tantry, US; Teng, R; Wei, C; Wilson, V | 1 |
| Bhatt, DL | 1 |
| Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J | 1 |
| del Río, A; Heras, M | 1 |
| Tomoda, H | 1 |
| Atar, D; Serebruany, VL | 1 |
| Serebruany, VL | 8 |
| Parra, D; Rosenstein, RS | 1 |
| Lotfi, A; Rothberg, M; Wartak, SA | 1 |
| Jilma, B; Krumphuber, J; Siller-Matula, JM | 1 |
| Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Keltai, M; Khurmi, NS; Kontny, F; Lewis, BS; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Stone, GW | 1 |
| Anderson, SD; Epstein, BJ; Shah, NK; Yim, J | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Cattaneo, M; Podda, GM | 1 |
| Antonino, MJ; Bliden, KP; Butler, K; Eikelboom, JW; Gurbel, PA; Henderson, D; Husted, S; Kereiakes, DJ; Nielsen, T; Patel, DV; Rasmussen, L; Sabe-Affaki, G; Storey, RF; Tantry, US; Teng, R; Wei, C | 1 |
| Lip, GY; Shantsila, E; Tapp, L | 1 |
| Guo, KW; Tan, JW | 1 |
| Aylward, PE; Behan, MW; Chew, DP | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Storey, RF | 1 |
| Chew, DP; Prakash, R; Wong, YW | 1 |
| Adams, HP | 1 |
| Dixon, SR; Grines, CL; O'Neill, WW | 1 |
| Erdem, G; Flather, MD; Geisler, T | 1 |
| Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS | 1 |
| Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C | 1 |
| Butler, K; Teng, R | 1 |
| Gratsianskiĭ, NA | 1 |
| Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| Armstrong, M; Barratt, BJ; Becker, RC; Horrow, J; Husted, S; James, S; Katus, H; Shah, SH; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L | 1 |
| Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Desai, B; Ecob, R; Emanuelsson, H; Husted, S; Patil, SB; Storey, RF; Wallentin, L | 1 |
| Ardissino, D; Caracciolo, M; D'Urbano, M; De Servi, S | 1 |
| Morais, J | 1 |
| Radke, PW; Schunkert, H | 1 |
| Abergel, E; Nikolsky, E | 1 |
| Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD | 1 |
| Pollack, CV | 1 |
| Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C | 1 |
| Beitelshees, AL | 1 |
| Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C | 1 |
| Fusco, JA; Huang, NS; Master, HH; Park, ZH | 1 |
| Jilma, B; Siller-Matula, JM | 1 |
| Frey, N; Ivandic, B | 1 |
| Asenblad, N; Bassand, JP; Becker, RC; Cannon, CP; Claeys, MJ; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Nicolau, JC; Scirica, BM; Storey, RF; Vintila, M; Wallentin, L; Ycas, J | 1 |
| Schneider, DJ | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Buffet, P; Cottin, Y; Gudjoncik, A; L'Huillier, I; Lorgis, L; Richard, C; Zeller, M | 1 |
| Gaglia, MA; Waksman, R | 1 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| Hamm, CW; Rassaf, T | 1 |
| Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M | 1 |
| White, HD | 1 |
| Ohman, EM; Roe, MT | 1 |
| Becker, RC; Harrington, RA; James, SK; Wallentin, L | 1 |
| Scharf, RE | 1 |
| Storey, RF | 1 |
| Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Michelson, EL; Pais, P; Raev, D; Scirica, BM; Spinar, J; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M | 1 |
| Cattaneo, GJ; Cattaneo, M; Podda, GM | 1 |
| Easton, JD | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC | 1 |
| Timmis, A | 1 |
| Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; Husted, S; James, SK; Katus, H; Morais, J; Roe, MT; Steg, PG; Stevens, S; Storey, RF; Wallentin, L | 1 |
| Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Storey, RF; Tantry, U; Wei, C | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Bliden, KP; Gesheff, M; Gurbel, PA; Jeong, YH; Storey, RF; Tantry, US; Wei, C | 1 |
| Alber, HF; Frick, M; Huber, K; Pachinger, O | 1 |
| Bonello, L; de Labriolle, A; Doazan, JP; Lemesle, G | 1 |
| Becker, RC; Cairns, R; Cannon, CP; Cools, F; Cooper, A; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Khurmi, NS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Hinneburg, I | 1 |
| Becker, RC; Cannon, CP; Cools, F; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Katus, HA; Khurmi, NS; Lim, ST; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Chauhan, A; More, RS; Morgan, KP | 1 |
| D'Urbano, M; De Servi, S; Navarese, EP; Savonitto, S | 1 |
| Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J | 2 |
| De Mey, JG; Feijge, MA; Heemskerk, JW; Kuijpers, MJ; Megens, RT; Nikookhesal, E; oude Egbrink, MG; van Giezen, JJ | 1 |
| Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Brilakis, ES; de Lemos, JA | 1 |
| Akerblom, Å; Åsenblad, N; Becker, RC; Buck, K; Budaj, A; Giannitsis, E; Horrow, J; Husted, S; James, SK; Katus, HA; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Armstrong, PW; Clemmensen, P; Fu, Y; Harrington, RA; Horrow, J; James, SK; Katus, H; Siha, H; Steg, PG; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Jeger, R; Kaiser, C; Pfisterer, M | 1 |
| Collet, JP; De Luca, L; Wouter Jukema, J | 1 |
| Damman, P; de Winter, RJ; James, SK; Kuijt, WJ; Woudstra, P | 1 |
| Braunwald, E | 1 |
| Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL | 1 |
| Janknegt, R; Ruiters, L; Ten Cate, H | 1 |
| Calvi, V; Capodanno, D; Tamburino, C | 1 |
| Davies, JE; Francis, DP; Nijjer, SS | 1 |
| Angiolillo, DJ; Cannon, CP; Cantor, WJ; Clare, R; Goodman, SG; Harrington, RA; Husted, S; James, SK; Kilhamn, J; Mahaffey, KW; Nicolau, JC; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Castriota, F; Grzesk, E; Grzesk, G; Kozinski, M; Krzyzanowski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM | 1 |
| Kern, MJ | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Grześk, G; Koziński, M; Kubica, J | 1 |
| Grajek, S | 1 |
| Bliden, K; Butler, K; Gurbel, PA; Husted, SE; Høimark, L; Storey, RF; Tantry, US; Teng, R; Wei, C | 1 |
| Lavi, R; Lavi, S | 1 |
| Armstrong, PW; Das, D; Fu, Y; James, S; Siha, H; Storey, RF; Wallentin, L; Westerhout, CM; Zheng, Y | 1 |
| Held, C | 1 |
| Ferro, A; Floyd, CN; Passacquale, G | 1 |
| Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF | 1 |
| Verheugt, FW | 1 |
| Angiolillo, DJ; Azmoon, S | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA | 1 |
| Alexopoulos, D; Goudas, P; Goumenos, D; Koutroulia, E; Plakomyti, TE; Xanthopoulou, I | 1 |
| Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T | 1 |
| Freynhofer, MK; Höchtl, T; Huber, K; Mahla, E; Prüller, F | 1 |
| Heptinstall, S; Joshi, R; Wijeyeratne, YD | 1 |
| Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L | 1 |
| Ahmad, S; Storey, RF | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Grove, EL; Hvas, AM; Kristensen, SD | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Antonino, MJ; Bliden, KP; Gurbel, PA; Jeong, YH; Park, KS; Tantry, US | 1 |
| Huber, K | 1 |
| Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J | 1 |
| Harrison, P | 1 |
| Bernlochner, I; Sibbing, D | 1 |
| Burgess, S; Juergens, CP; Mallard, TA | 1 |
| Lincoff, AM; May, CH | 1 |
| Becker, RC; Cornel, JH; Goodman, SG; Harrington, R; Horrow, J; Husted, S; James, S; Katus, H; Santoso, A; Steg, G; Storey, RF; Sun, JL; Vintila, M; Wallentin, L | 1 |
| Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Alström, U; Åsenblad, N; Becker, RC; Brandrup-Wognsen, G; Cannon, CP; Held, C; Hogue, CW; Horrow, J; James, S; Mahaffey, KW; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| DiNicolantonio, JJ; Serebruany, VL | 6 |
| Kastrati, A | 1 |
| Cattaneo, M; Faioni, EM | 1 |
| Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A | 1 |
| Akerblom, A; Asenblad, N; Becker, RC; Budaj, A; Claeys, MJ; Horrow, J; Husted, S; James, SK; Katus, H; Siegbahn, A; Storey, RF; Wallentin, L | 1 |
| Bennett, MR | 1 |
| Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A | 1 |
| Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A | 1 |
| Kiss, RG | 1 |
| Butler, K; Maya, J; Teng, R | 1 |
| Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L | 1 |
| Asanin, M; Brdar, N; Cvetinovic, N; Djuricic, N; Krljanac, G; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L; Stankovic, S; Stojanovic, M | 1 |
| Clemmensen, P; Dridi, NP; Holmvang, L | 1 |
| Aronow, WS | 1 |
| Armstrong, PW; Westerhout, CM | 1 |
| Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H | 1 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| Asseburg, C; Giannitsis, E; Katus, H; Theidel, U | 1 |
| Hauge, J; Kragh, R; Poulsen, BK | 1 |
| Alexopoulos, D; Davlouros, P; Mavronasiou, E; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I | 1 |
| Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C | 1 |
| Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US | 1 |
| Becker, RC; Cannon, CP; Harrington, RA; James, SK; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Stiefelhagen, P | 1 |
| Wang, H; Wang, WE; Wang, X; Zeng, C | 1 |
| Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K | 1 |
| Coleman, CI; Limone, BL | 1 |
| Eikelboom, J; Fitchett, D; Mazer, CD; Verma, S | 1 |
| Oprea, AD; Popescu, WM | 1 |
| Biondi-Zoccai, G; Dinicolantonio, JJ | 1 |
| Enar, R | 1 |
| Göddertz, R | 1 |
| Huber, K; Lip, GY | 1 |
| Wheatcroft, S | 1 |
| Berger, JS | 1 |
| Dixon, T; Freeman, WD; Hanel, RA; Johns, G; Miller, DA; Navarro, R; Nordeen, JD; Sapin, M; Taussky, P; Tawk, RG | 1 |
| Armstrong, PW; Fu, Y; Harrington, RA; James, S; Katus, H; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Andersson, D; Bergström, G; Bernfort, L; Janzon, M; Kaul, P; Lamm, CJ; Levin, LÅ; Storey, RF; Wallentin, L | 1 |
| Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL | 1 |
| Emanuelsson, H; Gibson, CM; Harrington, RA; Horrow, J; James, SK; Katus, H; Kunadian, V; Maya, J; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Wu, J; Zorkun, C | 1 |
| Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D | 1 |
| Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Biondi-Zoccai, G; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Niazi, AK; Tomek, A | 1 |
| Dinicolantonio, JJ; Norgard, NB | 1 |
| Aylward, PE; Sinhal, AR | 1 |
| Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Moertl, D; Steiner, S | 1 |
| Grove, EL; Würtz, M | 2 |
| Chua, D; Nishi, C | 1 |
| Curkovic, I; Egbring, M; Kullak-Ublick, GA | 1 |
| Gasche, D; Greiner, RA; Meier, B; Ulle, T | 1 |
| Ecob, R; Hossain, R; Joshi, RR; Judge, HM; Karunakaran, A; Morton, AC; Storey, RF; Wales, C; Walker, JV | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| DiNicolantonio, JJ; Tomek, A | 1 |
| Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J | 1 |
| Adsett, G; Jayasinghe, R; Markham, R | 1 |
| Bansilal, S; Bonaca, MP; Sabatine, MS | 1 |
| Albertsson, P; Åström-Olsson, K; Dellborg, M; Hansson, EC; Hesse, C; Jeppsson, A; Shams Hakimi, C; Wallén, H | 1 |
| Becker, RC; Cannon, CP; Cornel, JH; Giannitsis, E; Harrington, RA; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lindholm, D; Mahaffey, KW; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L; Wernroth, L | 1 |
| Campbell, CL; Moliterno, DJ | 1 |
| Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q | 1 |
| DiNicolantonio, JJ; Serebruany, VL; Sibbing, D | 1 |
| Cohen, D | 1 |
| Horowitz, JD; Karnon, JD; Pekarsky, B; Sorich, MJ; Sorich, W; Wiese, MD | 1 |
| Bonello, L; Camoin-Jau, L; Condo, J; Dignat-George, F; Frere, C; Fromonot, J; Gariboldi, V; Guieu, R; Helal, O; Kipson, N; Laine, M; Mancini, J; Paganelli, F; Thuny, F | 1 |
| Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I | 1 |
| Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Belalcazar-Portacio, A; Keough, LA; Ramanathan, KB; Shah, R | 1 |
| Caiazzo, G; De Rosa, S; Giampà, S; Gulletta, E; Indolfi, C; Micieli, M; Mongiardo, A; Palella, E; Spaccarotella, C; Torella, D | 1 |
| Hirschl, MM | 1 |
| Cheng, VE; Haikerwal, D; Natarajan, D; Oppermen, A; Pereira, J | 1 |
| Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Diamantopoulos, A; Karnabatidis, D; Katsanos, K; Kitrou, P; Pastromas, G; Siablis, D; Spiliopoulos, S | 1 |
| Francis, SE; Judge, HM; Steiner, T; Storey, RF; West, LE | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Tantry, US | 1 |
| Christoph, M; Ibrahim, K; Jellinghaus, S; Kolschmann, S; Mues, C; Pfluecke, C; Quick, S; Schmeinck, S; Schmieder, K; Schoener, L; Steiding, K; Strasser, RH; Wunderlich, C | 1 |
| Sabouret, P; Taiel-Sartral, M | 1 |
| Henriksson, M; Janzon, M; Nikolic, E; Ohna, A; Wallentin, L | 1 |
| Blondeau, M; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Marquis, JF; Maze, R; Moudgil, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY | 1 |
| Caldeira, D; Ferreira, JJ; Pinto, FJ | 1 |
| Bouatou, Y; Gabrielli, A; Saudan, P | 1 |
| Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU | 1 |
| Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Taylor, J | 1 |
| Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D | 1 |
| Er Ching, M; Ho, HH; Ong, PJ; Ooi, YW | 1 |
| Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P | 1 |
| Elosua, R; Marrugat, J; Vila, J | 1 |
| Daiber, A; Gori, T; Jurk, K; König, J; Krahn, U; Lackner, K; Munzel, T; Schnorbus, B; Warnke, S | 1 |
| Fortmann, SD; Serebruany, VL | 2 |
| Massberg, S; Sibbing, D | 1 |
| Harrington, RA; Himmelmann, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Bataille, V; Carrié, D; Garcia, C; Lhermusier, T; Lipinski, MJ; Mejean, S; Murat, G; Sié, P; Voisin, S | 1 |
| Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Budaj, A; Macioch, T; Niewada, M; Pawęska, J; Perkowski, P | 1 |
| Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B | 1 |
| Maggioni, AP | 1 |
| Baek, YS; Kim, DH; Kim, SH; Kwan, J; Park, KS; Park, SD; Shin, SH; Woo, SI | 1 |
| Drucker, AG; Januzzi, JL; Manchette, AM | 1 |
| Emanuelsson, H; Hiasa, Y; Teng, R | 1 |
| Schühlen, H | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Vanassche, T; Weitz, JI | 1 |
| Alström, U; Bertilsson, M; Braun, OÖ; Cannon, CP; Held, C; Himmelmann, A; James, SK; Mahaffey, KW; Scirica, BM; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Delle Karth, G; Siller-Matula, JM | 1 |
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
| Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E | 1 |
| Gaglia, MA | 1 |
| Baber, U; Badimon, JJ; Crippa, M; Giannarelli, C; Mehran, R; Rodriguez, D; Sartori, S; Tewar, MP; Vorchheimer, DA; Zafar, MU | 1 |
| Adlam, D; Choudhury, RP; Hadley, G; Harrison, P | 1 |
| Ge, J; Qian, J; Wang, Q; Wu, H; Zhou, J | 1 |
| Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P | 1 |
| Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U | 1 |
| Fauchère, I; Schreiber, P; Wyss, C | 1 |
| Cannon, CP; Henriksson, M; James, S; Janzon, M; Mellström, C; Nicolau, JC; Storey, RF; Wallentin, L | 1 |
| Becker, RC; Cannon, CP; Ducrocq, G; Harrington, RA; Held, C; Himmelmann, A; Lassila, R; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Vengoechea, F | 1 |
| Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Lee, JY; Park, MK; Park, TH; Yi, SJ | 1 |
| Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, L; Maya, J; Price, MJ; Teng, R | 1 |
| Agostoni, P; Stella, PR; Timmers, L | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Anselmi, CV; Bacci, M; Mendolicchio, GL; Quagliuolo, V; Rota, LL; Roveda, M; Ruggeri, ZM; Zavalloni, D | 1 |
| Al-Turbak, H; Hibbert, B; Le May, MR; Moudgil, R; Osborne, C; So, DY | 1 |
| Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H | 1 |
| Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P | 1 |
| Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Goodman, SG; Gupta, A; Honeycutt, E; Messenger, JC; Peterson, ED; Wang, TY | 1 |
| Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG | 1 |
| Cavallini, C; De Servi, S; Ferlini, M; Leonardi, S | 1 |
| Anderson, JL; Goto, S; Huo, Y; Jeong, YH; Levine, GN; Mega, JL; Smith, SC; Taubert, K | 1 |
| Cho, JH; Ihm, CG; Jeong, KH; Kim, JB; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS | 1 |
| Assinger, A; Kral, JB; Scharbert, G; Schrottmaier, WC; Weber, T; Wetzel, L | 1 |
| Jiang, M; You, JH | 3 |
| Roffman, DS | 1 |
| Anstrom, KJ; Cannon, CP; Cowper, PA; Davidson-Ray, L; Harrington, RA; Janzon, M; Kaul, P; Levin, LÅ; Mark, DB; Nikolic, E; Pan, W; Wallentin, L | 1 |
| Hlatky, MA; Kazi, DS | 1 |
| Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A | 1 |
| Baker, N; Bliden, KP; Chen, F; Escarcega, RO; Gurbel, PA; Lhermusier, T; Lipinski, MJ; Magalhaes, MA; Minha, S; Ota, H; Pendyala, L; Tantry, US; Tian, W; Torguson, R; Waksman, R | 1 |
| Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S | 1 |
| Steg, PG; Wiviott, SD | 1 |
| Arnaud, L; Bonello, L; Cointe, S; Dignat-George, F; Frere, C; Guieu, R; Kerbaul, F; Laine, M; Lemesle, G; Mancini, J; Paganelli, F; Sabatier, F; Thuny, F | 1 |
| Heitmeier, S; Laux, V; Perzborn, E | 1 |
| Bednar, F; Knot, J; Maly, M; Motovska, Z; Ondrakova, M; Ulman, J | 1 |
| Aires, D; Deibert, B; Fischer, R; Fraga, G; Gillihan, R; Gollub, S; Laarman, R; Maybrook, RJ | 1 |
| Biasco, L; Clemmensen, P; De Backer, O; Engstrøm, T; Helqvist, S; Holmvang, L; Jørgensen, E; Kelbaek, H; Olivecrona, G; Pedersen, F; Ratcovich, H; Saunamäki, K; Tilsted, HH | 1 |
| Gao, F; Liu, XL; Shen, H; Wang, ZJ; Yang, SW; Zhou, YJ | 1 |
| Calcagno, S; Cavallo, E; Di Roma, A; Fedele, F; Guadagni, F; Lucisano, L; Mancone, M; Palmirotta, R; Pennacchi, M; Placentino, F; Sardella, G; Stio, RE | 1 |
| Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM | 1 |
| Cherepanov, V; Kim, MH; Serebruany, VL; Tomek, A | 1 |
| Birnbaum, GD; Birnbaum, Y; Nanhwan, MK; Nylander, S; Perez-Polo, JR; Ye, Y | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 6 |
| Hu, SD; Qu, Y; Xia, JG; Xu, D; Xu, J; Yin, CL | 1 |
| Amerena, J; Aylward, PE; Gunasekara, A; Harding, SA; Mussap, CJ; Schrale, R; Van Gaal, WJ | 1 |
| Alexopoulos, D; Bhatt, DL; Hamm, CW; Steg, PG; Stone, GW | 1 |
| Chua, T; Gruntowicz, D; Johnson, SG; Morlock, RJ | 1 |
| Bangalore, S; Bavishi, C; Messerli, FH; Panwar, S | 1 |
| Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R | 1 |
| Bouatou, Y; Daali, Y; Desmeules, J; Fontana, P; Samer, CF | 1 |
| Guimarães, PO; Tricoci, P | 1 |
| Chong, AY; Qutub, MA; So, DY | 1 |
| Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Collet, JP; Costa, F; Kereiakes, DJ; Lee, CW; Lincoff, AM; Mauri, L; Montalescot, G; Park, SJ; Sabatine, MS; Udell, JA; Valgimigli, M | 1 |
| Chen, Y; Cong, H; Dong, W; Hong, T; Li, Z; Wan, Z; Yin, T | 1 |
| Åberg, B; Barbu, M; Bjursten, H; Dreifaldt, M; Hansson, EC; Holmgren, A; Ivert, T; Jeppsson, A; Jidéus, L; Nozohoor, S; Svedjeholm, R | 1 |
| Duraj, L; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J | 1 |
| Bednar, F; Kopa, M; Kroupa, J; Motovska, Z; Ondrakova, M; Osmancik, P | 1 |
| Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X | 1 |
| Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ | 1 |
| Al Khalifa, A; Al Shouli, S; Bonneau, C; Chung, J; Currie, ME; Fagan, A; Lee, MM; Mewhort, HE; Ruel, M; Teoh, H; Verma, S; White, CW; Yamashita, MH; Yanagawa, B | 1 |
| Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, LC; Maya, J; Price, MJ; Teng, R | 1 |
| Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| O'Donoghue, ML; Sarma, A | 1 |
| Kim, MH; Pokov, AN; Serebruany, VL; Tomek, A | 1 |
| Ajjan, RA; Dockrell, DH; Ecob, R; Faulkner, RE; Judge, HM; Khan, H; Outteridge, SN; Phoenix, F; Sabroe, I; Sangha, GK; Storey, RF; Thomas, MR; West, LE | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 2 |
| Giusti, B; Grifoni, E; Marcucci, R | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Suryapranata, H; Verdoia, M | 1 |
| Dong, C; Liu, X; Ren, C; Ren, Q; Zhang, X | 1 |
| Bergmeijer, TO; de Boer, MJ; de Vrey, E; Deneer, VH; Groenemeijer, BE; Heestermans, AA; Ishak, M; Janssen, PW; Jukema, JW; Kelder, JC; Qaderdan, K; ten Berg, JM; van't Hof, AW; Vos, GJ; Voskuil, M | 1 |
| Abtan, J; Amour, J; Barthélémy, O; Brugier, D; Collet, JP; Kerneis, M; Leprince, P; Martin, R; Mercadier, A; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL | 1 |
| Sachdeva, A | 1 |
| Bougouin, W; Cariou, A; Dumas, F; Gouffran, G; Jakamy, R; Joffre, J; Lamhaut, L; Rosencher, J; Varenne, O | 1 |
| Croce, KJ; Falcão, FC; Falcão, JL; Lemos, PA; Medeiros, F; Mont'Alverne-Filho, JR; Nicolau, JC; Rodrigues-Sobrinho, CR; Serruys, PW; Silva, RC; Valgimigli, M | 1 |
| Dobesh, PP; Doyle, M; Varnado, S | 1 |
| Eichinger, S; Kaider, A; Kollars, M; Kyrle, PA; Traby, L; Wolzt, M | 1 |
| Fu, Q; Huang, YJ; Zhang, N; Zhang, Q; Zhu, K | 1 |
| Bai, J; Han, Q; Huang, XH; Liu, C; Shen, DL; Wang, B; Zhang, JY | 1 |
| Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY | 1 |
| Chava, S; Schneider, DJ | 1 |
| Alexopoulos, D; Barampoutis, N; Davlouros, P; Gkizas, V; Hahalis, G; Karanikas, S; Karvounis, H; Kontoprias, K; Koutsogiannis, N; Patsilinakos, S; Tsigkas, G; Xanthopoulou, I; Ziakas, A | 1 |
| Bui, AH; Cannon, CP; Guo, J; Held, C; Himmelmann, A; Husted, S; Im, K; James, SK; Michelson, EL; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Bolek, T; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M | 1 |
| Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weber, S; Zhou, Q | 1 |
| Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Singh, K; Wilson, RE; Zenni, MM | 1 |
| Abtan, J; Angiolillo, DJ; Ardissino, D; Gabriel Steg, P; Harrington, RA; Hellkamp, A; Himmelmann, A; Husted, S; James, SK; Katus, HA; Meier, B; Schulte, PJ; Storey, RF; Velders, MA; Wallentin, L | 1 |
| Bernat, I; Dragounová, E; Hromádka, M; Jirouš, Š; Pechman, V; Rokyta, R; Seidlerová, J; Tůmová, P | 1 |
| Parker, WA; Storey, RF | 1 |
| Li, Y; Li, Z; Miao, W; Su, G; Zhang, T | 1 |
| Barbieri, L; Bellomo, G; Daffara, V; Luca, GD; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Angiolillo, DJ; Carlson, G; Franchi, F; Khan, N; Mehran, R; Raveendran, G; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB | 1 |
| Basabe-Desmonts, L; Gilmartin, N; Jose, B; Kenny, D; Kent, NJ; McCluskey, P; Ricco, AJ; Somers, M | 1 |
| Chong Tou, TJ; Lei Put, PZ; Lei Sio, ZW; Lei Sok, SM; Liu, PM; O U, YF; Sio Cham, ZC; Wang, JF; Wu, W; Zhou, SX | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Tang, N; Yin, SY | 1 |
| Arbel, Y; Lev, EI; Mosseri, M; Musallam, A; Orvin, K; Perl, L; Roguin, A | 1 |
| Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hahalis, G; Hamilos, M; Kanakakis, I; Pentara, I; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I | 1 |
| Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R | 1 |
| Deliargyris, EN; Fan, W; Plent, S; Prats, J | 1 |
| Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P | 1 |
| Thachil, J | 1 |
| Chen, KY; Li, G; Liu, T; Xu, G; Zhang, N; Zhao, J | 1 |
| Ruiz-Nodar, JM | 1 |
| Biscaglia, S; Campo, G; Ferrari, R; Pavasini, R; Tebaldi, M; Tumscitz, C | 1 |
| Jain, N; Reilly, RF | 1 |
| De Luca, G; Verdoia, M | 1 |
| Bonello, L; Dignat-Georges, F; Fromonot, J; Guieu, R; Kipson, N; Mottola, G; Paganelli, F; Rossi, P; Ruf, J | 1 |
| Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB | 1 |
| Dong, X; Han, Y; He, M; Li, M; Li, Y; Liu, B; Lu, S; Pan, Y; Shi, J; Sun, D; Zhao, S; Zheng, W | 1 |
| Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A | 1 |
| Broe, A; Diness, TG; Emneus, M; Gislason, GH; Green, A; Hasvold, P; Pottegård, A | 1 |
| de Mol, BA; Li, WW; Manshanden, JS; Schotborgh, MA; Tomšič, A | 1 |
| Berbis, J; Bonello, L; Dignat-George, F; Frere, C; Kerbaul, F; Laine, M; Lemesle, G; Paganelli, F; Roch, A; Thuny, F | 1 |
| Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C | 2 |
| Baber, U; Berger, PB; Currier, J; Dave, RH; Henry, TD; Mehran, R; Nayyar, P; Rafique, AM; Tobis, J; Wang, TY | 1 |
| Blackman, D; Curzen, N; Dalby, M; Flather, M; Gershlick, AH; Greenwood, JP; Hetherington, S; Kelly, DJ; Khan, JN; Lai, FY; McCann, GP; Nazir, SA; Peebles, C; Swanton, H; Wong, J | 1 |
| Cotton, JM; Cox, AR; Khan, N | 1 |
| Bernlochner, I; Gross, L; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Orban, M; Rössner, L; Sibbing, D | 1 |
| Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| Anstrom, K; Bhandary, DD; Cannon, CP; Choudhry, NK; Cohen, DJ; Davidson-Ray, LD; Doll, JA; Fonarow, GC; Henry, TD; Khan, N; Peterson, ED; Wang, TY | 1 |
| Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D | 1 |
| Guo, YM; Li, HZ; Li, Z; Sun, HL; Zhang, L; Zhao, ZC | 1 |
| Aksakal, E | 1 |
| French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S | 1 |
| Goudevenos, JA; Ntalas, IV; Tatsidou, PT; Tselepis, AD; Tsoumani, ME | 1 |
| Chao, TH; Chen, IC; Chen, Y; Cheng, CL; Fang, CC; Lee, CH; Li, YH; Lin, CC; Lin, CY; Yu, CL | 1 |
| Caiazzo, G; Carino, A; De Rosa, S; Filippis, C; Indolfi, C; Mongiardo, A; Polimeni, A; Sabatino, J; Sorrentino, S; Spaccarotella, C; Strangio, A; Torella, D | 1 |
| Cattaneo, M; Cipriani, M; Femia, EA; Frigerio, M; Morici, N; Oliva, F; Perna, E | 1 |
| Khan, N | 1 |
| Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L | 1 |
| Ahn, JM; Chang, M; Kang, SJ; Kim, YH; Lee, CW; Lee, HS; Lee, SW; Moon, DH; Oh, M; Park, DW; Park, SJ; Park, SW | 1 |
| Gearman, DJ; Ingimarsson, JP; Krambeck, AE; Scales, J; Sharma, V; Westerman, ME | 1 |
| Cattabiani, MA; Di Vito, L; Gatto, L; Limbruno, U; Marco, V; Micari, A; Pawlowski, T; Prati, F; Romagnoli, E; Trivisonno, A; Versaci, F | 1 |
| Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
| Cheng, Q; Coelho, PG; Cronstein, BN; Mediero, A; Reddy, VS; Tovar, N; Whatling, C; Wilder, T; Witek, L | 1 |
| Barbieri, L; Bellomo, G; Daffara, V; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Cai, Q; Chen, L; Gao, L; Gu, Y; Li, P; Liu, J; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X | 1 |
| Althouse, AD; Conrad Smith, AJ; Khandhar, SJ; Kudaravalli, M; Lee, JS; Marroquin, OC; Mulukutla, SR; Schindler, JT; Sharbaugh, MS; Toma, C | 1 |
| Bhat, A; Pang, M; Wu, Y; Zhang, H; Zhang, Y; Zhao, Y; Zhuang, K | 1 |
| Alexopoulos, D; Lekakis, J; Moulias, A; Xanthopoulou, I | 1 |
| Barbato, E; Colaiori, I; Di Sciascio, G; Lauria Pantano, A; Mangiacapra, F; Panaioli, E; Pozzilli, P; Ricottini, E | 1 |
| Andersson, TL; Carlson, GF; Nylander, S; Teng, R | 1 |
| Agueznai, M; Ardouin, P; Beygui, F; Blanchart, K; Collet, JP; Lemaître, A; Milliez, P; Montalescot, G; Roule, V; Sabatier, R | 1 |
| Bianco, D; Brunelli, C; Chiarella, F; Massobrio, L; Rosa, GM; Valbusa, A | 1 |
| Baek, YS; Kim, DH; Kwan, J; Kwon, SW; Lee, MJ; Park, KS; Park, SD; Shin, SH; Woo, SI | 1 |
| Gurbel, PA; Kubica, J; Myat, A; Tantry, US | 1 |
| Bernick, J; Chong, AY; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Lugomirski, P; Marquis, JF; Maze, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY; Wells, G | 1 |
| Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M | 1 |
| Badimon, L; Capdevila, A; Carlsson, L; Carreras, F; Casani, L; Gutiérrez, M; Hidalgo, A; Pons-Lladó, G; Varela, L; Vilahur, G | 1 |
| Cheema, AN; Cieza, T; Dehghani, P; Déry, JP; Fisher, HN; Goodman, SG; Henderson, MA; Kokis, A; Lavi, S; Lutchmedial, S; Mehta, SR; Siega, AJ; Welsh, RC; Wong, BY; Zhang, X; Zhu, YE | 1 |
| Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC | 1 |
| Baumgartner, I; Berger, JS; Blomster, J; Conte, MS; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C; White, CJ | 1 |
| Gao, Y; Guan, QG; Guo, L; Jia, DL; Li, YZ; Qi, GX; Sun, YX; Tian, W; Xin, YG; Xu, F; Yu, HJ; Zhang, HS; Zhang, XG; Zhang, YL | 1 |
| Bagai, A; Brass, N; Cheema, AN; Dehghani, P; Dery, JP; Ducas, J; Fisher, HN; Fung, A; Goodman, SG; Kassam, SA; Kim, HH; Mehta, SR; Quraishi, AU; Schampaert, E; Wang, TY; Welsh, RC; Zhang, X; Zhu, YE | 1 |
| Fernández-Ruiz, I | 1 |
| Bian, S; Dong, P; Yang, X | 1 |
| Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME | 1 |
| Bustos, L; De la Puente, C; Lanas, F; Vallejos, C; Velasquez, M; Zaror, C | 1 |
| Blinc, A; Fister, M; Mijovski, MB; Mikuz, U; Noc, M; Steblovnik, K | 1 |
| Franchi, F; Rollini, F | 2 |
| Ardati, AK; DiDomenico, RJ; Kim, K; Lee, TA; Touchette, DR; Walton, SM | 3 |
| Akhmedov, A; Beer, JH; Bonetti, NR; Camici, GG; Gaul, DS; Glanzmann, M; Keller, S; Lüscher, TF; Matter, CM; Reiner, MF; Ruf, W; Savarese, G; Stivala, S; Yang, Z; Zhu, C | 1 |
| Chen, J; Li, X; Lv, Q; Wang, Q; Xue, Y | 1 |
| Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J | 1 |
| Amstalden, H; Beer, JH; Benussi, S; Bonetti, NR; Breitenstein, A; Camici, GG; Falk, V; Glanzmann, M; Holy, EW; Keller, S; Lüscher, TF; Maisano, F; Reiner, MF; Savarese, G; Stämpfli, SF; Steffel, J | 1 |
| Lipinski, MJ; Torguson, R; Waksman, R; Westman, PC | 1 |
| Amann, M; Bömicke, T; Ferenc, M; Hauschke, D; Hochholzer, W; Kleiner, P; Löffelhardt, N; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM; Younas, I | 1 |
| Chen, N; Ding, P; Liu, H; Wei, Y | 1 |
| Lee, VWY; Liew, D; Wang, Y; Yan, BP | 1 |
| Beauloye, C; Claeys, MJ; Pourbaix, S; Sinnaeve, PR | 1 |
| Barbour, C; Gesheff, T | 1 |
| Angiolillo, DJ; Gaglia, MA; Kiramijyan, S; Lhermusier, T; Lipinski, MJ; Pokharel, S; Steinvil, A; Storey, RF; Torguson, R; Waksman, R; Wallentin, L | 1 |
| Hu, D; Li, C; Shen, X; Sun, Y; Tao, M; Wang, DW; Yu, T; Zhang, L; Zhang, X | 1 |
| Chan, R; Kong, SL; Kwok, J; Lee, S; Shea, C; Siu, D; Tam, CC; Tang, WH; Wong, A; Yung, A | 1 |
| Andrea, R; Brugaletta, S; Caixal, G; Flores-Umanzor, E; Freixa, X; Garcia, J; Hernandez-Enriquez, M; Jiménez-Brítez, G; Martin, V; Masotti, M; Regueiro, A; Sabaté, M; San Antonio, R | 1 |
| Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M | 1 |
| Cui, JG; Huang, XH; Liu, G; Lu, J; Wu, X; Zhao, XY; Zheng, XX | 1 |
| Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J | 1 |
| Aquila, G; Balla, C; Biscaglia, S; Campo, G; Cimaglia, P; Contoli, M; Del Franco, A; Ferrari, R; Fortini, F; Gallo, F; Pavasini, R; Pecoraro, A; Pestelli, G; Rizzo, P; Tonet, E; Vieceli Dalla Sega, F | 1 |
| Ihm, CG; Jeong, KH; Kim, JB; Kim, JS; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS | 1 |
| Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y | 1 |
| Kanic, V; Kanic, Z; Kompara, G; Markota, A; Penko, M; Vollrath, M | 1 |
| Cao, Y; Chen, G; Chen, W; Li, H; Li, J; Li, X; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wang, Z; Wu, J; Xu, Y; Zhang, G; Zhao, X | 1 |
| Boasi, V; Cattunar, S; Mascelli, G; Perri, D; Pistis, G; Sànchez, FA; Secco, GG; Tacchi, C; Vercellino, M | 1 |
| Carr, K; Ghamasaee, P; Grandhi, R; Johnson, J | 1 |
| Becker, RC; Cannon, CP; Hagström, E; Himmelmann, A; James, SK; Katus, HA; Lindholm, D; López-Sendón, JL; Maurer, G; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Adeeb, N; Alturki, A; Foreman, PM; Griessenauer, CJ; Harrigan, MR; Levy, EI; Moore, JM; Motiei-Langroudi, R; Ogilvy, CS; Shallwani, H; Siddiqui, AH; Thomas, AJ | 1 |
| Dixon, SR; Gurm, HS; Khandelwal, A; LaLonde, TA; Seth, M; Sukul, D | 1 |
| Eichelberger, B; Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Panzer, S; Pultar, J; Seidinger, D; Wadowski, PP | 1 |
| Choe, YH; Choi, JH; Choi, SH; Chun, WJ; Gwon, HC; Hahn, JY; Kim, EK; Park, TK; Song, YB; Yang, JH | 1 |
| Bellomo, G; Carriero, A; Daffara, V; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Verdoia, M | 1 |
| Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K | 1 |
| Alemayehu, M; D'Alfonso, S; Gong, I; Kim, RB; Lavi, R; Lavi, S; Mansell, SE; Wall, S | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Van de Werf, F | 1 |
| Adeeb, N; Griessenauer, CJ; Gupta, R; Moore, JM; Ogilvy, CS; Patel, AS; Shallwani, H; Siddiqui, A; Thomas, AJ; Youn, R | 1 |
| Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH | 1 |
| Radke, PW | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V | 1 |
| Sinnaeve, PR; Van de Werf, F | 1 |
| Cai, Y; Chen, S; Du, C; Gao, Y; Lai, W; Qin, C; Yang, C; Zhou, J | 1 |
| Aldazabal, A; Cerrato, E; Echavarría-Pinto, M; Escaned, J; Fernández-Ortiz, A; Gonzalo, N; Jimenez-Quevedo, P; Macaya, C; Mejia-Renteria, H; Nombela-Franco, L; Núñez-Gil, IJ; Quirós, A; Rumoroso, JR; Ryan, N; Salinas, P | 1 |
| Godier, A; Houssany-Pissot, S; Martin, AC; Taylor, G; Zlotnik, D | 1 |
| Choi, KN; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Park, YA; Seo, JS; Shin, HC; Yang, TH | 1 |
| Kakkos, S; Moris, D; Patelis, N | 1 |
| Moris, D; Siasos, G; Tousoulis, D | 1 |
| Hiatt, WR; Jones, WS; Patel, MR | 1 |
| Bognetti, P; Cardile, A; De Servi, S; Demarchi, A; Ferlini, M; Frattini, S; Grieco, N; Ielasi, A; Lettieri, C; Mafrici, A; Musumeci, G; Rossini, R; Russo, A; Sponzilli, C; Vecchiato, C; Visconti, LO | 1 |
| Becker, RC; Cannon, CP; Davoudi, F; Diercks, DB; Himmelmann, A; James, SK; Lim, ST; Pollack, CV; Schulte, PJ; Spinar, J; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Giedraitiene, A; Kupstyte, N; Lesauskaite, V; Tatarunas, V; Zaliunas, R | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Himmelmann, A; Huber, K; James, SK; Katus, HA; Lowenstern, A; Morais, J; Neely, M; Siegbahn, A; Steg, PG; Storey, RF; Sun, JL; Wallentin, L | 1 |
| Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y | 1 |
| Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R | 1 |
| Bachelot-Loza, C; Belleville-Rolland, T; Gaussem, P; Godier, A; Helley, D; Martin, AC | 1 |
| Christoph, M; Ende, G; Ibrahim, K; Jellinghaus, S; Loehn, T; Mierke, J; Pfluecke, C; Poitz, DM; Quick, S; Richter, B; Schoener, L; Speiser, U; Strasser, RH | 1 |
| Angiolillo, DJ; Cavallari, LH; Franchi, F; Kureti, M; Moon, JY; Rivas Rios, JR; Rollini, F | 1 |
| de Mast, Q; El Messaoudi, S; Gerretsen, J; Gomes, M; Kiers, D; Kox, M; Pickkers, P; Riksen, NP; Rongen, GA; van der Heijden, WA; van der Ven, AJ; van Ede, L | 1 |
| Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL | 1 |
| Budaj, A; Ramotowski, B; Żuk, A | 1 |
| Alcalde Martinez, V; Brugaletta, S; Caballero, J; Cequier, A; Correa Vilches, C; Gomez-Hospital, JA; Gomez-Lara, J; Jimenez Fernandez, M; Joyera, M; Molina Navarro, E; Ñato, M; Ortega-Paz, L; Romaguera, R; Sabate, M; Teruel, L | 1 |
| Eipeldauer, M; Hobl, EL; Litschauer, B; Weisshaar, S; Wolzt, M | 1 |
| Chen, S; Geng, Y; Gu, J; Hao, Q; Qi, P; Wang, H; Wang, L; Zhang, Y | 1 |
| Candela Sánchez, E; Carrillo Alemán, L; Esteve-Pastor, MA; Lozano, T; MacíasVillanego, MJ; Marín, F; Orenes-Piñero, E; PerniasEscrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruíz-Nodar, JM; Sandín Rollán, M; Tello-Montoliu, A; Valdés, M; Véliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Anuwatworn, A; Kumar, V; Petrasko, M; Stys, A; Yee, J | 1 |
| Giedraitiene, A; Jakstas, V; Kupstyte, N; Lesauskaite, V; Skipskis, V; Tatarunas, V; Zvikas, V | 1 |
| Desai, RJ; Gagne, JJ; Mogun, H; Spoendlin, J | 1 |
| Alexopoulos, D; Goudevenos, J; Hamilos, M; Kanakakis, J; Kochiadakis, G; Lekakis, J; Petousis, S; Sitafidis, G; Skalidis, E; Vardas, PE; Vavouranakis, M; Xanthopoulou, I | 1 |
| Baber, U; Badimon, JJ; Contreras, J; Escolar, G; Fuster, V; Linares-Koloffon, CA; Mehran, R; Rey-Mendoza, J; Sartori, S; Smith, DA; Zafar, MU | 1 |
| Bhatt, DL; Cannon, CP; Ellis, SG; Gropper, S; Harper, R; Hohnloser, SH; Januzzi, JL; Kimura, T; Kleine, E; Lip, GYH; Maeng, M; Manassie, J; Merkely, B; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Zeymer, U | 1 |
| Bash, LD; Patel, MD; Simpson, RJ; Vyas, A | 1 |
| Fairley, S; Harding, SA; Holley, A; Larsen, PD; Simmonds, M; Wilkins, B | 1 |
| Grove, EL; Hvas, AM; Kristensen, SD; Larsen, ML; Pedersen, OH | 1 |
| Han, Y; Li, C; Li, J; Li, Y; Qi, J; Tang, Y; Wang, H | 1 |
| Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Zimmermann, RH | 1 |
| Adamson, PD; Anand, A; Dias, S; Lee, KK; McAllister, DA; Mills, NL; Newby, DE; Shah, AS; Welton, N | 1 |
| Cattabiani, MA; De Palma, R; Guastaroba, P; Marino, M; Menozzi, A; Rasia, M; Solinas, E; Tadonio, I; Vignali, L | 1 |
| Alexopoulos, D; Davlouros, P; Despotopoulos, S; Xanthopoulou, I | 1 |
| Cho, JY; Hong, SJ; Joo, HJ; Kim, KA; Lee, SH; Lim, DS; Park, JH; Park, JY; Yu, CW | 1 |
| Cai, WY; Yang, J; Zeng, P | 1 |
| Dudek, D; Dziewierz, A; Kleczyński, P; Plens, K; Rakowski, T; Siudak, Z | 1 |
| Chao, TH; Chen, JY; Cheng, CL; Kao Yang, YH; Lee, CH; Li, YH | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| He, B; Lin, H; Tobe, RG; Wu, B; Zhang, L | 1 |
| Beavers, JC | 1 |
| Alestock, TD; Alsip, J; Anderson, RD; Ardati, AK; Beitelshees, AL; Brott, BC; Brown, L; Cavallari, LH; Chumnumwat, S; Clare-Salzler, MJ; Coons, JC; Cooper-DeHoff, RM; Dave, CV; Denny, JC; Dillon, C; Duarte, JD; Elsey, AR; Empey, PE; Gong, Y; Hamadeh, IS; Harada, S; Hillegass, WB; Hines, L; Horenstein, RB; Howell, LA; Jeng, LJB; Johnson, JA; Kelemen, MD; Kimmel, SE; Kreutz, RP; Lee, CR; Lee, YM; Limdi, NA; Magvanjav, O; McDonough, CW; Montasser, M; Nelson, DR; Nutescu, EA; Nwaba, DC; Pakyz, RE; Palmer, K; Peterson, JF; Pollin, TI; Pratt, VM; Quinn, AH; Robinson, SW; Schub, J; Shuldiner, AR; Skaar, TC; Smith, DM; Sriramoju, VB; Starostik, P; Stevenson, JM; Stouffer, GA; Stys, TP; Varunok, N; Vesely, MR; Voora, D; Wake, DT; Weck, KE; Weitzel, KW; Wilke, RA; Willig, J; Winterstein, AG; Zhao, RY | 1 |
| Carugo, S; Castini, D; Cazzaniga, S; Centola, M; Ferrante, G; Lucreziotti, S; Persampieri, S; Salerno-Uriarte, D; Sponzilli, C | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Branny, M; Cervinka, P; Dusek, J; Hlinomaz, O; Hromadka, M; Jarkovsky, J; Kala, P; Knot, J; Kramarikova, P; Majtan, B; Miklik, R; Motovska, Z; Mrozek, J; Ostransky, J; Rokyta, R; Simek, S; Svoboda, M; Tousek, F; Varvarovsky, I; Widimsky, P | 1 |
| Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Pon, Q; Yang, A; Zimmermann, RH | 1 |
| Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C | 1 |
| Landmesser, U; Stähli, BE | 1 |
| He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z | 1 |
| Alves, CMR; Berwanger, O; Bianco, HT; Caixeta, A; Carvalho, ACC; Damiani, LP; Fonseca, FAH; Fonseca, HA; França, CN; Izar, MC; Klassen, A; Maugeri, IML; Moreira, FT; Pinto, IM; Soriano Lopes, A; Szarf, G; Tavares, MFM | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Deharo, P; Fernandez, M; Fourcade, L; Ibrahim, M; Johnson, TW; Morange, PE; Quilici, J; Suchon, P; Verdier, V | 1 |
| Cherepanov, V; Fortmann, SD; Hyun Kim, M; Litvinov, O; Marciniak, TA; Mihalev, K; Serebruany, VL | 1 |
| Baumgartner, I; Berger, JS; Björck, M; Blomster, JI; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Wojdyla, DM | 1 |
| Ascarrunz, SD; Cho, MY; Peralta-Bazan, F; Rodriguez, AE; Rodriguez-Granillo, AM | 1 |
| Assanelli, EM; Camisasca, P; Chizzola, G; Corrada, E; De Servi, S; Demarchi, A; Farina, A; Ferlini, M; Grieco, N; Lettieri, C; Mafrici, A; Musumeci, G; Oltrona Visconti, L; Pedrinazzi, C; Rossini, R; Sponzilli, C | 1 |
| Boland, P; Bourke, M; Chan, V; Chong, AY; Dupuis, JY; Goubran, D; Hibbert, B; James, TE; Lordkipanidzé, M; Malhotra, N; Perrault, L; Rubens, F; Ruel, M; Russo, JJ; Singh, K; So, DY; Tanguay, JF; Tran, DT; Wells, GA | 1 |
| Åkerblom, A; Aukrust, P; Becker, RC; Bertilsson, M; Ghukasyan, T; Himmelmann, A; James, SK; Kontny, F; Michelsen, AE; Siegbahn, A; Storey, RF; Ueland, T; Wallentin, L | 2 |
| Cooper, R; Curzen, N; Kemp, I; Khanna, V; Mars, C; Shahzad, A; Shaw, M; Stables, RH; Wilson, K | 1 |
| Cho, YR; Kim, MH; Kim, YD; Park, JS; Park, K; Park, TH | 2 |
| de Belder, MA; Freeman, P; Johnson, T; Kontopantelis, E; Kwok, CS; Ludman, P; Mamas, MA; Sirker, A; Zaman, A | 1 |
| Berthe, A; Diaby, V; Ezendu, K; Okere, AN | 1 |
| Aga, U; Atalay, B; Doganay, O; Karadag, E; Tugrul, M | 1 |
| Ajjan, RA; Bertilsson, M; Gabrysch, K; Himmelmann, A; James, SK; Siegbahn, A; Storey, RF; Sumaya, W; Wallentin, L | 1 |
| Hlinomaz, O; Máchal, J | 1 |
| Hess, S; Jesel, L; Kibler, M; Marchandot, B; Messas, N; Meyer, N; Morel, O; Ohlmann, P; Ristorto, J; Schaeffer, M; Tuzin, N | 1 |
| Baumbach, A; Byrne, J; Curzen, N; de Belder, MA; Hildick-Smith, DJR; Kinnaird, T; Ludman, P; Mamas, MA; Olier, I; Rashid, M; Sirker, A | 1 |
| Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM | 1 |
| Ardissino, D; Becker, RC; Cairns, R; Cannon, CP; Himmelmann, A; James, SK; Katus, HA; Mahaffey, KW; Storey, RF; Vignali, L; Wallentin, L | 1 |
| Abdel-Latif, A; Aoi, S; Kim, SM; Misumida, N; Ziada, KM | 1 |
| Baele, P; Kahn, D; Lamberts, V; Liistro, G | 1 |
| Antoni, D; Hitzke, E; Hoffmann, E; Ott, A; Rieber, J; Schmidtler, F; Selhorst, G; Tomelden, J | 1 |
| Harrington, RA; Yancy, CW | 1 |
| Averkov, O; Berwanger, O; Candido, CT; Carvalho, AC; Damiani, LP; de Barros E Silva, PGM; De Luca, FA; Fonseca, FA; Goodman, SG; Granger, CB; Guimaraes, HP; Jiang, L; Lasagno, CMR; Lopes, RD; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Paisani, DM; Parkhomenko, A; Piegas, LS; Saraiva, JFK; Tajer, C; Valeis, N; White, HD | 1 |
| Agarwal, M; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Kureti, M; Moon, JY; Nagaraju, D; Nawaz, A; Rivas Rios, J; Rivas, A; Rollini, F; Shaikh, Z; Soffer, D; Suryadevara, S; Wali, M; Zenni, MM | 1 |
| Gach, O; Lancellotti, P; Magne, J; Nyssen, A; Oury, C; Pirlet, C | 1 |
| Berti, S; Bolognese, L; D'Ascenzo, F; De Luca, L; De Servi, S; Gallo, P; Granatelli, A; Gulizia, MM; Musumeci, G; Pennacchi, M; Rigattieri, S | 1 |
| Ahn, Y; Chae, IH; Chae, JK; Chae, SC; Cho, MC; Han, JK; Hur, SH; Jeong, MH; Kang, HJ; Kang, J; Kim, HS; Kim, YJ; Koo, BK; Park, KW; Seong, IW; Seung, KB; Yang, HM | 1 |
| Abenhaim, L; Benichou, J; Bonello, L; Cottin, Y; Dallongeville, J; Danchin, N; Delarche, N; Falissard, B; Furber, A; Ghanem, F; Grimaldi-Bensouda, L; Leclercq, F; Morel, O; Puymirat, E | 1 |
| Akkerhuis, KM; Ariotti, S; Brugaletta, S; Gianni, U; Janssens, GN; Karagiannis, A; Leonardi, S; Ortega-Paz, L; Rimoldi, SF; Valgimigli, M; van den Berge, JC; van Leeuwen, M; Windecker, S | 1 |
| Onwordi, ENC; Parker, WA; Storey, RF | 1 |
| Carrero, JJ; Edfors, R; Evans, M; James, SK; Jernberg, T; Lagerqvist, B; Renlund, H; Sahlén, A; Spaak, J; Szummer, K; Varenhorst, C | 1 |
| Bertling, A; Fender, AC; Geißler, G; Jakubowski, JA; Kehrel, BE; Kelsch, R; Mergemeier, K; Rumpf, M; Schüngel, L; Sibrowski, W; Waltenberger, J | 1 |
| Fonarow, GC; Ge, J; Han, Y; Hao, Y; Huo, Y; Liu, J; Ma, C; Morgan, L; Nie, S; Smith, SC; Taubert, KA; Wang, X; Zhao, D; Zhao, G; Zhou, M | 1 |
| Abu-Assi, E; Alegre, O; Alexopoulos, D; Alfonso, E; Ariza-Solé, A; Cequier, A; Chen, Y; Correia, L; D'Ascenzo, F; Fan, JY; Filipiak, K; Formiga, F; Fujii, T; Gaita, F; Garay, A; García-Acuña, JM; Giordana, F; González-Juanatey, JR; Henriques, JPS; Huczek, Z; Ikari, Y; Kalpak, O; Kawaji, T; Kawashiri, MA; Kedev, S; Kikkert, WJ; Kowara, M; Liebetrau, C; Lorente, V; Möllmann, H; Moretti, C; Nakahashi, T; Nie, SP; Nuñez-Gil, I; Osman, N; Raposeiras-Roubín, S; Sakata, K; Sánchez-Salado, JC; Saucedo, J; Shiomi, H; Song, X; Southern, D; Terol, B; Wang, X; Wilton, SB; Xanthopoulou, I; Yamagishi, M; Yan, Y; Zhang, D | 1 |
| Cervantes, A; Cicci, JD; Clarke, M; Hamrick, K; Howell, LA; Lee, CR; Lee, JA; Madan, S; Polasek, MJ; Sriramoju, VB; Stouffer, GA; Varunok, N; Weck, KE | 1 |
| Ahn, JM; Jang, S; Kang, DY; Lee, CH; Lee, PH; Lim, HS; Park, DW; Park, SJ; Park, SW; Yun, SC | 1 |
| He, B; Liu, Y; Tobe, RG; Wu, B | 1 |
| Billinger, M; Blöchlinger, S; Heg, D; Hunziker, L; Karagiannis, A; Koskinas, KC; Moro, C; Moschovitis, A; Pilgrim, T; Praz, F; Räber, L; Räsänen, M; Seiler, C; Stortecky, S; Temperli, F; Valgimigli, M; Windecker, S; Zanchin, C; Zanchin, T | 1 |
| Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Cho, MC; Choi, DJ; Gwon, HC; Hur, SH; Hwang, JY; Jeong, MH; Joo, SJ; Kim, CJ; Kim, DI; Kim, HS; Oh, SK; Park, JS; Rha, SW; Seong, IW; Seung, KB; Sim, DS; Yoon, JH | 2 |
| Alexopoulos, D; Andreou, I; Briasoulis, A; Ikonomidis, I; Pappas, C | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JHW; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Giri, J; Nathan, A | 1 |
| Akkerhuis, KM; Ariotti, S; Brugaletta, S; Gianni, U; Janssens, G; Karagiannis, A; Leonardi, S; Ortega-Paz, L; Rimoldi, SF; Valgimigli, M; van den Berge, JC; van Leeuwen, M; Windecker, S | 1 |
| Armstrong, PW; Bansilal, S; Becker, RC; Cannon, CP; Clare, RM; Davoudi, F; Held, C; Himmelmann, A; James, SK; Mahaffey, KW; Pieper, KS; Schulte, PJ; Scirica, BM; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, JS; Ko, YG | 1 |
| Guo, S; Li, W; Li, Z; Pan, W; Sun, X; Sun, Y; Wang, L; Wang, S | 1 |
| Brignardello-Petersen, R | 1 |
| Averkov, O; Berwanger, O; Candido, CT; Carvalho, AC; Damiani, LP; de Barros E Silva, PGM; Fonseca, F; Goodman, S; Granger, CB; Guimaraes, HP; Jiang, L; Kerr Saraiva, JF; Lasagno, CMR; Lopes, RD; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Paisani, DM; Parkhomenko, A; Piegas, LS; Tajer, C; Valeis, N; White, H | 1 |
| Abdalla, A; Ahmed, S; Bachuwa, G; Barbarawi, M; Bhatt, DL; Hassan, M; Haykal, T; Hicks, M; Kheiri, B; Osman, M; Zayed, Y | 1 |
| Dawood, BB; Hayes, J; Hoskins, HC; Protty, MB; Wilkins, SJ | 1 |
| Abramson, BL; Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FGR; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Lopes, RD; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C; Rockhold, FW | 1 |
| Backman, JT; Holmberg, MT; Neuvonen, M; Neuvonen, PJ; Niemi, M; Paile-Hyvärinen, M; Tarkiainen, EK; Tornio, A | 1 |
| Dai, W; Li, L; Su, Q; Ye, Z | 1 |
| Bai, J; Fu, Q; Gao, CZ; Liu, R; Ma, QQ; Wang, F; Wei, P; Wu, J; Yang, XJ | 1 |
| Badimon, L; Ben-Aicha, S; Capdevila, A; Carlsson, L; Carreras, F; Casani, L; Gutiérrez, M; Hidalgo, A; Lambert, C; Mendieta, G; Pons-Lladó, G; Vilahur, G | 1 |
| Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM | 1 |
| Bortone, AS; Cecere, A; Ciccone, MM; D'Alessandro, P; Favale, S; Fumarola, F; Giordano, A; Guaricci, AI; Marchese, A; Pepe, M | 1 |
| Calnan, MW; Crawford, AN | 1 |
| Angiolillo, DJ; Brugaletta, S; Caballero, J; Cequier, A; Fernandez, MJ; Gomez-Hospital, JA; Gomez-Lara, J; Joyera, M; Martinez, VA; Ñato, M; Navarro, EM; Ortega-Paz, L; Romaguera, R; Sabate, M; Teruel, L; Vilches, CC | 1 |
| Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A | 1 |
| Niu, P; Ouyang, S; Xiao, M; Zhuo, B; Zhuo, X | 1 |
| Ortega-Paz, L; Valgimigli, M | 1 |
| Hong, SJ; Jeong, HS; Kim, JH | 1 |
| Fong, AYY; Koh, KT; Ong, TK; Tan, SSN; Tiong, LL | 1 |
| Calabria, S; Cimminiello, C; Dondi, L; Maggioni, AP; Martini, N; Pedrini, A; Ronconi, G | 1 |
| Ahn, J; Cha, KS; Choe, JC; Choi, JH; Hong, TJ; Jeong, MH; Lee, HC; Lee, HW; Oh, JH; Park, JS | 1 |
| Fan, CJ; Hu, HY; Li, XY; Su, GH; Wang, GX | 1 |
| Aradi, D; Bonello, L; Burtey, S; Dabry, T; Frere, C; Laine, M; Lemesle, G; Mancini, J; Paganelli, F; Puymirat, E; Sibbing, D; Thuny, F | 1 |
| Le Bras, A | 1 |
| Alonso-Orcajo, N; Carbonell, R; Cid, B; Cruz-Gonzalez, I; Cuellas, C; de Prado, AP; Diego-Nieto, A; Fernandez-Vazquez, F; Lopez-Benito, M; Martin-Herrero, F; Martin-Moreiras, JC; Moreno-Samos, JC; Pascual, C; Sanchez, PL; Vidriales, MB | 1 |
| Desai, RJ; Gagne, JJ; Lewey, JJ; Patorno, E; Schneeweiss, S; Spoendlin, J | 1 |
| Abellán-Huerta, J; Jurado-Román, A; López-Lluva, MT; Lozano-Ruiz Poveda, F; Piqueras-Flores, J; Sánchez-Pérez, I | 1 |
| Guan, W; Lu, H; Yang, K | 1 |
| Czepulis, N; Karpinski, K; Korybalska, K; Luczak, J; Rutkowski, R; Witowski, J | 1 |
| Garcia-Garcia, HM; Shlofmitz, E | 1 |
| Chang, CC; Chen, SM; Chen, YC; Cheng, SM; Chuang, CL; Lin, FY; Lin, RH; Lin, YW; Sheu, JS; Tsai, CS | 2 |
| Barlow, CW; Sadeque, SA | 1 |
| Cui, XR; Jia, M; Li, RB; Wang, D; Yang, XH; Zhang, JD | 1 |
| Farag, M; Gorog, DA; Gue, YX; Spinthakis, N; Srinivasan, M; Wellsted, DM | 1 |
| Calafiore, AM; Di Mauro, M | 1 |
| Diao, X; Feng, W; Hu, S; Xu, F; Zhang, Y; Zheng, Z; Zhou, Z | 1 |
| Chan, EW; Chen, L; Cheung, KS; Guo, CG; Isshiki, T; Leung, WK; Wong, ICK | 1 |
| Liao, H; Liu, L; Liu, Y; Xiao, C; Zhong, S | 1 |
| Hou, J; Jiang, Z; Liu, Q; Sun, M; Wang, S; Wang, W; Wang, Y; Yu, B; Zhang, H; Zhang, R; Zhao, Q | 1 |
| Bizzozero, C; Blum, S; Bolliger, D; Buser, A; Gebhard, C; Glauser, S; Grapow, MTR; Siegemund, M; Vuilliomenet, T | 1 |
| Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Mulder, H; Norgren, L; Olivier, CB; Patel, MR; Rockhold, FW | 1 |
| Cho, YR; Choi, SY; Kim, MH; Min Lee, K; Park, TH; Sung Park, J; Yun, SC | 1 |
| Graipe, A; Mooe, T; Söderström, L | 1 |
| Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Henry, TD; Kini, A; Krucoff, M; Leisman, DE; Mehran, R; Moliterno, D; Pocock, SJ; Sartori, S; Steg, PG; Witzenbichler, B | 1 |
| Dayoub, EJ; Giri, J; Groeneveld, PW; Khatana, SAM; Kobayashi, T; Kolansky, DM; Nathan, AS; Seigerman, M; Tuteja, S | 1 |
| Body, R; Jarman, H; Morris, N; Moss, P; Reynard, C | 1 |
| Bai, S; Chen, T; Du, R; Li, Q; Li, R; Li, X; Liu, H; Liu, J; Wang, L; Wang, X; Wu, H; Zhang, L | 1 |
| Anstrom, KJ; Bhandary, D; Cannon, CP; Choudhry, NK; Cohen, DJ; Fonarow, GC; Henry, TD; Kaltenbach, LA; Khan, ND; Peterson, ED; Wang, TY | 1 |
| Bastos Fernandez, G; Baz Alonso, JA; Calvo Iglesias, F; Cequier Fillat, A; Cruz Gonzalez, I; De Miguel Castro, A; Fernandez Barbeira, S; Iñiguez Romo, A; Jimenez Diaz, VA; Juan Salvadores, P; Molina Navarro, E; Moreno, R; Ocampo Miguez, J; Ortiz Saez, A; Paredes Galan, E; Raposeiras Roubin, S; Romaguera, R; Serra Peñaranda, A; Tello-Montoliu, A; Valdes Chavarri, M | 1 |
| Candela-Sanchez, E; Carrillo-Aleman, L; Esteve-Pastor, MA; Lozano, T; Macías, M; Marín, F; Martínez-Martínez, JG; Orenes-Piñero, E; Pernias-Escrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Sandín-Rollan, M; Veliz, A; Vicente-Ibarra, N | 1 |
| Benichou, J; Blin, P; Bonello, L; Dallongeville, J; Danchin, N; Droz, C; Dureau-Pournin, C; Falissard, B; Jové, J; Lassalle, R; Moore, N; Thomas-Delecourt, F | 1 |
| Chen, XH; Zhao, HL | 1 |
| Easton, JD; Kim, AS | 1 |
| Backchine, S; Foussier, C; Gawlitza, M; Litré, CF; Manceau, PF; Pierot, L; Soize, S | 1 |
| Cheng, CI; Chung, WJ; Hsueh, SK; Lee, CH; Lin, CJ; Tsai, TH | 1 |
| Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, DS; Kim, JS; Ko, YG; Lee, H; Oh, SK; Park, J; Shin, DH | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Eikelboom, JW; Fan, Y; Li, C; Li, J; Mei, L; Niles, K; Wang, F; Xu, K; Yang, L; Zhang, J; Zhang, S; Zhu, H; Zou, F | 1 |
| Henriksson, R; Mooe, T; Söderström, L; Ulvenstam, A | 1 |
| Albertsson, P; Angerås, O; Dworeck, C; Erlinge, D; Haraldsson, I; Ioanes, D; Koul, S; Odenstedt, J; Omerovic, E; Persson, J; Petursson, P; Råmunddal, T; Redfors, B; Völz, S | 1 |
| Li, L; Long, M; Ye, Z | 1 |
| Angiolillo, DJ; Budaj, AJ; Cornel, JH; Franchi, F; Ghukasyan Lakic, T; Himmelmann, A; James, SK; Katus, HA; Keltai, M; Kontny, F; Lewis, BS; Storey, RF; Wallentin, L | 1 |
| Fan, ZG; He, SH; Ji, J; Tian, NL; Xu, B; Zhang, WL | 1 |
| Katoh, N; Kawasaki-Nagano, M; Masuda, K; Nakae, M; Nakagawa, H; Tamagawa-Mineoka, R; Wakabayashi, Y | 1 |
| Capodanno, D; Capranzano, P | 1 |
| Ahn, KT; Chae, SC; Cho, MC; Choi, SW; Choi, UL; Gwon, HC; Jeong, JO; Jeong, MH; Jin, SA; Kim, CJ; Kim, HS; Kim, JH; Kim, YJ; Lee, JH; Seong, IW; Seong, SW | 1 |
| Bilotta, F; Campo, G; Parodi, G; Pavasini, R; Serenelli, M; Tonet, E; Vitali, F | 1 |
| Adlam, D; Chang, CC; Chichareon, P; Édes, I; Garg, S; Hamm, C; Hildick-Smith, D; Jüni, P; Kogame, N; Krackhardt, F; Modolo, R; Onuma, Y; Rademaker-Havinga, T; Serruys, PW; Spitzer, E; Steg, PG; Takahashi, K; Tijssen, JGP; Tomaniak, M; van de Harst, P; Verheugt, FWA; Vranckx, P; Walsh, SJ | 1 |
| Hicks, GL | 1 |
| Chen, S; Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhou, S | 1 |
| Airaksinen, J; Biancari, F; Dalén, M; De Feo, M; Gatti, G; Gherli, R; Holm, M; Khodabandeh, S; Kinnunen, EM; Mariscalco, G; Maselli, D; Nicolini, F; Onorati, F; Perrotti, A; Reichart, D; Rosato, S; Rubino, AS; Ruggieri, VG; Santarpino, G; Santini, F; Zanobini, M | 1 |
| Averkov, O; Berwanger, O; Damiani, LP; de Barros E Silva, PGM; Fonseca, FA; Goodman, SG; Granger, CB; Guimaraes, HP; Jiang, L; Lopes, RD; Malaga, G; Miranda, TA; Moia, DDF; Nicholls, SJ; Nicolau, JC; Paisani, DM; Parkhomenko, A; Piegas, LS; Santos, RHN; Saraiva, JFK; Tajer, C; Valeis, N; White, HD | 1 |
| Araszkiewicz, A; Grajek, S; Grygier, M; Hengstenberg, C; Komosa, A; Krasiński, Z; Lesiak, M; Mitkowski, P; Mularek-Kubzdela, T; Olasińska-Wiśniewska, A; Pyda, M; Siller-Matula, JM; Siniawski, A; Skorupski, W | 1 |
| Chaitongrat, S; Lertsuwunseri, V; Mahachai, V; Pittayanon, R; Piyachaturawat, P; Prueksapanich, P; Rerknimitr, R; Srimahachota, S | 1 |
| Aggarwal, D; Bishnoi, A; Daroach, M; Panda, P; Parsad, D; Radotra, BD | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GYH; Mauri, L; Miede, C; Montalescot, G; Nordaby, M; Oldgren, J; Ozkor, M; Steg, PG; Ten Berg, JM; Vardas, P | 1 |
| Cao, X; Chen, X; Hu, W; Li, J; Liu, Z; Sun, Y; Xin, Y; Zhao, Y | 1 |
| Bonney, PA; Brinjikji, W; Walcott, BP; Yim, B | 1 |
| Angiolillo, DJ; Kalkman, DN; Mehran, R | 1 |
| Altındağ, R; Altıntaş, B; Baysal, E; Bilge, Ö; Burak, C; Ede, H; Karahan, MZ; Öztürk, Ö; Tanboğa, İH; Yaylak, B | 1 |
| Batista, DV; Feitosa, MPM; Lima, EG; Linhares Filho, JPP; Lobo Filho, HG; Serrano Júnior, CV; Soffiatti, CD | 1 |
| Angiolillo, DJ; Chan, KT; Del Aguila, M; Girotra, S; Han, Y; Huang, WC; Paek, D; Patti, G; Sibbing, D; Yakovlev, A | 1 |
| Azzalini, L; Li, L; Li, Y; Mao, Q; Tian, J; Tong, W; Xie, L; Zhao, X; Zheng, W; Zhou, D | 1 |
| Chang, K; Choi, IJ; Choo, EH; Chung, WS; Hwang, BH; Kim, CJ; Lee, JM; Lee, KY; Lim, S | 1 |
| Liu, R; Nie, S; Qin, X; Shaqdan, A; Wang, C; Wang, X; Yuan, L; Zhao, X; Zheng, W | 1 |
| Björklund, F; Henriksson, R; Mooe, T | 1 |
| Carriero, A; De Luca, G; Kedhi, E; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Tonon, F; Verdoia, M | 1 |
| Carrillo-Alemán, L; Esteve-Pastor, MA; Lozano, T; Macías-Villanego, MJ; Marín, F; Martínez, J; Orenes-Piñero, E; Pernías-Escrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Sandín-Rollán, M; Tello-Montoliú, A; Veliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Bo, WL; Feng, W; He, MJ; Li, S; Li, Y; Liu, GZ; Liu, YY; Shi, J; Sun, DH; Wang, WN; Wang, ZH; Zhang, CY; Zhang, S; Zheng, LQ | 1 |
| Abramson, BL; Berger, JS; Blomster, JI; Dombrowski, KE; Fowkes, FGR; Hiatt, WR; Jones, WS; Jordan, JD; Katona, BG; Kolls, BJ; Leiva-Pons, JL; Mahaffey, KW; Norgren, L; Patel, MR; Prieto, JC; Rockhold, FW; Sapp, S; Sokurenko, G | 1 |
| Ao, H; Liu, X | 1 |
| Åkerblom, A; Becker, RC; Cannon, CP; de Souza Brito, F; Himmelmann, A; James, SK; Katus, HA; Lopes, RD; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Hu, L; Jiang, HY; Li, ZZ; Xue, J; Yue, YH; Zhang, XG; Zhu, XQ | 1 |
| Audrone, V; Jurgaityte, J; Kupstyte-Kristapone, N; Lesauskaite, V; Norvilaite, R; Skipskis, V; Stuoka, M; Tamakauskas, V; Tatarunas, V | 1 |
| Brust, K; Garncarek, M; Jagas, J; Roleder, T; Witkiewicz, W | 1 |
| Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J | 1 |
| Calvert, PA; Doshi, SN; George, S; Giblett, JP; Hildick-Smith, D; Hodson, J; Khan, SQ; Kinnaird, T; Kwok, CS; Ludman, PF; Mamas, MA; Orzalkiewicz, M; Townend, JN | 1 |
| Aznaouridis, K; Georgakopoulos, C; Ioakeimidis, N; Koutouzis, M; Latsios, G; Pietri, P; Rigatou, A; Terentes-Printzios, D; Tousoulis, D; Toutouzas, K; Vaina, S; Vlachopoulos, C | 1 |
| Benedetto, U; Doble, B; Harris, J; Johnson, TW; Lasserson, D; Loke, Y; Mumford, A; Pithara, C; Pufulete, M; Redwood, S; Reeves, BC; Rogers, CA; Sterne, JAC; Wordsworth, S | 1 |
| Hengstenberg, C; Siller-Matula, JM | 1 |
| Andric, T; Haller, PM; Huber, K; Jäger, B; Kahl, BS; Piackova, E; Stojkovic, S; Vargas, KG; Wojta, J | 1 |
| Carriero, A; De Luca, G; Kedhi, E; Marcolongo, M; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Silverman, E | 1 |
| Jüni, P; Serruys, P; Valgimgli, M; Vranckx, P; Windecker, S | 1 |
| Martí, D; Sanmartín, M | 1 |
| Koroleva, LY; Korotaeva, ES; Kovaleva, GV; Kuzmenko, EA; Nosov, VP | 1 |
| Chunhacha, P; Fujise, K; Halim, H; Pinkaew, D; Sinthujaroen, P; Thiagarajan, P | 1 |
| Blažević, N; Jovanović, I; Ljevak, J; Poljaković, Z; Radoš, M; Starčević, K; Toljan, K | 1 |
| Al Sultan, AA; Almekhlafi, MA; Assis, Z; Goyal, M; Kashani, N; Podlasek, A | 1 |
| Wang, TKM; Wei, D | 1 |
| Alapati, V; Benson, MM; Brener, SJ; Chan, D; Cunn, G; Khan, S; Kutkut, I; Narayanan, CA; O'Laughlin, JP; Sacchi, TJ | 1 |
| Cho, MS; Kim, S; Kim, YJ; Nam, GB; Park, DW; Park, JJ; Park, K; Yun, JE | 1 |
| Farrokh, S; Hui, F; Lara, LR; Nault, K; Owusu, K; Spoelhof, B | 1 |
| Bernard, MP; Chen, YE; Christian, BD; Kuszynski, DS; Lauver, DA; Markham, BE; Teuber, JP; Zhang, H | 1 |
| Cavallari, LH; Lee, CR | 1 |
| Ding, LY; Li, XZ; Liu, Y | 1 |
| Andric, T; Haller, PM; Huber, K; Jäger, B; Piackova, E; Spittler, A; Stojkovic, S; Wisgrill, L; Wojta, J | 1 |
| Aradi, D; Hille, L; Leggewie, S; Nührenberg, TG; Schrör, K; Sibbing, D; Stratz, C; Trenk, D | 1 |
| Lüscher, TF | 1 |
| Boivin-Proulx, LA; Costa, F; Marquis-Gravel, G | 1 |
| Asselbergs, FW; Barbato, E; Bergmeijer, TO; Boersma, C; Claassens, DMF; de Boer, A; Deneer, VHM; Dewilde, WJM; Hermanides, RS; Herrman, JR; Janssen, PWA; Kelder, JC; Morisco, C; Mosterd, A; Postma, MJ; Ten Berg, JM; Tjon Joe Gin, RM; van 't Hof, AWJ; van der Harst, P; Vos, GJA | 1 |
| Cairns, JA; Cantor, WJ; Džavík, V; Jolly, SS; Kedev, S; Lavi, S; Meeks, B; Moreno, R; Sidhu, RS; Stankovic, G; Welsh, RC; Yuan, F | 1 |
| Cao, X; Li, JL; Liu, XJ; Xin, YG | 1 |
| Kheiri, B; Moreland, JA; Osman, K; Osman, M; Saleem, M; Sengupta, PP; Shigle, AJ | 1 |
| Basu, A; Carlson, JJ; Guzauskas, GF; Veenstra, DL | 1 |
| Intini, A; Sahadevan, J; Tsushima, T | 1 |
| Angiolillo, DJ; Capranzano, P | 2 |
| Açıkel, S; Aker, M; Algül, E; Çimen, T; Dural, M; Erat, M; Felekoğlu, MA; Guliyev, İ; Sunman, H; Tulmaç, M | 1 |
| Armstrong, DG; Caro, J; Clavijo, LC; Dhillon, AS; Rowe, V; Shavelle, DM; Tun, H | 1 |
| Goto, S | 1 |
| Biancari, F; Dalén, M | 1 |
| Bongiovanni, D; Cassese, S; Kastrati, A; Nowak, B; Schunkert, H; Stritzke, J; Tebbe, U; von Scheidt, M; Zhao, Q; Zhu, Y | 1 |
| Wang, P; Wang, XZ; Yao, Y; Zhang, L; Zhao, W; Zhao, X; Zhou, TN | 1 |
| Jiang, J; Li, C; Shen, X; Sun, Y; Tao, M; Wang, DW; Wang, Y; Yan, J; Ye, H; Yu, B; Yu, T; Zeng, H; Zhang, L | 1 |
| Baumgartner, I; Berger, JS; Blomster, JI; Fowkes, FG; Hiatt, WR; Huang, Z; Jones, WS; Kansal, A; Katona, B; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Biolè, C; Blanco, PF; Boccuzzi, G; Cequier, A; Correia, L; D'Amico, M; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fabrizio, U; Fernández, MC; Fujii, T; Gallo, D; Garay, A; Gili, S; González-Juanatey, JR; Grosso, A; Grossomarra, W; Henriques, JPS; Huczek, Z; Iñiguez-Romo, A; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Lopez-Cuenca, A; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Nie, SP; Nuñez-Gil, I; Paz, RC; Peyracchia, M; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Saglietto, A; Taha, S; Usmiani, T; Velicki, L; Wilton, SB; Xanthopoulou, I | 1 |
| Gimbel, ME; Kelder, JC; Nguyen, TA; Ten Berg, JM; Vos, GJA | 1 |
| Cao, B; Fu, Q; Gao, C; Jiang, C; Liu, X; Ma, Q; Qu, F; Wei, P | 1 |
| Alam, M; Bandeali, S; Chan, PS; Hamzeh, I; Hira, R; Jones, PG; Khalid, U; Kleiman, NS; Lakkis, N; Virani, SS | 1 |
| Doukas, D; Schimmer, H; Zehtabchi, S | 1 |
| Colombo, A; Marchese, A; Resta, F; Tito, A | 1 |
| Cui, H; Dai, J; Hunt, SL; Jain, N; Mahnken, JD; Mehta, JL; Phadnis, MA; Rasu, RS; Shireman, TI | 1 |
| Bolognese, L; Cantor, WJ; Cequier, Á; Chettibi, M; Collet, JP; Diallo, A; Ecollan, P; Fabris, E; Goodman, SG; Hamm, CW; Hammett, CJ; Hermanides, RS; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Merkely, B; Montalescot, G; Silvain, J; Storey, RF; Tavenier, AH; Ten Berg, JM; van 't Hof, AWJ; Vicaut, E; Willems, FF; Zeymer, U | 1 |
| Pinto, DS; Sharma, RK | 1 |
| Airaksinen, J; Hasvold, P; Khanfir, H; Kytö, V; Prami, T; Reissell, E | 1 |
| Baumgartner, I; Berger, JS; Blomster, JI; Fowkes, FGR; Hiatt, WR; Huang, Z; Jones, WS; Katona, BG; Mahaffey, KW; Mehta, R; Norgren, L; Patel, MR; Povsic, TJ; Rockhold, FW; Vemulapalli, S; Ward, R | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Jansky, P; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Seung, KB; Steg, PG; Ten Berg, JM; Zateyshchikov, DA | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Biolè, C; Biondi-Zoccai, G; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; Conrotto, F; Correia, L; D'Ascenzo, F; De Ferrari, GM; Dominguez-Rodriguez, A; Durante, A; Fabrizio, U; Fernández, MC; Fujii, T; Gaido, F; Gallo, D; Garay, A; Gili, S; González-Juanatey, JR; Grosso, A; Henriques, JPS; Huczek, Z; Iñiguez-Romo, A; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Nie, SP; Nuñez-Gil, I; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rettegno, S; Rognoni, A; Song, X; Stone, GW; Taha, S; Templin, C; Valdés, M; Velicki, L; Wilton, SB; Xanthopoulou, I | 1 |
| Liao, YWB; Wang, TKM | 1 |
| Budnik, M; Dignat-George, F; Eyileten, C; Filipiak, KJ; Gasecka, A; Harrison, P; Lacroix, R; Leroyer, A; Nieuwland, R; Opolski, G; Pluta, K; Postuła, M; Siljander, P; Siller-Matula, JM; van der Pol, E | 1 |
| Caballero-Jambrina, I; Diarte-de Miguel, JA; Fuertes-Ferre, G; Jimeno-Sánchez, J; Ortas-Nadal, MR; Ruiz-Aranjuelo, A | 1 |
| Dalén, M | 1 |
| Ahn, JH; Ahn, Y; Hong, YJ; Hur, SH; Hwang, JY; Jeong, MH; Kim, JH; Kim, MC; Oh, SK; Seong, IW; Sim, DS; Yoon, JH | 1 |
| Achilli, F; Avalli, L; Bozzano, A; Calchera, I; Camisasca, P; Colombo, V; Lettino, M; Maggioni, E; Mauro, A; Montemerlo, E; Righetti, S; Sala, D; Soffici, F | 1 |
| Gorog, DA; Gue, YX; Kanji, R; Srinivasan, M; Wellsted, DM; Wyatt, S | 1 |
| Fu, G; Huang, Y; Ji, X; Jia, Z; Sun, J | 1 |
| Andò, G; Trio, O | 1 |
| Daiber, A; Gori, T; Jurk, K; Koenig, J; Lackner, KJ; Münzel, T; Schnorbus, B; Warnke, S | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Kastrati, A; Schüpke, S | 1 |
| Graham, MM; Har, B; James, MT; Koshman, SL; Turgeon, RD; Wilton, SB; Youngson, E | 1 |
| Gao, L; Geng, L; Guo, W; Li, H; Li, J; Wan, Q; Wang, X; Wang, Y; You, J; Zhang, Q | 1 |
| Claeys, MJ; De Luca, L; Dörler, J; Erne, P; Jukema, JW; Lüscher, TF; Matter, CM; Radovanovic, D; Weidinger, F; Zeymer, U | 1 |
| Colombo, A; Gallo, F; Giannini, F; Khokhar, AA; Laricchia, A; Mangieri, A; Sticchi, A | 1 |
| Han, Y; Jiang, Z; Li, Y; Li, Z; Ma, S; Song, H; Yu, P | 1 |
| Angioli, P; Bolognese, L; Ducci, K; Falsini, G; Liistro, F; Porto, I; Ventoruzzo, G; Vergallo, R | 1 |
| Al-Badriyeh, D; AlMukdad, S; Elewa, H | 1 |
| Jeong, YJ; Kim, YD; Park, K | 1 |
| Beitelshees, AL; Cavallari, LH; Diaby, V; Dillon, C; Duarte, JD; Empey, PE; Garbett, S; Gong, Y; Graves, J; Hillegass, WB; Holmes, AM; Johnson, JA; Lee, CR; Limdi, NA; Peterson, JF; Pisu, M; Skaar, TC; Zhou, Z | 1 |
| Chen, W; Liu, L; Meng, X; Pan, Y; Wang, Y; Yang, Y | 1 |
| Dingemanse, J; Schilling, U; Ufer, M | 1 |
| Aurigemma, C; Borovac, JA; Buffon, A; Burzotta, F; Canonico, F; Ceccarelli, I; Crea, F; D'Amario, D; Flex, A; Franceschi, F; Francese, F; Galli, M; Leone, AM; Limbruno, U; Migliaro, S; Montone, RA; Niccoli, G; Porto, I; Restivo, A; Tinelli, G; Trani, C; Vergallo, R | 1 |
| Carrabba, N; De Gregorio, MG; Giusti, B; Gori, AM; Marchionni, N; Marcucci, R; Migliorini, A; Paniccia, R; Valenti, R; Vergara, R | 1 |
| Antman, EM; Huang, S; Neely, M; Ohman, EM; Roe, MT; Sun, MT; Wallentin, L; Wiviott, SD; Wong, CX | 1 |
| Álvarez-Antón, S; Carballeira, D; Concepción, R; Dejuán-Bitriá, C; Del Castillo, H; Delgado-Calva, FA; López-Soberón, E; Marschall, A; Martí, D; Morales, MJ; Palazuelos, J; Pérez-Guzmán, J | 1 |
| Cang, H; He, M; Li, J; Li, Y; Liu, G; Mu, H; Shi, J; Sun, D; Wang, J; Wang, W; Xu, M; Zhang, C; Zhang, H; Zhang, Z; Zhao, C; Zhao, S | 1 |
| Ferlini, M; Galvani, M; Visconti, LO | 1 |
| Cui, CS; Hou, AJ; Luan, B; Luo, DF; Meng, QK; Tao, J; Wang, CF; Wang, Y; Zhang, XJ; Zhao, HW; Zhu, Y | 1 |
| Bergmeijer, TO; Claassens, DMF; Deneer, VHM; Hermanides, RS; Hinrichs, DL; Tavenier, AH; Ten Berg, JM; van 't Hof, AWJ; Vos, GJA | 1 |
| Chai, M; Liang, J; Liu, W; Liu, X; Xi, Z; Yu, Y; Zhao, Y; Zhou, Y | 1 |
| Ajjan, RA; Naseem, KM; Sagar, RC | 1 |
| Hugenberg, DW; Kreutz, RP; Mshelbwala, FS | 1 |
| Butala, NM; Faridi, KF; Garratt, KN; Kennedy, KF; Maddox, TM; Secemsky, EA; Yeh, RW | 1 |
| Si, LY; Su, Y; Wang, Z; Xu, Q; Zhou, DY | 1 |
| Li, O; Xu, W; Zhang, B; Zhang, N | 1 |
| den Uil, CA; Mandigers, L; Rietdijk, WJR | 1 |
| Basu, A; Branch, KR; Carlson, JJ; Suh, K | 1 |
| Jeong, MH; Johnson, TW; Kim, Y | 1 |
| Chen, F; Chen, ZQ; Li, L | 1 |
| Park, DW; Park, SJ | 1 |
| Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS | 1 |
| Akhtar, IN; Akinci, Y; French, B; Gao, X; Jahngir, MU; Kraus, J; Liaqat, J; Lobanova, I; Qualls, K; Qureshi, AI; Ramiro Gomez, C; Siddiq, F; Uzun, G | 1 |
| He, M; Kong, Y; Li, Y; Liu, G; Shi, J; Sun, D; Yan, W; Yuan, Y; Zhang, Y | 1 |
| Baldetti, L; Beneduce, A; Calvo, F; Capodanno, D; Cappelletti, AM; D'Ascenzo, F; De Ferrari, GM; Gallone, G; Godino, C; Gramegna, M; Melillo, F; Moroni, F; Pagnesi, M; Venuti, A | 1 |
| Ai, G; Gu, C; Han, Y; Hao, Y; Liu, Y; Qiu, M; Wang, X; Xu, P; Yang, X; Zhang, J; Zhang, L; Zhao, D; Zhao, X; Zhou, M | 1 |
| Gwak, HS; Lee, N; Seong, JM; Yoon, HY | 1 |
| Chen, S; Jiang, J; Wu, Q; Wu, X; Wu, Z; Yan, H; Ye, F; You, W | 1 |
| Gevaert, SA; Sinnaeve, PR | 1 |
| Bergmeijer, T; de Vrey, E; den Hartog, F; Deneer, V; Gimbel, M; Heestermans, T; Hermanides, R; Hofma, S; Jukema, W; Kelder, J; Qaderdan, K; Ten Berg, J; Tjon Joe Gin, M; von Birgelen, C; Voskuil, M; Waalewijn, R; Willemsen, L | 1 |
| Black, RM; Crona, DJ; Lee, CR; Ratner, L; Stouffer, GA; Weck, KE; Williams, AK; Wiltshire, T | 1 |
| Allou, N; Allyn, J; Brulliard, C; Caron, M; Charpentier, T; Cordier, C; Emery, M; Ferdynus, C; Lair, T; Valance, D | 1 |
| Hsieh, MH; Hsieh, YC; Huang, CY; Lin, YK; Liu, JC; Wang, CA; Yeh, JS | 1 |
| Cannata, F; Cao, D; Chiarito, M; Condorelli, G; De Caterina, R; Ferrante, G; Godino, C; Panico, C; Regazzoli, D; Reimers, B; Sanz-Sánchez, J; Stefanini, GG; Sturla, M | 1 |
| Ahtarovski, KA; Engstrøm, T; Ghotbi, AA; Göransson, C; Høfsten, DE; Kelbæk, H; Kyhl, K; Køber, L; Lønborg, J; Nepper-Christensen, L; Sabbah, M; Sadjadieh, G; Schoos, MM | 1 |
| Athanasiou, A; Iliopoulos, DC; Paschou, SA; Siasos, G; Spartalis, E; Spartalis, M; Tzatzaki, E; Voudris, V | 1 |
| Huynh, K | 1 |
| Dabus, G; Linfante, I; Ravipati, K; Reyes, D; Starosciak, AK | 1 |
| Atar, S; Bernaud, C; Fahrni, G; Frenoux, JM; Hmissi, A; Moccetti, T; Mueller, C; Schelfaut, D; Sinnaeve, P; Spirito, A; Ufer, M; Valgimigli, M | 1 |
| Bonello, L; Burtey, S; Canault, M; Cayla, G; Laine, M; Lemesle, G; Paganelli, F; Pankert, M; Puymirat, E; Quaino, G; Range, G | 1 |
| De Luca, G; Khedi, E; Suryapranata, H; Verdoia, M | 1 |
| Al Faraidy, KA; Al-Ali, AK; Al-Mansori, MA; Al-Muhanna, FA; Al-Rubaish, AM; Alali, RA; Alshehri, AM; Asselbergs, FW; Claassens, DMF; Cyrus, C; Khalil, RM; Sulieman, MM; Ten Berg, JM; Vatte, C | 1 |
| Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP | 1 |
| Cimino, S; Cirillo, P; Coscioni, E; Esposito, G; Ferrone, M; Gargiulo, G; Giugliano, G; Ilardi, F; Morisco, C; Paolillo, R; Perrino, C; Schiattarella, GG; Stabile, E; Verde, N | 1 |
| Che, JJ; Chen, KY; Liu, T; Rha, SW; Tao, HY; Wang, JR; Wang, P; Wang, WD; Wang, XW; Xu, LX; Xue, ZK; Zhang, YR | 1 |
| Kwan, YH; Lin, YY; Png, WY; Tan, DS; Wee, HL; Wee, JW; Wong, XY | 1 |
| Li, D; Li, X; Shen, S; Wu, H; Xiang, X | 1 |
| Murphy, SA; O'Donoghue, ML; Sabatine, MS | 1 |
| Antonucci, E; Calabrò, P; Cavallari, I; Cesaro, A; Cirillo, P; Gaudio, C; Gragnano, F; Gresele, P; Ielasi, A; Marcucci, R; Moscarella, E; Pafundi, PC; Palareti, G; Patti, G; Pelliccia, F; Pengo, V; Pignatelli, P; Sasso, FC | 1 |
| Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Yan, H; Zhao, H; Zhou, J; Zhou, P | 1 |
| Chen, Q; Li, D; Lu, C; Wang, C; Wang, S; Wang, Y; Wang, Z; Xu, T; Xuan, H; Zhang, H; Zhang, Y | 1 |
| Ahuja, N; Baker, MC; Robinson, WH; Rohatgi, N; Weng, Y | 1 |
| Choi, WG; Kim, DW; Kim, GC; Kim, HY; Lee, CH | 1 |
| Berghold, A; Mahla, E; Pregartner, G; Schoerghuber, M; Seitelberger, R; Toller, W; Voetsch, A | 1 |
| Cheung, BMY; Fei, Y; Feng, Q; Li, HL; Tsoi, MF | 1 |
| Chen, R; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P | 1 |
| Choi, YH; Deppe, AC; Gerfer, S; Liakopoulos, O; Schlachtenberger, G; Wahlers, TCW; Zeriouh, M | 1 |
| De Servi, S; Landi, A | 1 |
| Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H | 1 |
| Clopton, P; Giang, K; Penny, WF; Stallings, HE; Stubbs, MK | 1 |
| Hu, Z; Jing, Y; Li, X; Lv, Q; Seybert, A; Wang, J; Wu, H; Xie, X; Xue, Y | 1 |
| Abraham, NS; Herrin, J; Inselman, J; Ngufor, C; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yang, EH; Yao, X | 1 |
| Bergmark, BA | 1 |
| Albertsson, P; Angerås, O; Dworeck, C; Haraldsson, I; Hirlekar, G; Ioanes, D; Myredal, A; Odenstedt, J; Omerovic, E; Petursson, P; Råmunddal, T; Redfors, B; Völz, S | 1 |
| AbdElghany, M; El-Abhar, HS; Mohareb, MW; Zaki, HF | 1 |
| Banai, S; Hershkoviz, R; Isakov, O; Lupu, L; Shepshelovich, D | 1 |
| Anastasiou, I; Goudevenos, J; Hahalis, G; Hamilos, M; Kanakakis, J; Karvounis, C; Koutouzis, M; Michalis, L; Raisakis, K; Stakos, D; Tsiafoutis, I; Vardas, P; Vasilikos, V | 1 |
| Ahn, Y; Chang, K; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Kim, CJ; Kim, HY; Kim, MC; Park, CS; Park, MW; Seung, KB; Yoo, KD | 1 |
| Atmaca, Y; Erol, Ç; Esenboga, K; Göksülük, H; Ozyuncu, N; Tan, TS | 1 |
| Chang, CJ; Chang, SH; Kuo, CT; Liu, JR; See, LC; Tung, YC | 1 |
| De Servi, S; Landi, A; Savonitto, S | 1 |
| Åkerblom, A; Aukrust, P; Becker, RC; Gregersen, I; Halvorsen, B; Himmelmann, A; James, SK; Johansen, HT; Kontny, F; Lakic, TG; Lindbäck, J; Lunde, NN; Michelsen, AE; Ryeng Skagen, K; Siegbahn, A; Skjelland, M; Solberg, R; Storey, RF; Ueland, T; Wallentin, L | 1 |
| Graham, MM; Turgeon, RD; Youngson, E | 1 |
| Abbott, JD; Bae, JH; Bailey, K; Baudhuin, L; Bell, M; Cagin, C; Chavez, I; Farkouh, ME; Fu, YP; Geller, N; Goodman, SG; Gordon, P; Hasan, A; Iturriaga, E; Jeong, MH; Lennon, R; Lerman, A; Mathew, V; Pereira, NL; Rihal, C; Rosenberg, Y; Sidhu, M; So, D; Tanguay, JF; Wang, L; Weinshilboum, R; Welsh, R | 1 |
| Gremmel, T; Hoberstorfer, T; Kopp, CW; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C | 1 |
| Disney, BR; McFarlane, M | 1 |
| He, H; Zhou, T | 1 |
| Alfredsson, J; Erlinge, D; Hofmann, R; Jernberg, T; Lindahl, B; Montez-Rath, ME; Ravn-Fischer, A; Svensson, P; Szummer, K | 1 |
| Gao, R; Guo, T; Li, J; Li, Y; Qiao, S; Qiu, H; Tang, Y; Wang, Y; Xu, B; Yan, L; Yang, Y; Zheng, J | 2 |
| De Luca, G; Fierro, N; Gioscia, R; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Sagazio, E; Tonon, F; Verdoia, M | 1 |
| Elgendy, IY | 1 |
| Kelsey, MD; Newby, LK | 1 |
| Bangalore, S; Bhalla, N; Bhandary, DD; DeRita, R; Diercks, DB; Frost, A; Heitner, JF; Johnson, C; Khan, ND; Peacock, WF; Pollack, CV; Rao, SV; Silber, SH | 1 |
| Ang, YK; De Silva, DA; Narasimhalu, K; Tan, DSY; Tan, KB | 1 |
| Adamson, PD; Loganath, K; Moss, AJ | 1 |
| Bath, PM; Xiong, Y | 1 |
| Fu, ML; Li, YY; Luo, LM; Pang, ZQ; Tu, L; Xu, XZ | 1 |
| Zhao, J | 1 |
| Baumgartner, I; Berger, JS; Blomster, JI; Fowkes, FG; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, K; Mulder, H; Narcisse, DI; Norgren, L; Patel, MR; Rockhold, F; Rymer, JA | 1 |
| Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Wali, M; Zenni, MM | 1 |
| Granger, CB; Nanna, MG | 1 |
| Ahmed, SH; Benitez, RM; Hartzell, SA; Kalich, BA; Lusk, KA | 1 |
| Bates, ER | 1 |
| Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC | 1 |
| Gao, M; Hou, YL; Jia, XM; Ma, LP; Ren, MY; Wang, JR; Zhang, M; Zhang, P; Zhang, Y | 1 |
| Al-Khalidi, HR; Baumgartner, I; Berger, JS; Blomster, JI; Fowkes, FGR; Hiatt, WR; Jones, WS; Katona, BG; Kochar, A; Lopes, RD; Mahaffey, KW; Mulder, H; Norgren, L; Patel, MR; Rockhold, FW | 1 |
| Lee, CH; Lee, NY; Li, YH; Lin, HW; Lin, SH | 1 |
| Beygui, F; Blanchart, K; Boccara, F; Boueri, Z; Brunel, P; Cayla, G; Collet, JP; Dillinger, JG; Ducrocq, G; Dumaine, R; El Kasty, M; Guedeney, P; Kala, P; Labeque, JN; Laredo, M; Larrieu-Ardilouze, E; Lattuca, B; Lhermusier, T; Montalescot, G; Motovska, Z; Pouillot, C; Rangé, G; Silvain, J; Vicaut, E | 1 |
| Bhatt, DL; Cannon, CP; Costa, F; Hohnloser, SH; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Valgimigli, M | 1 |
| Baek, JW; Heo, YJ; Jeong, HW; Jin, SC; Kim, HJ; Kim, JS; Kim, SB; Kim, SH; Kim, ST; Lee, H; Park, JH | 1 |
| Aranganathan, P; Balasundaram, R; Boopathi, A; Rangan, A; Wilson, B | 1 |
| Li, FL; Liu, M; Ma, L | 1 |
| Jamali, HK; Khan, S; Kheiri, B; Osman, M; Saleem, M; Waqar, F | 1 |
| Baumann, M; Dingemanse, J; Dobrow, M; Juif, PE; Riederer, MA; Schilling, U; Ufer, M | 1 |
| Corbett, SJ; Ftouh, S; Lewis, S; Lovibond, K | 1 |
| Chen, Y; Wang, B; Wang, W; Wei, S | 1 |
| Chan, MYY; Kim, JH; Tan, DS | 1 |
| Chen, WT; Chien, LN; Hsieh, YC; Hsu, CY; Huang, CY; Yeh, JS | 1 |
| Fang, W; Gou, X; Hou, K; Li, F; Li, Y; Lv, N; Xu, D | 1 |
| Al-Badriyeh, D; AlMukdad, S; Arafa, S; Elewa, H | 1 |
| Liuzzo, G; Patrono, C | 1 |
| Altun, S; Çetinbaş, A; Okur, Mİ; Özercan, İ; Öztan, M; Yıldız Altun, A | 1 |
| Han, Y; Li, J; Li, X; Li, Y; Ma, S; Na, K; Qi, Z; Qiu, M | 1 |
| Jeong, YH; Kim, HK; Kubica, J | 1 |
| Gupta, A; Krumholz, HM; You, SC | 1 |
| Beasley, M; Brown, TM; Cai, A; Clarkson, SA; Dillon, C; Heindl, B; Limdi, N | 1 |
| Chen, W; Dang, H; Hou, H; Li, Y; Xiao, Q; Xu, X; Zhang, C; Zhao, J | 1 |
| Alfredsson, J; Desta, L; Erlinge, D; Hagström, E; Jernberg, T; Lindahl, B; Mellbin, L; Nilsson, J; Omerovic, E; Szummer, KE; Träff, E; Venetsanos, D; Zwackman, S | 1 |
| Asselbergs, FW; Barbato, E; Bergmeijer, TO; Claassens, DMF; Deneer, VHM; Dewilde, WJM; Hermanides, RS; Herrman, JR; Janssen, PWA; Kelder, JC; Mahmoodi, BK; Morisco, C; Mosterd, A; Ten Berg, JM; Tjon Joe Gin, RM; van 't Hof, AWJ; van der Harst, P; Vos, GJA | 1 |
| Fajar, JK; Heriansyah, T; Ilmawan, M; Mahdi, BA; Mahendra, AI; Mazen, M; Pikir, BS; Purnamasari, Y; Rohman, MS; Tamara, F; Yamin, M | 1 |
| Cho, JY; Lee, SY; Oh, SK; Yun, KH | 1 |
| Kakouros, N; Kassas, I; Rade, J; Soueid, AE | 1 |
| Charytan, DM; Kamal, O; Mavrakanas, TA | 1 |
| Dong, Z; Pan, L; Zhai, H; Zhang, B | 1 |
| Aggarwal, S; Ali, T; Ding, WY; Elamin, A; Fisher, M; Grainger, R; Hasara, J; Heseltine, T; Kasolo, Y; Khand, A; Kirmani, BH; Meah, MN; Mullen, L; Obeidat, M; Patel, B; Rashid, M; Shahzad, A; Shaw, M; Thatchil, J | 1 |
| Borrelli, C; Emdin, M; Gentile, F; Giannoni, A; Mirizzi, G; Passino, C | 1 |
| Jneid, H; Kamran, H; Kayani, WT; Khalid, U; Levine, GN; Nambi, V; Virani, SS | 1 |
| Asselbergs, FW; Barbato, E; Bergmeijer, TO; Claassens, DMF; de Vrey, EA; den Hartog, FR; Deneer, VHM; Dewilde, W; Gimbel, ME; Heestermans, TACM; Hermanides, RS; Herrman, JR; Hofma, SH; Jukema, JW; Mahmoodi, BK; Morisco, C; Mosterd, A; Ten Berg, JM; Tjon Joe Gin, RM; van der Harst, P; Van't Hof, AWJ; von Birgelen, C; Vos, GJA; Voskuil, M; Waalewijn, RA | 1 |
| Che, J; Chen, K; Dou, S; Liu, H; Liu, X; Wang, W; Wang, X; Zhang, X; Zhou, X | 1 |
| Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G | 1 |
| Barbieri, L; De Luca, G; Verdoia, M | 1 |
| Clemmensen, P; Desch, S; Dudek, D; Feistritzer, HJ; Freund, A; Fuernau, G; Geisler, T; Haller, P; Hausleiter, J; Huber, K; Kleeberger, J; Massberg, S; Montalescot, G; Neumer, A; Noc, M; Orban, M; Ouarrak, T; Schneider, S; Thiele, H; Zeymer, U | 1 |
| Bae, JW; Cho, DK; Choi, SH; Gwon, HC; Hahn, JY; Jeong, JO; Oh, JH; Park, YH; Rha, SW; Song, PS; Song, YB | 1 |
| Bierer, J; Bisleri, G; Cartier, A; Dagher, O; Dhingra, NK; Eikelboom, R; Forgie, K; Kirubaharan, A; Luc, J; Makhdoum, A; Vaillancourt, O; Verma, S; Vo, TX; Yanagawa, B; Yau, TM | 1 |
| Lam, ASM; Lee, VWY; Yan, BPY | 1 |
| Gaudino, M; Sandner, S | 1 |
| Baumgartner, I; Berger, JS; Blomster, JI; DeVore, AD; Fowkes, FGR; Hellkamp, A; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Samsky, MD | 1 |
| Hsieh, KP; Hwang, SJ; Li, YS; Wang, SH; Yang, YH | 1 |
| Eskola, M; Hautamäki, M; Hernesniemi, J; Lehtimäki, T; Lyytikäinen, LP; Nikus, K; Oksala, N; Tynkkynen, J | 1 |
| Barbato, E; Barthélémy, O; Bauersachs, J; Bhatt, DL; Böhm, M; Collet, JP; Cornel, JH; Crea, F; Dendale, P; Dorobantu, M; Edvardsen, T; Ferreiro, JL; Folliguet, T; Frey, N; Gale, CP; Giannitsis, E; Gilard, M; Hamm, CW; Huber, K; James, S; Jobs, A; Jüni, P; Kubica, J; Lambrinou, E; Lewis, BS; Mehilli, J; Mehran, R; Meliga, E; Merkely, B; Morais, J; Mueller, C; Navarese, EP; Roffi, M; Rutten, FH; Sibbing, D; Siontis, GCM; Storey, RF; Thiele, H; Valgimigli, M; Vranckx, P | 1 |
| Abou Jaoude, P; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X | 1 |
| Cong Luu, T; Le Phuong, T; Manh Pham, H; Mellstrom, C; Quang Nguyen, T; Thi Thu Nguyen, T; Van Do, D; Van Hoang, S | 1 |
| Bastos-Fernandez, G; Baz-Alonso, JA; Cruz-González, I; De Miguel-Castro, A; Fernández-Barbeira, S; Figueiras-Guzman, A; Iñiguez-Romo, A; Jimenez-Diaz, VA; Molina-Navarro, E; Moreno, R; Ortiz-Saez, A; Paredes-Galán, E; Romaguera, R; Salvadores, PJ; Tello-Montoliu, A; Trejo-Velasco, B | 1 |
| Bliden, KP; Dahlen, J; Fisher, R; Gurbel, PA; Speros, PC; Sukavaneshvar, S; Tantry, US | 1 |
| Becker, RC; Chan, MY; Grenier, JC; Hussin, JG; Jolicœur, EM; Lopes, RD; Lordkipanidzé, M; Mehanna, P; Neely, ML; Newby, LK; Ruiz, M; Samman, KN; Takla, E; Wang, TY | 1 |
| Franke, K; Hochholzer, W; Kille, A; Leibundgut, G; Neumann, FJ; Nührenberg, T; Tsimikas, S; Valina, CM | 1 |
| Adamczak, S; Blatt, T; Brzezicki, G; Chalouhi, N; Dodd, WS; Geh, N; Ghosh, R; Gooch, MR; Goutnik, M; Hoh, B; Laurent, D; Polifka, AJ; Porche, K; Small, C | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solè, A; Bianco, M; Biolè, CA; Boccuzzi, G; Careggio, A; Cerrato, E; Correia, L; D'Ascenzo, F; De Ferrari, GM; Destefanis, P; Dominguez-Rodriguez, A; Durante, A; Fujii, T; Gonzàlez Juanatey, JR; Henriques, JPS; Huczek, Z; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Luciano, A; Manzano-Fernàndez, S; Montagna, L; Morbiducci, U; Nie, SP; Nunez-Gil, I; Quadri, G; Quiros, A; Raposeiras-Roubin, S; Rognoni, A; Song, X; Spirito, A; Templin, C; Ugo, F; Varbella, F; Velicki, L; Wilton, SB | 1 |
| Case, BC; Doros, G; Medranda, GA; Waksman, R; Weintraub, WS; Yerasi, C; Zhang, C | 1 |
| Flahive, J; Fraielli, K; Gill, K; Servati, N | 1 |
| Arévalos, V; Brugaletta, S; Caballero-Borrego, J; Gil-Jimenez, T; Gomez-Hospital, JA; Gomez-Lara, J; Moreno-Terribas, G; Ortega-Paz, L; Oyarzabal, L; Rodriguez-Arias, JJ; Romaguera, R; Sabate, M; Teruel, L | 1 |
| Chang, CJ; Chang, SC; Juang, HT; Lee, CK; Lin, DS; Pan, HY; Wang, TD | 1 |
| Aznaouridis, K; Bei, E; Iakovou, I; Kalantzis, C; Kalogeras, K; Katsianos, E; Kosmas, E; Leucker, TM; Moldovan, CM; Oikonomou, E; Papaioannou, TG; Siasos, G; Stasinopoulou, M; Tountopoulou, A; Tousoulis, D; Toutouzas, K; Vavuranakis, M; Vavuranakis, MA; Voudris, V; Vrachatis, D | 1 |
| Agid, R; Hilario, A; Kortman, H; Kostynskyy, A; Krings, T; Nicholson, P; Ozaki, T; Park, KY; Pereira, VM | 1 |
| Butt, JH; Engstrøm, T; Fosbøl, EL; Gislason, G; Glinge, C; Holmvang, L; Jabbari, R; Jacobsen, MR; Køber, L; Pedersen, F; Sørensen, R; Torp-Pedersen, C | 1 |
| Cao, X; Li, X; Zhang, G | 1 |
| Deng, L; Jia, HZ; Li, MC; Zhu, W | 1 |
| Abusnina, W; Al-Abdouh, A; Alshebani, Y; Bizanti, A; Dahal, K; Gill, G; Houssien, A; Kanmanthareddy, A | 1 |
| Bainey, KR; Leung, R; Shavadia, JS; Tyrrell, BD; Welsh, RC; Zheng, Y | 1 |
| Han, J; Li, W; Lin, B; Lin, Y; Peng, W; Shi, X; Wang, Y; Yan, J; Zhang, Y; Zheng, Z | 1 |
| Adali, MK; Buber, I; Kilic, O; Turkoz, A; Yilmaz, S | 1 |
| Baumgartner, I; Berger, JS; Blomster, JI; Fowkes, FGR; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Mulder, H; Norgren, L; North, R; Patel, MR; Rockhold, FW | 1 |
| Benit, E; Diletti, R; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; Mc Fadden, EP; Odutayo, A; Onuma, Y; Räber, L; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Windecker, S | 1 |
| Bartuś, S; Cyran-Stemplewska, S; Januszek, R; Kręcisz, B; Siudak, Z; Zabojszcz, M | 1 |
| Aronow, HD; Barbour, M; Belviso, N; Don, PK; Kogut, S; Lawal, OD; Wen, X; Wyss, R; Zhan, SY; Zhang, Y | 1 |
| Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD | 1 |
| Gasecka, A; Jaguszewski, MJ; Malysz, M; Pruc, M; Rafique, Z; Szarpak, L | 1 |
| Lyu, SQ; Shao, XH; Wang, J; Wu, S; Yang, YM; Zhang, H; Zhu, J | 1 |
| Cheung, BMY; Cheung, CL; Fei, Y; Feng, Q; Tsoi, MF | 1 |
| Abbas, KS; Abdelazeem, B; Adhikari, G; Baral, N; El-Shahat, NA; Hassan, M; Khan, H; Shehata, J | 1 |
| Jim, J; Liang, P; Marcaccio, CL; Patel, PB; Rastogi, V; Schermerhorn, ML; Schneider, PA; Stangenberg, L | 1 |
| Jo, S; Jo, YS; Kim, SJ; Moon, H; Park, K | 1 |
| Makhdom, F; Menezes, RG; Motiani, V; Naeem, U; Nizam, MA; Ram, P; Rizwan, T; Shahid, I; Siddiqi, TJ; Usman, MS | 1 |
| Camargo, LM; Janot, K; Lima, PCTM; Maldonado, IL | 1 |
| Chan, YH; Chang, CJ; Chang, SH; Kuo, CT; Liu, JR; See, LC; Tung, YC | 1 |
| Bath, PM; Chang, L; Dong, Q; Feng, Y; Jiang, Y; Jing, J; Johnston, SC; Li, G; Li, H; Li, W; Li, Z; Lin, J; Liu, L; Man, H; Meng, X; Niu, S; Pan, Y; Wang, A; Wang, B; Wang, L; Wang, Y; Xie, X; Xu, A; Xu, J; Zhao, J; Zhao, X; Zhuang, X | 1 |
| Ahn, Y; Choi, DH; Gwon, HC; Hwang, JY; Jeong, MH; Ki, YJ; Kim, HK; Kim, HS; Kim, SS; Koh, YY; Park, KH; Rha, SW | 1 |
| Han, Y; He, P; Huang, L; Jin, J; Li, J; Li, Y; Luo, X; Wang, X | 1 |
| Chen, CC; Chen, CT; Chien, SC; Hsieh, PC; Liu, YT; Liu, ZH; Wang, AY; Wang, YC; Yeap, MC | 1 |
| Andersen, M; Linder, M | 1 |
| Luijkx, J; van 't Hof, A; Winkler, P | 1 |
| Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Zitikyte, G | 1 |
| Alaamri, S; Dalbhi, SA | 1 |
| Chen, Y; Li, D; Li, L; Sun, Y; Wang, D; Ye, X | 1 |
| Chang, H; Ghamraoui, AK; Maldonado, TS; Ricotta, JJ | 1 |
| Go, YI; Kim, GW | 1 |
| Ferro, A; Passacquale, G; Perera, D; Sharma, P | 1 |
| Abu-Assi, E; Bruno, F; Cerrato, E; Chieffo, A; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; De Filippo, O; Dominguez-Rodriguez, A; Elia, E; Gallone, G; Henriques, JPS; Iannaccone, M; Kinnaird, T; Leonardi, S; Liebetrau, C; Manzano-Fernández, S; Omedè, P; Patti, G; Piroli, F; Raposeiras-Roubin, S; Wańha, W | 1 |
| Chen, S; Han, Y; Li, J; Li, X; Li, Y; Ma, S; Na, K; Qi, Z; Qiu, M | 1 |
| Ahmad, H; Bandyopadhyay, D; Chakraborty, S; Chaturvedi, A; Combs, WG; Gupta, R; Mahajan, P; Malik, AH; Mehta, SS; Patel, NC; Sreenivasan, J; Vyas, AV; Yandrapalli, S; Zaid, S | 1 |
| Atassi, B; Baumann Kreuziger, L; Berger, JS; Berry, S; Bochicchio, G; Cheng, Y; Cushman, M; de Oliveira Antunes, M; Farkouh, ME; Gong, MN; Greenstein, Y; Hade, EM; Hochman, JS; Hudock, K; Hyzy, R; Khatri, P; Kim, KS; Kindzelski, A; Kirwan, BA; Kornblith, LZ; Lawler, PR; Leifer, E; Lopes, RD; Lopez-Sendon Moreno, J; Lopez-Sendon, J; Luther, JF; McVerry, BJ; Neal, MD; Nigro Maia, L; Quigley, J; Reynolds, HR; Sherwin, R; Wahid, L; Wilson, J | 1 |
| Chen, S; Han, Y; Jiang, Z; Li, J; Li, Y; Ma, S; Na, K; Qi, Z; Qiu, M | 1 |
| Abu-Assi, E; Bianco, M; Bo, M; Breviario, S; Bruno, F; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; de Filippo, O; Elia, E; Iannaccone, M; Manai, R; Patti, G; Raposeiras-Roubin, S; Wańha, W | 1 |
| Schäfer, A | 1 |
| Bai, N; Ma, Y; Niu, Y; Shang, YS; Wang, ZL; Zhong, PY | 1 |
| Bergh, N; Myredal, A; Nivedahl, P; Petzold, M; Wallerstedt, SM; Wartenberg, C; Zarin, S | 1 |
| Abbott, JD; Aronow, H; Bavishi, C; Heinl, RE; Hyder, ON; Kadiyala, V; Kah, MO; Kennedy, KF; Lang, WR; Long, S; Mitsuyama, R; Ovide, G; Sharma, E; Wark, T; Williams, MU | 1 |
| Akin, I; Bernlochner, I; Cassese, S; Gewalt, S; Hemetsberger, R; Ibrahim, T; Joner, M; Kastrati, A; Kufner, S; Lahu, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Sager, HB; Schunkert, H; Schüpke, S; Valina, C; Witzenbichler, B; Wöhrle, J; Xhepa, E | 1 |
| Friebel, J; Hassanein, A; Jakobs, K; Landmesser, U; Puccini, M; Rauch, C; Rauch, U | 1 |
| Aguiar, MO; Azevedo, L; Baracioli, LM; Berwanger, O; Chiang, HP; Dalcoquio, TF; de Luca, F; Ferrari, AG; Furtado, RHM; Giugliano, RP; Goodman, S; Lima, FG; Matthias, W; Menezes, FR; Nicolau, JC; Scanavini-Filho, MA | 1 |
| Joundi, RA | 1 |
| Bach, RG | 1 |
| Ip, A; Lau, KK; Ng, AK; Ng, PY; Siu, CW | 1 |
| Dong, Y; Graham, MM; Koshman, SL; Turgeon, RD | 1 |
| Cui, Y; Gong, Y; Jiang, J; Liu, Z; Ma, L; Mu, G; Xiang, Q; Xie, Q; Zhang, Z; Zhou, S | 1 |
| Alraies, MC; Cuisset, T; Faisaluddin, M; Fischman, DL; Khalil, F; Pasha, AK; Rao, SV; Sabouret, P; Sandhyavenu, H; Savage, MP; Ullah, W; Zahid, S | 1 |
| Angelini, F; Baldetti, L; Bocchino, PP; Chieffo, A; Conrotto, F; D'Ascenzo, F; de Ferrari, GM; DE Filippo, O; DE Lio, G; Melillo, F; Montefusco, A; Omedè, P; Piroli, F; Saglietto, A | 1 |
| Berghold, A; Lindenau, I; Mahla, E; Pregartner, G; Schoerghuber, M; Voetsch, A; Zirlik, A; Zweiker, R | 1 |
| Angiolillo, DJ; Bass, TA; Been, L; Franchi, F; Galli, M; Geisler, T; Jaoude, PA; Jennings, LK; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X | 1 |
| Li, X; Lv, Q; Wang, Z; Xia, L; Yao, Y; Ye, Y; Zou, Y | 1 |
| French, JK; Juergens, CP; Kadappu, K; Leung, DY; Lo, S; Mussap, CJ; Nguyen, P; Premawardhana, U; Rajaratnam, R; Xu, J | 2 |
| Han, X; He, M; Kong, Y; Li, Y; Liu, G; Ren, J; Shi, J; Yan, W; Zhang, Y; Zhao, Z | 1 |
| Liu, S; Shah, J; Yu, W | 1 |
| An, HJ; He, YY; Li, S; Sheng, XY; Ye, YF; Zhao, JL | 1 |
| Ding, H; Guo, L; Huang, R; Meng, S; Wang, J; Wu, S; Ye, Z | 1 |
| Doundoulakis, I; Farmakis, IT; Giannakoulas, G; Karagiannidis, E; Karvounis, H; Kassimis, G; Michalis, LK; Moysidis, DV; Pagiantza, A; Stalikas, N; Zafeiropoulos, S | 1 |
| Grisafi, L; Mennuni, M; Patti, G; Rognoni, A; Spinoni, EG | 1 |
| D Tangonan, R; Guterman, L; Kass-Hout, O; Kass-Hout, T; Morsi, RZ; Stern, J; Thind, S | 1 |
| Chilbert, MR; Denny, O; Mills, K; Woodruff, AE | 1 |
| Andréka, P; Bársony, G; Ferenci, T; Jánosi, A; Szabóné Póth, A; Vajer, P | 1 |
| Arnous, S; Arockiam, S; Coughlan, JJ; Kiernan, TJ; Suleiman, S | 1 |
| Averkov, O; Berwanger, O; Brass, N; Cantor, WJ; Damiani, LP; Dehghani, P; Goodman, SG; Granger, CB; Lavi, S; Lopes, RD; Lutchmedial, S; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Parkhomenko, A; Piegas, LS; Tajer, CD; Tan, M; White, HD | 1 |
| Chen, C; Chen, Z; Gu, X; Liu, W; Mao, X; Ren, S; Tao, L; Zhang, L; Zhao, Y | 1 |
| Amos, D; Brieger, D; Chew, DP; Hou, M; Hyun, K; Kritharides, L | 1 |
| Angiolillo, DJ; Bhatt, DL; Davidson-Ray, L; Dell'Anna, C; Diaz, M; Edwards, L; El-Sabae, H; Garratt, KN; Ohman, EM; Rymer, JA; Salahuddin, K; Tasissa, G; Waksman, R; Wang, TY; Washam, JB | 1 |
| Baumgartner, I; Berger, JS; Blomster, J; Bonaca, MP; Fowkes, FGR; Hess, C; Hsia, J; Jones, WS; Katona, B; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Szarek, M | 1 |
| Hu, F; Qi, G; Wang, P; Xing, Y; Yang, J; Zhang, X | 1 |
| Chanfreau-Coffinier, C; Dong, OM; Friede, KA; Voora, D | 1 |
| Bath, PM; Chen, G; Huang, P; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, F; Wang, Y; Xie, X; Zhao, X; Zuo, Y | 1 |
| Cao, Z; Dong, S; Guo, S; Liu, G; Shen, J; Sheng, L; Sun, X; Tian, Y; Wu, G | 1 |
| Lin, J; Qin, Q; Xie, C; Zhu, J | 1 |
| Liu, J; Liu, X; Suo, M; Wang, Y; Wang, Z; Wu, X; Yang, N; Zhang, X; Zhao, D | 1 |
| Deneer, VHM; Gimbel, ME; Ten Berg, JM; van den Broek, WWA; van Paassen, JG; Vreman, RA | 1 |
| Bath, PM; Cheng, J; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, Y; Wang, Z; Xie, X; Yang, H; Zhao, X | 1 |
| D'Oria, M; Lepidi, S | 1 |
| Demchuk, AM; Jahn, B; Menon, BK; Micieli, A; Siebert, U; Singh, N | 1 |
| Anastasiou, I; Hamilos, M; Kochiadakis, G; Lazopoulos, G; Pagonidis, K; Petousis, S; Skalidis, E; Vardas, P; Zacharis, E | 1 |
| Peng, F; Xu, B; Xuan, M; Yan, L; Yu, Z; Zhou, Y | 1 |
| Adar, A; Akbay, E; Akıncı, S; Çoner, A; Müderrisoğlu, H | 1 |
| Caminiti, G; Muscoli, S; Perrone, MA; Pradhan, A; Salimei, C; Sethi, R; Tiwari, A | 1 |
| Chen, W; Guo, L; Jiang, L; Liu, L; Pan, Y; Wang, Y; Xu, Y; Yao, D; Zhao, X | 1 |
| Abrahams, T; Brown, A; Pol, D | 1 |
| Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C | 1 |
| Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC | 1 |
| Conner, CM; Hashim, SW; Ingrassia, JJ; Loya, DS; Mather, JF; McKay, RG; McMahon, SR; Mosleh, W; Sutton, TS; Takata, ET; Yaffee, DW | 1 |
| Chen, B; Chen, J; Chen, Y; Chen, Z; Liang, J; Liu, X; Tang, L; Tu, S; Xia, J | 1 |
| Al-Sayaghi, KM; Albadrani, MS; Alotaibi, YA; Elhusein, AM; Fadlalmola, HA; Hussein, MK; Mamanao, DM; Masada, HK; Mohamedsalih, WE | 1 |
| Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B | 1 |
| de Borst, GJ; Hannink, G; Kramers, K; Maas, DPMSM; Mees, BME; Reijnen, MMPJ; Riksen, NP; Ten Cate, H; van der Vijver-Coppen, RJ; Warlé, MC; Willems, LH; Zeebregts, CJ | 1 |
| Calderone, D; Capodanno, D; Scalia, L | 1 |
| Damasceno, NRT; Fonseca, FAH; Izar, MC; Lotfollahi, Z; Machado, LO; Mathias, AF; Mello, APQ; Neto, AMF; Oliveira, CLP | 1 |
| Angiolillo, DJ; Been, L; Franchi, F; Galli, M; Rollini, F; Zenni, MM | 1 |
| Gao, R; Gao, Y; Guo, T; Li, J; Qiu, H; Qiu, Z; Wang, Y; Xi, Z; Zheng, J | 1 |
| Li, X; Lv, Q; Wang, Z; Xia, L; Xu, Q; Yao, Y; Ye, Y; Zou, Y | 1 |
| Han, X | 1 |
| Beohar, N; Escolar, E; Gazzhal, A; Gjergjindreaj, M; Ibrahim, M; Lacy, SC; Perez, J; Saint Croix, G; Shehadeh, M; Torres, C; Vedantam, K | 1 |
| Al-Hindi, L; Dai, J; Hedayati, SS; Jain, N; Martin, BC; Mehta, JL; Phadnis, MA; Rasu, RS; Shireman, TI | 1 |
| Boytsov, SA; Erlikh, AD; Kukava, NG; Pevsner, DV; Rytova, YK; Shakhnovich, RM; Tereschenko, SN | 1 |
| Alfredsson, J; Alpkvist, K; Sederholm Lawesson, S; Skibniewski, M; Träff, E; Venetsanos, D; Zwackman, S | 1 |
| DE Luca, G; Gioscia, R; Kedhi, E; Nardin, M; Rognoni, A; Suryapranata, H; Verdoia, M | 1 |
| Moustafa, B; Testai, FD | 1 |
| Kanny, O; Khan, H; Qadura, M; Syed, MH | 1 |
| Chen, W; Jiang, T; Li, C; Ling, L; Liu, M | 1 |
| Han, K; Huang, X; Ma, M; Sun, T; Yang, S; Zhao, Z; Zhou, Y | 1 |
| Baryshnikova, E; Di Dedda, U; Giannetta, M; Mazzaccaro, D; Milani, V; Nano, G; Ranucci, M; Righini, P | 1 |
| Batra, G; Becker, RC; Harrington, RA; Held, C; James, SK; Kempf, T; Lindbäck, J; Lopes, RD; Mahaffey, KW; Siegbahn, A; Steg, PG; Storey, RF; Swahn, E; Wallentin, L; Wollert, KC | 1 |
| Lin, J; Xie, C; Zhang, Y | 1 |
| Allen, JM; Angiolillo, DJ; Beitelshees, AL; Cavallari, LH; Coons, JC; Duarte, JD; Empey, PE; Franchi, F; Giri, J; Gong, Y; Johnson, JA; Kreutz, RP; Lee, CR; Lee, JC; Limdi, NA; McDonough, CW; Skaar, TC; Stevenson, JM; Stouffer, GA; Thomas, CD; Tuteja, S | 1 |
| Alexopoulos, D; Benetou, DR; Dragona, VM; Kanakakis, I; Kintis, K; Lianos, I; Mantis, C; Patsilinakos, S; Sionis, D; Varlamos, C | 1 |
| Ahn, Y; Chang, K; Choi, IJ; Choo, EH; Hwang, BH; Jeon, DS; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Lim, S; Moon, D; Park, MW; Seok Choi, Y; Yoo, KD | 1 |
| Kim, HH; Yoo, KJ; Youn, YN | 1 |
| Chyrchel, B; Kruszelnicka, O; Surdacki, A | 1 |
| Farley, JF; Kumar, A; Lutsey, PL; Rajpurohit, A; Schommer, JC; St Peter, WL; Van't Hof, JR | 3 |
| Li, X; Lin, Y; Peng, W; Zhang, Y | 1 |
| Fonarow, GC; Ge, J; Han, Y; Hao, Y; Huo, Y; Liu, J; Ma, C; Morgan, L; Smith, JSC; Yang, N; Zhao, D | 1 |
| Ding, LP; Do, HP; Ge, WH; Li, YC; Liu, T; Shao, TF; Wang, R; Xu, MM; Yi, MM; Zhuang, Z | 1 |
| Bath, PM; Cao, M; Chen, W; Jiang, Y; Jing, J; Li, H; Li, J; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, F; Wang, Y; Xie, X; Xu, J; Zhao, X; Zuo, Y | 1 |
| Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X | 1 |
| Cavallari, LH; Lee, CR; Thomas, CD; Williams, AK | 1 |
| Li, X; Lv, Q; Wang, Z; Xu, S; Yao, Y | 1 |
| Barreau, X; Berge, J; Cagnazzo, F; Collemiche, FL; Costalat, V; Dargazanli, C; Derraz, I; Ferreira, I; Gariel, F; Gascou, G; Lefevre, PH; Marnat, G; Papaxanthos, J; Radu, RA; Riquelme, C | 1 |
| Dangas, G; Dasgupta, S; Feng, Y; Giustino, G; Hooda, A; Khera, S; Kini, AS; Koshy, AN; Krishnamoorthy-Melarcode, P; Kumar, KR; Mehran, R; Sartori, S; Serrao, GW; Sharma, R; Sharma, SK; Snyder, C; Sweeny, J | 1 |
| Aldica, M; Anchidin, OI; Blendea, D; Moldovan, H; Molnar, A; Nemes, A; Pop, D; Rosianu, SH | 1 |
| Arthur, JM; Arulprakash, N; Corken, A; Dai, J; Davis, O; Hedayati, SS; Jain, N; Mehta, JL; Phadnis, MA; Rahmatallah, Y; Smyth, S; Ware, J | 1 |
| Baron, SJ; Dani, SS; Ganatra, S; Ijaz, SH; Kulbak, G; Levy, M; Resnic, F; Shahnawaz, A | 1 |
| Gentry, CA; Kliewer, BS; Thind, SK; Whitman, CM; Williams, RJ | 2 |
| Cazzola, M; Hanania, NA; Matera, MG; Rogliani, P | 1 |
| Jing, J; Li, H; Li, Z; Liu, H; Meng, X; Wang, A; Wang, Y; Xu, Q | 1 |
| Ahn, Y; An, M; Cho, K; Hong, Y; Jeong, MH; Kim, J; Kim, Y | 1 |
| Atar, D; Gurvich, ML; Marciniak, TA; Serebruany, VL; Tanguay, JF | 1 |
| Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J | 1 |
| Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S | 1 |
| Cavallari, LH; Franchi, F | 1 |
| An, L; Lei, M; Li, C; Li, Y; Sun, X; Wang, J; Xue, Z; Yang, Y; Zhao, Z | 1 |
| Bektasoglu, G; Dogan, Z; Yurtdas, M | 1 |
| Jia, S; Wu, H | 1 |
| Brown, JD; Cavallari, LH; Thomas, CD; Wang, Y; Winterstein, AG | 1 |
| Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P | 1 |
| He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L | 1 |
| Angiolillo, DJ; Bhatt, DL; Franchi, F; Giordano, S; Ortega-Paz, L; Pollack, CV; Rollini, F | 1 |
| De Caterina, R | 1 |
| Bai, J; Chen, Y; Dong, P; Gong, X; Hua, R; Ke, Y; Li, C; Liu, K; Wang, Q; Wang, X; Wu, T; Xiao, J; Ying, L; Zhang, B; Zhang, J; Zhang, W; Zhang, X; Zhu, L | 1 |
| Leon, SJ; Shah, AH; Tangri, N; Whitlock, R; Wiens, EJ | 1 |
| Mantri, N; McNulty, E; Mutyala, R; Sachdeva, A; Solomon, M; Zhu, S | 1 |
| Alfredsson, J; Erlinge, D; James, S; Jernberg, T; Lindahl, B; Mohammad, MA; Omerovic, E; Szummer, K; Tjerkaski, J; Venetsanos, D | 1 |
| Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Xu, Q; Zhao, X | 1 |
| Gao, A; Gao, R; Gao, Y; Lu, Q; Qiu, H; Wang, Y; Xi, Z | 1 |
| Briasoulis, A; Fujisaki, T; Kuno, T; Latib, A; Misumida, N; Takagi, H | 1 |
| Ghani, A; Haider, J; McKay, R; Nagle, C; Patail, H; Rizvi, A | 1 |
| Bhushan, DB; Nair, PK; Wagh, HD | 1 |
| Alex, AG; Attumalil, TV; Dave, RG; Geevar, T; George, P; Gowri, SM; Joseph, G; Mony, PK; Nair, SC; Perla, HT; Thomson, VS | 1 |
| Charlot, MG; Engstrøm, T; Freeman, P; Glinge, C; Grove, EL; Holmvang, L; Jabbari, R; Jacobsen, MR; Kelbæk, H; Køber, L; Maeng, M; Pedersen, F; Sørensen, R; Torp-Pedersen, C; Veien, K | 1 |
| An, L; Hau, WK; Lei, M; Li, Y; Nie, S; Wang, J; Wang, X; Xue, Z; Yang, Y; Zhao, Z; Zhou, H | 1 |
| Han, Y; Li, J; Li, P; Li, Y; Liu, H; Na, K; Qi, Z; Qiu, M; Wang, B; Xu, K; Zhou, H | 1 |
| Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X | 1 |
| Benedetto, U; Doble, B; Harris, J; Hopewell-Kelly, N; Johnson, T; Lasserson, D; Loke, Y; Mahadevan, K; Mumford, A; Pithara, C; Pouwels, KB; Pufulete, M; Redwood, S; Reeves, B; Rogers, C; Sterne, J; Wordsworth, S | 1 |
| Al-Roub, NM; Almarzooq, ZI; Kinlay, S | 1 |
| Ge, P; Guo, Y; Li, Z; Xiao, J; Xie, L | 1 |
| Buranakiti, B; Chotayaporn, T; Phrommintikul, A; Ueapornpanith, P; Yoodee, V | 1 |
| Bath, PM; Claiborne Johnston, S; Jiang, Y; Jing, J; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X | 1 |
| Abdalkader, M; Bath, PM; Detaram, HD; Dhillon, PS; Harrington, T; Krishnan, K; Ma, A; Nguyen, TN; Podlasek, A; Qiu, Z; Qureshi, AI; Siopis, G; Steinfort, B | 1 |
| Ge, F; Li, M; Lin, H; Shi, J; Yang, Q; Zhang, X | 1 |
| Abaci, O; Barman, HA; Bulat, Z; Dogan, O; Kılıçarslan, O; Kocas, C; Mirzayev, K; Yildiz, A; Yumuk, MT | 1 |
| Bangalore, S; Bhatt, DL; Cuisset, T; Deharo, P; Fujisaki, T; Kohsaka, S; Kuno, T; Mehran, R; Shoji, S; Stone, GW; Takagi, H; Ueyama, H; Watanabe, A | 1 |
| Chen, HC; Chen, TY; Fang, CY; Fang, HY; Fang, YN; Hsieh, YY; Lee, WC; Tsai, YH; Wu, PJ | 1 |
| Cai, Y; Chen, Z; He, Y; Li, C; Zhang, J | 1 |
| Chen, W; Fu, K; Li, X; Qiu, X | 1 |
| Chang, YM; Lee, TL; Sung, PS | 1 |
| Gao, ST; Ma, L; Wang, Y | 1 |
| Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ | 1 |
| Burgess, SN; Figtree, GA; Graham, MM; Kinnaird, T; Kontopantelis, E; Ludman, P; Mamas, MA; Rashid, M; Sharp, ASP; Shoaib, A | 1 |
| Ahn, JM; Cha, SJ; Jang, MH; Kang, DY; Kim, AR; Kim, JH; Kim, S; Kim, T; Kim, TO; Lee, J; Lee, JH; Lee, PH; Lee, YJ; Oh, HJ; Park, DW; Park, SJ | 1 |
| Bessette, LG; Cervone, A; Cheng, S; Glynn, RJ; Kim, DH; Ko, D; Lee, SB; Lin, KJ; Pande, A | 1 |
| Jovanovic, M; Sabovic, M | 1 |
| Bath, PM; Jia, W; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Xie, X; Xu, Q; Zhang, X; Zhao, X | 1 |
| Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Wang, CC; Wu, CH | 1 |
| Liu, C; Ma, L | 1 |
254 review(s) available for clopidogrel and ticagrelor
| Article | Year |
|---|---|
Strategies for targeting the P2Y
Topics: Central Nervous System; Ligands; Microglia; Platelet Aggregation; Receptors, Purinergic P2Y12; Signal Transduction | 2022 |
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Humans; Membrane Proteins; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2007 |
ADP receptor antagonism: what's in the pipeline?
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2007 |
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2008 |
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2009 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Animals; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Vasoconstriction | 2009 |
Advances in antiplatelet treatment for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor | 2010 |
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
State of the art of new P2Y12 antagonists.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
The year in interventional cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Foramen Ovale, Patent; Hospital Mortality; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Radiology, Interventional; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom | 2010 |
New antithrombotic agents--insights from clinical trials.
Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor: a novel oral antiplatelet agent.
Topics: Adenosine; Administration, Oral; Aged; Clopidogrel; Drug Approval; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Ticagrelor: from discovery to Phase III clinical trial.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Clinical Trials, Phase III as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Standard of Care; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
[Coronary heart disease - what is of importance after coronary intervention?].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Current options to manage clopidogrel poor responsiveness].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
[Myocardial infarction: Role of new antiplatelet agents].
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors | 2011 |
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Ticagrelor for acute coronary syndrome?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Female; Genetic Association Studies; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Interactions; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2011 |
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Drug Interactions; Genotype; Humans; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine | 2011 |
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
P2Y12 platelet inhibition in clinical practice.
Topics: Adenosine; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
A comprehensive comparative review of adenosine diphosphate receptor antagonists.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
InforMatrix: ADP antagonists in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Information Services; Drugs, Generic; Evidence-Based Medicine; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO.
Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Perioperative management of antiplatelet agents in patients undergoing cardiac surgery.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Ticlopidine | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
[Platelet function: new drugs, new assays : possible impacts on operative medicine?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Predictive Value of Tests; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Advances in the monitoring of anti-P2Y12 therapy.
Topics: Adenosine; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Thienopyridines and other ADP-receptor antagonists.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Review of ticagrelor in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2012 |
Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine | 2012 |
New anti-platelet agents: the end of resistance?
Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Why does ticagrelor induce dyspnea?
Topics: Adenosine; Clopidogrel; Dyspnea; Humans; Models, Biological; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sensory Receptor Cells; Ticagrelor; Ticlopidine | 2012 |
A critical overview on ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Double-Blind Method; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
The discovery of a new class of synaptic transmitters in smooth muscle 50 years ago and amelioration of coronary artery thrombosis.
Topics: Adenosine; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; History, 20th Century; Humans; Muscle, Smooth; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; Ticagrelor; Ticlopidine | 2013 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
[Novel agents for antithrombotic therapy in cardiology].
Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2012 |
Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications.
Topics: Adenosine; Blood Loss, Surgical; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Surgical Procedures, Operative; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions].
Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
New antiplatelet agents for cardiovascular disease.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2013 |
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
Topics: Acute Lung Injury; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Sulfonamides; Ticagrelor; Ticlopidine; Transfusion Reaction | 2014 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases | 2014 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors.
Topics: Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Reduction Behavior; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Role of phenotypic and genetic testing in managing clopidogrel therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Genetic Testing; Humans; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[Dual platelet inhibitors in intensive care units].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Humans; Hypothermia, Induced; Intensive Care Units; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Risk Assessment; Shock, Cardiogenic; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
Topics: Adenosine; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Research Design; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction.
Topics: Adenosine; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Survival Analysis; Ticagrelor; Ticlopidine | 2015 |
Practical experience with ticagrelor: an Australian and New Zealand perspective.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
Topics: Adenosine; Clopidogrel; Early Medical Intervention; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review.
Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Humans; Kidney Failure, Chronic; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
Topics: Acute Coronary Syndrome; Adenosine; Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2015 |
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.
Topics: Adenosine; Adult; Aged; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Stents; Ticagrelor; Ticlopidine | 2016 |
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Glomerular Filtration Rate; Hemorrhage; Humans; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Renal Insufficiency; Ticagrelor; Ticlopidine | 2015 |
On-treatment platelet reactivity: State of the art and perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Sex Factors; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges.
Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopidogrel; Colonic Neoplasms; Drug Therapy, Combination; Female; Humans; Lactones; Male; Mice; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neoplastic Cells, Circulating; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Factors; Species Specificity; Ticagrelor; Ticlopidine; Time Factors | 2015 |
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Transcatheter Aortic Valve Replacement | 2016 |
Type 2 Diabetes and ADP Receptor Blocker Therapy.
Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Antiplatelet therapy - a summary for the general physicians.
Topics: Adenosine; Clopidogrel; General Practitioners; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2016 |
Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Ticagrelor; Ticlopidine | 2016 |
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Topics: Adenosine; Antithrombins; Bayes Theorem; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Evidence-Based Medicine; Hirudins; Humans; Markov Chains; Monte Carlo Method; Network Meta-Analysis; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recombinant Proteins; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review.
Topics: Adenosine; Administration, Oral; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
[Subgroup analysis results of platelet inhibition trial in acute coronary syndrome patients (PLATO) who underwent intervention or medical treatment].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2013 |
Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Drug Interactions; Esomeprazole; Gastrointestinal Hemorrhage; Gene Expression; Humans; Hydrogen-Ion Concentration; Peptic Ulcer; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2017 |
Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; History, 20th Century; History, 21st Century; History, Ancient; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor; Ticlopidine | 2016 |
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Arylsulfonates; Aspirin; Clopidogrel; Disease Management; Humans; Nurse Practitioners; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2017 |
[Management of the bleeding risk associated with antiplatelet agents].
Topics: Adenosine; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
[Antiplatelet agents and transfusion].
Topics: Adenosine; Antidotes; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine | 2017 |
Role of genetic testing in patients undergoing percutaneous coronary intervention.
Topics: Adenosine; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Testing; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2018 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Failure | 2017 |
A Primer on Bleeding Risk and Management Strategies of Newer Oral Anti Platelet Agents in Cardiovascular Disease.
Topics: Adenosine; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Differences in relative and absolute effectiveness of oral P2Y
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Sex Characteristics; Ticagrelor; Treatment Outcome; Young Adult | 2018 |
Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: A meta-analysis.
Topics: Adenosine; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Asia; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2018 |
Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stents; Ticagrelor | 2018 |
Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Observational Studies as Topic; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Registries; Ticagrelor | 2018 |
Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Biotransformation; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Resistance; Humans; Myocardial Infarction; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome | 2019 |
Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Asia, Eastern; Asian People; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticagrelor; Treatment Outcome | 2018 |
Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Ticagrelor; Treatment Outcome | 2018 |
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.
Topics: Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Stroke; Survival Analysis; Thrombolytic Therapy; Ticagrelor | 2018 |
Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-anal
Topics: Clopidogrel; Humans; Observational Studies as Topic; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Ticagrelor | 2018 |
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Humans; Observational Studies as Topic; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2018 |
Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; France; Hemorrhage; Humans; Odds Ratio; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Survival Analysis; Ticagrelor; Treatment Outcome | 2018 |
Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: A systematic review and Meta-Analysis (2007-2017).
Topics: Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Ticagrelor; Ticlopidine | 2018 |
Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Ticagrelor; Treatment Outcome | 2018 |
Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y
Topics: Clopidogrel; Gastrointestinal Hemorrhage; Humans; Odds Ratio; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2019 |
Optimising antiplatelet utilisation in the acute care setting: a novel threshold for medical intervention in suspected acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Humans; London; Monte Carlo Method; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Time Factors | 2019 |
Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Observational Studies as Topic; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Ticagrelor | 2019 |
Drug eruption due to prasugrel hydrochloride: A case report and mini-review.
Topics: Aged, 80 and over; Clopidogrel; Desensitization, Immunologic; Drug Eruptions; Drug Substitution; Female; Glucocorticoids; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Skin; Skin Tests; Ticagrelor | 2019 |
Switching between P2Y
Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Cardiovascular Diseases; Clinical Decision-Making; Clopidogrel; Drug Substitution; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome | 2019 |
Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Safety; Ticagrelor; Treatment Outcome | 2019 |
Effectiveness and Safety of Platelet ADP -P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta-Analysis.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cigarette Smoking; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2019 |
Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis.
Topics: Acute Coronary Syndrome; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Humans; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Survival Analysis; Ticagrelor; Time Factors | 2019 |
Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice.
Topics: Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Stroke; Ticagrelor | 2019 |
De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Hospitalization; Humans; Patient Discharge; Prevalence; Ticagrelor | 2019 |
Acute Carotid Stent Thrombosis in an Ultrarapid Clopidogrel Metabolizer: Case Report and Literature Review.
Topics: Acute Disease; Administration, Intravenous; Angiography, Digital Subtraction; Angioplasty, Balloon; Carotid Stenosis; Clopidogrel; Computed Tomography Angiography; Cytochrome P-450 CYP2C19; Drug Substitution; Eptifibatide; Genotype; Humans; Male; Middle Aged; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Risk Factors; Stents; Thrombectomy; Thrombosis; Ticagrelor; Treatment Outcome | 2019 |
Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Self Expandable Metallic Stents; Ticagrelor; Treatment Outcome | 2020 |
Neuro-Interventional Use of Oral Antiplatelets: A Survey of Neuro-Endovascular Centers in the United States and Review of the Literature.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome; United States | 2021 |
Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options.
Topics: Administration, Oral; Antibodies, Monoclonal; Blood Platelets; Broadly Neutralizing Antibodies; Cardiology; Clopidogrel; Hemadsorption; Hemorrhage; Hemostasis; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk; Signal Transduction; Thrombosis; Ticagrelor | 2019 |
Ticagrelor after pharmacological thrombolysis in patients with ST-segment elevation myocardial infarctions: insight from a trial sequential analysis.
Topics: Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor | 2019 |
Syncope After Percutaneous Coronary Intervention.
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Stenosis; Drug Substitution; Drug-Eluting Stents; Electrocardiography; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Complications; Syncope; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor | 2020 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin | 2020 |
Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Heart Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticagrelor | 2020 |
Efficacy and Safety of Potent Oral P2Y
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
Topics: Acute Coronary Syndrome; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Costs; Humans; Patient Selection; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Ticagrelor; Treatment Outcome | 2020 |
Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor.
Topics: Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Dual Anti-Platelet Therapy; Eye Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2020 |
Antiplatelet therapies in diabetes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Primary Prevention; Secondary Prevention; Thrombosis; Ticagrelor | 2020 |
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
The risk of dyspnea in patients treated with third-generation P2Y
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Dyspnea; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticagrelor; Young Adult | 2020 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor | 2020 |
Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine | 2020 |
Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Ticagrelor; Time Factors; Treatment Outcome | 2021 |
Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Withholding Treatment | 2020 |
Efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Off-Label Use; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
Risk of infections in patients treated with ticagrelor vs. clopidogrel: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Antiplatelet Therapy in Elderly Patients with Acute Coronary Syndromes: the Clopidogrel Revenge: Possible Reasons for a Bright Comeback.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Dual Anti-Platelet Therapy; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2021 |
Antiplatelet Therapy for Transient Ischemic Attack and Minor Stroke.
Topics: Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Risk Assessment; Secondary Prevention; Severity of Illness Index; Ticagrelor | 2020 |
Meta-Analysis Comparing Ticagrelor or Prasugrel Versus Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention.
Topics: Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta-analysis.
Topics: Clopidogrel; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thrombosis; Ticagrelor | 2021 |
Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticagrelor | 2020 |
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis.
Topics: Aspirin; Bayes Theorem; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Ticagrelor resistance: a case series and algorithm for management of non-responders.
Topics: Algorithms; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stents; Ticagrelor | 2022 |
Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Early Medical Intervention; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Mortality; Platelet Aggregation Inhibitors; Proportional Hazards Models; Secondary Prevention; Ticagrelor | 2021 |
The Function and Regulation of Platelet P2Y12 Receptor.
Topics: Blood Platelets; Clopidogrel; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor | 2023 |
Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2022 |
De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of Oral P2Y12 Inhibitors in Older Patients with Acute Coronary Syndrome: A Frequentist Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives.
Topics: Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Ticagrelor; Warfarin | 2022 |
Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Ischemic Attack, Transient; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Ticagrelor | 2022 |
Risk of bleeding with ticagrelor in elderly patients over 75 years old: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Saudi Arabia; Ticagrelor; Treatment Outcome | 2021 |
Antiplatelet therapy in cardiovascular disease: Current status and future directions.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2022 |
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Asian People; Clopidogrel; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor as Part of Dual Antiplatelet Therapy in Acute Coronary Syndrome-A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Ticagrelor | 2023 |
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2022 |
High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Dyspnea; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Comparative efficacy and safety of oral P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2022 |
Safety and Efficacy of Selective, Clopidogrel-Based Strategies in Acute Coronary Syndrome: A Study-Level Meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2022 |
A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2022 |
Efficacy and Safety of Ticagrelor in East Asian Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Asian People; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Treatment Outcome | 2022 |
Efficacy of ticagrelor compared to clopidogrel in improving endothelial function in patients with coronary artery disease: a systematic review.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor; Vitamin K | 2022 |
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2022 |
Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Ticagrelor; Treatment Outcome | 2022 |
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2022 |
Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy.
Topics: Anticoagulants; Aspirin; Clopidogrel; Factor X; Humans; Platelet Aggregation Inhibitors; Point-of-Care Testing; Rivaroxaban; Ticagrelor; Vascular Diseases | 2022 |
Pharmacogenetics of P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Utilization Trends In Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor and Cost Among Medicare Beneficiaries.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Humans; Medicare; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; United States | 2023 |
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Regression Analysis; Rivaroxaban; Stroke; Ticagrelor | 2023 |
Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab.
Topics: Acute Coronary Syndrome; Antibodies, Monoclonal; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2023 |
P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticagrelor; Treatment Outcome | 2023 |
Antiplatelet Therapy in Neurointervention.
Topics: Clopidogrel; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2023 |
Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Network Meta-Analysis; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Humans; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor | 2023 |
The effect of ticagrelor on coronary microvascular function after PCI in patients with ACS compared to clopidogrel: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Microcirculation; Percutaneous Coronary Intervention; Ticagrelor | 2023 |
Clinical Updates on Antiplatelet Therapy for Secondary Prevention in Acute Ischemic Stroke.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticagrelor | 2023 |
Refractory drug-induced systemic small-vessel vasculitis with two varied extracutaneous manifestations: a case report and review of the literature.
Topics: Aspirin; Clopidogrel; Hematuria; Humans; Immunoglobulin E; Male; Naproxen; Ticagrelor; Vasculitis; Young Adult | 2023 |
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Ticagrelor; Treatment Outcome | 2023 |
276 trial(s) available for clopidogrel and ticagrelor
| Article | Year |
|---|---|
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding Time; Clopidogrel; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Postmenopause; Ticagrelor; Ticlopidine | 2006 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine | 2007 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Retrospective Studies; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
Topics: Adenosine; Adenosine Diphosphate; Area Under Curve; Atherosclerosis; Clopidogrel; Dose-Response Relationship, Drug; Humans; Integrin beta3; Pharmacogenetics; Platelet Aggregation; Polymorphism, Single Nucleotide; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Double-Blind Method; Female; Humans; Interleukin-6; Male; Middle Aged; Peroxidase; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ischemia; Male; Platelet Aggregation Inhibitors; Proportional Hazards Models; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Dyspnea; Female; Heart; Humans; Lung; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine | 2010 |
Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
Topics: Adenosine; Adult; Clopidogrel; Dose-Response Relationship, Drug; Fasting; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2010 |
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Glucose; Clopidogrel; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Genotype; Humans; Male; Middle Aged; Pharmacokinetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
Topics: Acute Coronary Syndrome; Adenosine; Aged; Bradycardia; Clopidogrel; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States | 2011 |
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.
Topics: Adenosine; Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Oxygen Consumption; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Respiratory Function Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Creatinine; Cystatin C; Double-Blind Method; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Protein Precursors; Ticagrelor; Ticlopidine; Troponin I | 2012 |
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine | 2012 |
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Topics: Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Platelet Aggregation; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2012 |
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Troponin I; Troponin T | 2012 |
Lessons from platelet inhibition and patient outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Statistics as Topic; Ticagrelor; Ticlopidine; United States | 2012 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine | 2012 |
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.
Topics: Adenosine; Aged; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2012 |
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Stents; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm?
Topics: Adenosine; Cerebrovascular Disorders; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Analysis of Variance; Biomarkers; Clopidogrel; Cystatin C; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Severity of Illness Index; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drugs, Generic; Follow-Up Studies; Germany; Humans; Markov Chains; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Quality-Adjusted Life Years; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Quality of Life; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Follow-Up Studies; Heart Diseases; Humans; Internationality; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Diagnostic Imaging; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Health Care Costs; Hospitalization; Humans; Markov Chains; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Switzerland; Ticagrelor; Ticlopidine | 2013 |
Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; United Kingdom | 2014 |
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pneumonia; Sepsis; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition a
Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Clopidogrel; Electrocardiography; Growth Differentiation Factor 15; Hospital Mortality; Humans; Kaplan-Meier Estimate; Myocardial Revascularization; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Troponin T | 2014 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, Liquid; Clopidogrel; Cyclic AMP; Erythrocytes; Female; Humans; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2014 |
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Drug Dosage Calculations; Drug Substitution; Drug Synergism; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticagrelor; Ticlopidine | 2014 |
Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Denmark; Humans; Purinergic P2Y Receptor Antagonists; Sweden; Ticagrelor; Ticlopidine | 2014 |
A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study.
Topics: Adenosine; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Ticagrelor; Ticlopidine | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Sex Factors; Stents; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, control
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxidative Stress; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Clopidogrel; Coronary Circulation; Coronary Vessels; Humans; Microcirculation; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Research Design; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography | 2014 |
Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Young Adult | 2014 |
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cause of Death; Clopidogrel; Confidence Intervals; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors | 2014 |
Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin.
Topics: Adenosine; Adult; Antithrombins; Aspirin; Blood Coagulation; Clopidogrel; Cross-Over Studies; Drug Synergism; Female; Healthy Volunteers; Hirudins; Humans; Male; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thrombelastography; Ticagrelor; Ticlopidine | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time-to-Treatment | 2014 |
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
Topics: Acute Coronary Syndrome; Adenosine; Brazil; Clopidogrel; Cost-Benefit Analysis; Disease Management; Electrocardiography; Female; Germany; Health Care Costs; Humans; Male; Markov Chains; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Quality of Life; Quality-Adjusted Life Years; Secondary Prevention; Sweden; Ticagrelor; Ticlopidine; United Kingdom | 2015 |
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Hispanic or Latino; Humans; Middle Aged; Platelet Activation; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia.
Topics: Adenosine; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Research Design; Ticagrelor; Ticlopidine; Warfarin; Young Adult | 2015 |
Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2015 |
Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Topics: Adenosine; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Renal Dialysis; Single-Blind Method; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Flow Cytometry; Half-Life; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2015 |
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Female; Fibrinolysis; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Prospective Studies; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Antigens, CD34; Body Mass Index; Clopidogrel; Endothelial Progenitor Cells; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Research Design; Rivaroxaban; Ticagrelor; Ticlopidine; Warfarin | 2015 |
Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial.
Topics: Adenosine; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Genetic Variation; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
[Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention].
Topics: Adenosine; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction.
Topics: Adenosine; Aged; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Myocardial Infarction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Agonists; Ticagrelor; Ticlopidine | 2016 |
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
Topics: Adenosine; Administration, Oral; Aged; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hispanic or Latino; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Regression Analysis; Risk Assessment; Severity of Illness Index; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2015 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel; Cytokines; Endotoxins; England; Female; Fibrin Fibrinogen Degradation Products; Humans; Inflammation; Inflammation Mediators; Male; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2015 |
Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Transplantation, Homologous; Treatment Outcome | 2015 |
Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Brazil; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Emergency Medical Services; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; ST Elevation Myocardial Infarction; Thrombectomy; Ticagrelor; Ticlopidine; Time Factors; Time-to-Treatment; Treatment Outcome | 2016 |
Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
Topics: Adenosine; Adolescent; Adult; Area Under Curve; Aspirin; Austria; beta-Thromboglobulin; Biomarkers; Bleeding Time; Blood Platelets; Clopidogrel; Double-Blind Method; Healthy Volunteers; Hemostasis; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prothrombin; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; ROC Curve; Ticagrelor; Ticlopidine; Time Factors; Young Adult | 2016 |
Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction.
Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
Topics: Adenosine; Biomarkers; Blood Platelets; Clopidogrel; Electrocardiography; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine | 2016 |
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Cause of Death; Clopidogrel; Death, Sudden, Cardiac; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Tachycardia, Ventricular; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
Topics: Adenosine; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine | 2016 |
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for
Topics: Adenosine; Biomarkers; C-Reactive Protein; CD40 Ligand; Clinical Protocols; Clopidogrel; Endothelium, Vascular; Humans; Myocardial Infarction; P-Selectin; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; Sample Size; Ticagrelor; Ticlopidine | 2016 |
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Preoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Troponin | 2016 |
Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Troponin | 2016 |
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Extremities; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peripheral Arterial Disease; Prospective Studies; Severity of Illness Index; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study.
Topics: Adenosine; Aged; China; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation; Single-Blind Method; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Humans; Japan; Ticagrelor; Ticlopidine; Treatment Outcome; United States; White People | 2016 |
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Administration Schedule; Female; Humans; Magnetic Resonance Angiography; Male; Microvessels; Middle Aged; Myocardial Revascularization; Organ Size; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
Topics: Adenosine; Clopidogrel; Cost Sharing; Drug Costs; Financial Support; Health Care Costs; Health Expenditures; Humans; Logistic Models; Medication Adherence; Mortality; Multivariate Analysis; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Substitution; Female; Gene Expression Regulation; Humans; Male; MicroRNAs; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2016 |
Similar Impact of Clopidogrel or Ticagrelor on Carotid Atherosclerotic Plaque Inflammation.
Topics: Adenosine; Aged; Anti-Inflammatory Agents; Carotid Arteries; Carotid Stenosis; Clopidogrel; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Male; Middle Aged; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Radiopharmaceuticals; Republic of Korea; Severity of Illness Index; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
Topics: Abciximab; Adenosine; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Thrombectomy; Thrombosis; Ticagrelor; Ticlopidine; Tomography, Optical Coherence | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Long Term Adverse Effects; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients).
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2016 |
Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects.
Topics: Adenosine; Adult; Blood Component Removal; Blood Platelets; Body Mass Index; Case-Control Studies; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Hemostasis; Humans; Male; Platelet Aggregation Inhibitors; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Ticagrelor; Ticlopidine; Time Factors; Young Adult | 2016 |
Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial).
Topics: Adenosine; Aged; Clopidogrel; Creatine Kinase; Echocardiography; Female; Humans; Male; Microvessels; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Severity of Illness Index; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Vascular Resistance | 2016 |
A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Cross-Over Studies; Drug Administration Schedule; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Ontario; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.
Topics: Adenosine; Aged; Clopidogrel; Female; Humans; Lower Extremity; Male; Peripheral Arterial Disease; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
Topics: Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Leg; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study.
Topics: Activation, Metabolic; Adenosine; Clopidogrel; Coma; Humans; Hypothermia, Induced; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Resuscitation; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Randomized Comparison of Oral P2Y
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Disease; Drug Substitution; Female; Germany; Humans; Infusions, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Expression; Gene Frequency; Genotype; Genotyping Techniques; Humans; Male; Middle Aged; Mutation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.
Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytokines; Endothelium, Vascular; Female; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Nitric Oxide; Percutaneous Coronary Intervention; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Reactive Oxygen Species; Ticagrelor; Ticlopidine | 2017 |
The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis.
Topics: Adenosine; Adult; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Ticagrelor; Ticlopidine | 2017 |
Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design.
Topics: Adenosine; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Heterozygote; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Research Design; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Growth Differentiation Factor 15; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tablets; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology.
Topics: Adenosine; Blood Platelets; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Coronary Circulation; Diabetes Mellitus, Type 2; Humans; Microcirculation; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Risk Factors; Spain; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Vasodilation | 2017 |
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Clopidogrel; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
Topics: Adenosine; Administration, Intravenous; Adolescent; Adult; Aspirin; Cells, Cultured; Clopidogrel; Cytokines; Drug Therapy, Combination; Endotoxemia; Endotoxins; Healthy Volunteers; Humans; Inflammation; Inflammation Mediators; Male; Netherlands; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2017 |
TIcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER-BVS trial): Rationale and study design.
Topics: Absorbable Implants; Chronic Disease; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Occlusion; Female; Humans; Male; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Design; Randomized Controlled Trials as Topic; Recovery of Function; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Ticagrelor mitigates ischaemia-reperfusion induced vascular endothelial dysfunction in healthy young males - a randomized, single-blinded study.
Topics: Adenosine; Administration, Oral; Adolescent; Adult; Austria; Blood Flow Velocity; Clopidogrel; Drug Administration Schedule; Endothelium, Vascular; Forearm; Healthy Volunteers; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Regional Blood Flow; Reperfusion Injury; Single-Blind Method; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents; Young Adult | 2017 |
Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease.
Topics: Adenosine; Aged; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine; Warfarin | 2017 |
Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Renal Elimination; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
Topics: Adenosine; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Preoperative Care; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Low-Dose Ticagrelor Versus Clopidogrel in Patients With Prior Myocardial Infarction.
Topics: Aged; Clopidogrel; Cross-Over Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor | 2017 |
Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment.
Topics: Adult; Aged; Aspirin; Blood Platelets; Catechin; Clopidogrel; Coronary Stenosis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Republic of Korea; Ticagrelor; Ticlopidine | 2018 |
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Topics: Aged; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Humans; Male; Middle Aged; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; United States | 2018 |
1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.
Topics: Aged; Clopidogrel; Follow-Up Studies; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.
Topics: Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2018 |
Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute My
Topics: Adenosine; Anti-Inflammatory Agents; B-Lymphocytes; Biomarkers; Brazil; Clinical Protocols; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Enzyme-Linked Immunospot Assay; Ezetimibe; Female; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Magnetic Resonance Imaging; Male; Metabolomics; Platelet Aggregation Inhibitors; Proteomics; Research Design; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction; Stroke Volume; T-Lymphocytes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Female; France; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
Topics: Adenosine; Aged; Clopidogrel; Female; Hospitalization; Humans; Hypertension; Incidence; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome; Vascular Surgical Procedures | 2018 |
Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Osteoprotegerin; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Up-Regulation | 2018 |
Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Circulation; Female; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Republic of Korea; Ticagrelor; Time Factors; Treatment Outcome; Vascular Resistance; Young Adult | 2018 |
Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.
Topics: Acute Coronary Syndrome; Aged; Blood Coagulation; Clopidogrel; Double-Blind Method; Female; Fibrin; Fibrin Clot Lysis Time; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2018 |
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor | 2018 |
Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial.
Topics: Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Ticagrelor | 2018 |
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Topics: Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Function Tests; Prospective Studies; Ticagrelor | 2018 |
Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Endothelium, Vascular; Female; Humans; Male; Outcome Assessment, Health Care; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2018 |
High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor | 2018 |
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Clopidogrel; Coronary Vessels; Cross-Over Studies; Endothelium, Vascular; Europe; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome; Vasodilation | 2018 |
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis.
Topics: Acute Coronary Syndrome; Aged; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Clopidogrel; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Ticagrelor | 2018 |
Randomized Comparison of Strut Coverage between Ticagrelor and Clopidogrel in Acute Myocardial Infarction at 3-Month Optical Coherence Tomography.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Neointima; Prospective Studies; Prostheses and Implants; Ticagrelor; Ticlopidine; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
Topics: Adult; Aged; Anticoagulants; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Single-Blind Method; ST Elevation Myocardial Infarction; Ticagrelor | 2018 |
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Stents; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial.
Topics: Clopidogrel; Coronary Circulation; Coronary Occlusion; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2018 |
Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: Occurrences, reasons, and long-term clinical outcomes.
Topics: Aged; China; Clopidogrel; Coronary Thrombosis; Drug Costs; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
No Differences in Levels of Circulating Progenitor Endothelial Cells or Circulating Endothelial Cells Among Patients Treated With Ticagrelor Compared With Clopidogrel During Non- ST -Segment-Elevation Myocardial Infarction.
Topics: Aged; Clopidogrel; Electrocardiography; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Male; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Single-Blind Method; Ticagrelor; Vasodilation | 2018 |
DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Diamines; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Taiwan; Thiazoles; Ticagrelor | 2019 |
Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: A single-center randomized controlled trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor | 2019 |
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Topics: Aged; Ankle Brachial Index; Clopidogrel; Coronary Artery Bypass; Death; Extremities; Female; Hospitalization; Humans; Incidence; Ischemia; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor | 2019 |
Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Ticagrelor | 2019 |
Beneficial effect of ticagrelor on microvascular perfusion in patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.
Topics: Aged; China; Clopidogrel; Coronary Circulation; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Progression-Free Survival; Recovery of Function; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Time Factors; Ventricular Function, Left | 2019 |
Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
Topics: Aged; Clopidogrel; Cost Sharing; Drug Costs; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Ticagrelor | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Spain; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; MicroRNAs; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Stents; Taiwan; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor; Warfarin | 2019 |
Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Transfusion; Ticagrelor; Young Adult | 2019 |
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Comorbidity; Diabetes Mellitus; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Survival Rate; Ticagrelor; United States | 2019 |
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial.
Topics: Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2019 |
Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial.
Topics: Aged; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Long-Term Care; Male; Middle Aged; ST Elevation Myocardial Infarction; Survival Analysis; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2019 |
Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial.
Topics: Aged; Alanine; Anti-Ulcer Agents; Aspirin; Cilostazol; Clopidogrel; Cytoprotection; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Peptic Ulcer; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quinolones; Thailand; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Assessment; Stroke; Thromboembolism; Ticagrelor; Warfarin | 2019 |
Ticagrelor Does Not Improve Endothelial Dysfunction in Stable Survivors of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Blood Platelets; Brachial Artery; Clopidogrel; Endothelium, Vascular; Humans; Non-ST Elevated Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Republic of Korea; Ticagrelor; Time Factors; Treatment Outcome; Vasodilation | 2019 |
The introduction of ticagrelor is associated with lower rates of recurrent ischemic stroke after myocardial infarction.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Disease-Free Survival; Female; Humans; Male; Myocardial Infarction; Registries; Risk Factors; Stroke; Survival Rate; Ticagrelor | 2019 |
Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).
Topics: Acute Coronary Syndrome; Aged; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Treatment Outcome | 2019 |
Stroke in Patients With Peripheral Artery Disease.
Topics: Aged; Clopidogrel; Double-Blind Method; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Peripheral Arterial Disease; Stroke; Ticagrelor | 2019 |
Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor | 2019 |
Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticagrelor | 2019 |
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor | 2019 |
Effect of Ticagrelor Versus Clopidogrel on Aortic Stiffness in Patients With Coronary Artery Disease.
Topics: Aged; Aorta; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Single-Blind Method; Ticagrelor; Time Factors; Vascular Stiffness | 2019 |
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Stu
Topics: Acute Coronary Syndrome; Adult; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; United Kingdom | 2019 |
A Genotype-Guided Strategy for Oral P2Y
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Single-Blind Method; ST Elevation Myocardial Infarction; Stents; Ticagrelor | 2019 |
Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Circulation; Female; Hemodynamics; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Infectious complications in patients receiving ticagrelor or clopidogrel before coronary artery bypass grafting.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Cross Infection; Europe; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Preoperative Care; Propensity Score; Ticagrelor | 2020 |
Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor | 2019 |
Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial.
Topics: Aged; Amputation, Surgical; Clopidogrel; Double-Blind Method; Endovascular Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Short-term efficacy of ticagrelor in acute ST-segment elevation myocardial infarction patients undergoing an emergency percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial.
Topics: Aged; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; ST Elevation Myocardial Infarction; Survival Analysis; Thrombosis; Ticagrelor; Treatment Outcome | 2020 |
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Intention to Treat Analysis; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Residence Characteristics; Risk Factors; Ticagrelor; Time Factors | 2020 |
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Diabetes Mellitus; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel.
Topics: Clopidogrel; Endothelial Cells; Extracellular Vesicles; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Female; Fibrinolysis; Humans; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombelastography; Thrombosis; Ticagrelor | 2020 |
Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Vessels; Endothelium; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Drug Substitution; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Ticagrelor versus clopidogrel in patients undergoing implantation of paclitaxel-eluting stent in the femoropopliteal district: A randomized pilot study using frequency-domain optical coherence tomography.
Topics: Clopidogrel; Drug-Eluting Stents; Humans; Paclitaxel; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Stents; Ticagrelor; Tomography, Optical Coherence; Treatment Outcome | 2020 |
Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography.
Topics: Acute Coronary Syndrome; Ammonia; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Positron-Emission Tomography; Prospective Studies; Ticagrelor; Time Factors | 2020 |
Impact of smoking on platelet function of ticagrelor versus clopidogrel in minor stroke or transient ischaemic attack.
Topics: Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Smoking; Stroke; Ticagrelor | 2020 |
Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial.
Topics: Adolescent; Adult; Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Female; Fractional Flow Reserve, Myocardial; Humans; Ischemic Preconditioning, Myocardial; Male; Microvessels; Middle Aged; Myocardial Reperfusion Injury; Percutaneous Coronary Intervention; Pilot Projects; Preoperative Care; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome; Vascular Resistance; Young Adult | 2020 |
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Stents; Thromboembolism; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2020 |
60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Cross-Over Studies; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Single-Blind Method; Ticagrelor; Treatment Outcome | 2020 |
Ticagrelor versus clopidogrel for prevention of subclinical stent thrombosis detected by optical coherence tomography in patients with drug-eluting stent implantation-a multicenter and randomized study.
Topics: Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Thrombosis; Ticagrelor; Tomography, Optical Coherence | 2021 |
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Ticagrelor | 2020 |
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.
Topics: Adult; Aged; Aged, 80 and over; Body Weight; Clopidogrel; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Organophosphonates; Patient Safety; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Pyrimidines; Ticagrelor; Treatment Outcome | 2020 |
TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Secondary Prevention; Thrombosis; Ticagrelor; Young Adult | 2020 |
Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Topics: Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Humans; Multicenter Studies as Topic; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Point-of-Care Testing; Polymorphism, Genetic; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Saudi Arabia; ST Elevation Myocardial Infarction; Stents; Ticagrelor; Treatment Outcome | 2020 |
The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Egypt; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Young Adult | 2020 |
Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial.
Topics: Aged; Clopidogrel; Fibrinolysis; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2021 |
A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALO
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Topics: Acute Coronary Syndrome; Aged; Atherosclerosis; Case-Control Studies; Clopidogrel; Cysteine Endopeptidases; Cysteine Proteases; Death; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2020 |
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Female; Genotype; Genotyping Techniques; Hemorrhage; Heterozygote; Humans; Loss of Function Mutation; Male; Middle Aged; Percutaneous Coronary Intervention; Point-of-Care Testing; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Ticagrelor; Treatment Outcome | 2020 |
Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Topics: Aged; Amputation, Surgical; Cardiovascular Diseases; Clopidogrel; Comorbidity; Disease Progression; Female; Humans; Limb Salvage; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prognosis; Risk Assessment; Risk Factors; Symptom Assessment; Ticagrelor; Treatment Outcome | 2020 |
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: Th
Topics: Adult; Aged; Cardiovascular Diseases; Clopidogrel; Diabetes Complications; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Ticagrelor | 2020 |
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
Topics: Clopidogrel; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Adult; Aged; Clopidogrel; Cross-Over Studies; Double-Blind Method; Drug Interactions; Drug Substitution; Female; Humans; Male; Middle Aged; Organophosphonates; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyrimidines; Ticagrelor; Time Factors; Treatment Outcome; Young Adult | 2021 |
CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.
Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Shock, Cardiogenic; Ticagrelor | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2021 |
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Renal Insufficiency, Chronic; Ticagrelor | 2022 |
Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation.
Topics: Aged; Aged, 80 and over; Anemia; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; Comorbidity; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Spain; Ticagrelor; Time Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2021 |
Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Fatty Acids, Unsaturated; Female; Humans; Lipid Metabolism; Male; Metabolomics; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Long-Term Vascular Function in CTO Recanalization: A Randomized Clinical Trial of Ticagrelor vs. Clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Comparison of Ticagrelor Versus Clopidogrel on Cerebrovascular Microembolic Events and Platelet Inhibition during Transcatheter Aortic Valve Implantation.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Intracranial Embolism; Intraoperative Complications; Male; Platelet Aggregation Inhibitors; Ticagrelor; Transcatheter Aortic Valve Replacement; Ultrasonography, Doppler, Transcranial | 2021 |
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.
Topics: Clopidogrel; Humans; Internationality; Ischemia; Ischemic Stroke; Myocardial Infarction; Peripheral Arterial Disease; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Topics: Aged; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor versus Clopidogrel in
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Ischemic Attack, Transient; Ischemic Stroke; Loss of Function Mutation; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor | 2021 |
Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes.
Topics: Acute Coronary Syndrome; Clopidogrel; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Comorbidity; COVID-19; COVID-19 Drug Treatment; Extracorporeal Membrane Oxygenation; Female; Hemorrhage; Heparin; Hospital Mortality; Humans; Inpatients; Male; Medical Futility; Middle Aged; Outcome Assessment, Health Care; Oxygen Inhalation Therapy; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Respiration, Artificial; Thrombosis; Ticagrelor; Time Factors; Treatment Outcome | 2022 |
Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2022 |
Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction.
Topics: Adenosine Diphosphate; Clopidogrel; Humans; Microcirculation; Myocardial Infarction; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2022 |
Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study).
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Epinephrine; Fibrinolytic Agents; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial.
Topics: Clopidogrel; Hemorrhage; Humans; Morphine; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2022 |
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.
Topics: Clopidogrel; Humans; Lower Extremity; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Hypertension; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor versus clopidogrel in reducing inflammatory cell infiltration of thrombus aspirated in patients with ST-elevation myocardial infarction.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
In-hospital outcomes of Ticagrelor versus Clopidogrel in high bleeding risk patients with acute coronary syndrome: Findings from the CCC-ACS project.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Hospitals; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor or clopidogrel for dual antiplatelet therapy after transcarotid and transfemoral stenting of the carotid artery: are we ready for a randomized controlled trial?
Topics: Carotid Arteries; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stents; Ticagrelor; Treatment Outcome | 2022 |
Assessment of myocardial salvage in patients with STEMI undergoing thrombolysis: ticagrelor versus clopidogrel.
Topics: Clopidogrel; Humans; Myocardial Infarction; ST Elevation Myocardial Infarction; Stroke Volume; Thrombolytic Therapy; Ticagrelor; Ventricular Function, Left | 2022 |
Aspirin platelet reactivity on platelet function and clinical outcome in minor stroke or transient ischemic attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe
Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction.
Topics: Anticholesteremic Agents; Clopidogrel; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Myocardial Infarction; Prospective Studies; Rosuvastatin Calcium; Scattering, Small Angle; Simvastatin; Ticagrelor; X-Ray Diffraction | 2022 |
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor | 2022 |
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Biomarkers; Clopidogrel; Growth Differentiation Factor 15; Humans; Myocardial Infarction; Natriuretic Peptide, Brain; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Ticagrelor; Treatment Outcome | 2022 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
In-hospital outcomes of ticagrelor versus clopidogrel in patients 75 years or older with acute coronary syndrome: findings from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome Project.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; China; Clopidogrel; Hemorrhage; Hospitals; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality Improvement; Ticagrelor | 2022 |
Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Genotype; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease.
Topics: Adenosine; Clopidogrel; Female; Humans; Inflammation; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Infarction; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Drug-Eluting Stents; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; East Asian People; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2023 |
Early Effects of Ticagrelor Versus Clopidogrel on Peripheral Endothelial Function After Non-ST-Elevation Acute Coronary Syndrome and Assessment of Its Relationship With Coronary Microvascular Function.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Infarction; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack.
Topics: Aspirin; Body Mass Index; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Obesity; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor Versus Clopidogrel in Minor Stroke or Transient Ischemic Attack With Intracranial Artery Stenosis: A Post Hoc Analysis of CHANCE-2.
Topics: Arteries; Aspirin; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
593 other study(ies) available for clopidogrel and ticagrelor
| Article | Year |
|---|---|
Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Dogs; Humans; Niacin; Receptors, Purinergic P2Y12; Sulfonamides; Thrombosis | 2013 |
N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Humans; Indoles; Injections, Intravenous; Male; Models, Chemical; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridazines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2Y12; Thrombosis | 2014 |
Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
Topics: Adenosine; Antifibrinolytic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Future of oral antiplatelet therapy: four challenged hypotheses.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Test before you stop.
Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; Hemostasis; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine; Transfection | 2009 |
Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2009 |
The PLATO trial: do you believe in magic?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intracranial Hemorrhages; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
The TRITON versus PLATO trials: differences beyond platelet inhibition.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Research Design; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor in ACS: redefining a new standard of care?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
[Ticagrelor versus clopidogrel in patients with acute coronary syndromes: results of the PLATO study].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dose-Response Relationship, Drug; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Topics: Adenosine; Animals; Bleeding Time; Blood Coagulation; Clopidogrel; Coronary Circulation; Coronary Thrombosis; Disease Models, Animal; Dogs; Drug Therapy, Combination; Echocardiography; Female; Fibrinolytic Agents; Laser-Doppler Flowmetry; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Recurrence; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Tissue Plasminogen Activator | 2010 |
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2010 |
[The PLATO study].
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2010 |
Recent research on antithrombotics. News on the treatment of patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Cyclic N-Oxides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Ticagrelor; Ticlopidine | 2010 |
Diabetics with acute coronary syndrome: advances, challenges, and uncertainties.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Diabetic Angiopathies; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug Therapy, Combination; Emergency Medicine; Hemorrhage; Hospitalists; Humans; Imines; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Pyridines; Receptor, PAR-1; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Is ticagrelor the antiplatelet therapy panacea?
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2011 |
Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2011 |
[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Approval; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States | 2011 |
Resistance to anti-platelet agents.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified.
Topics: Acute Coronary Syndrome; Adenosine; Bias; Clinical Trials as Topic; Clopidogrel; Europe; Humans; Mortality; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2011 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine | 2011 |
Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Epidemiologic Research Design; Europe; Humans; Patient Selection; Practice Guidelines as Topic; Statistics as Topic; Survival Analysis; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2011 |
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5)
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Clopidogrel; Europe; Genetic Predisposition to Disease; Humans; Research Design; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2011 |
[Do genetic factors reduce the effects of clopidogrel?].
Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Humans; Isoenzymes; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Non-interventional management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2011 |
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States | 2011 |
The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines.
Topics: Adenosine; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Thienopyridines; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Cytoprotection; Platelet Activation; Protein Binding; Purinergic P2Y Receptor Antagonists; Rats; Rats, Inbred WKY; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
No free lunches: balancing bleeding and efficacy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug-Eluting Stents; Electrocardiography; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2012 |
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Clopidogrel; Muscle Contraction; Myocytes, Smooth Muscle; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Decision Making; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpretation, Statistical; Disclosure; Humans; Informed Consent; Multicenter Studies as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Research Support as Topic; Selection Bias; Ticagrelor; Ticlopidine; Treatment Refusal; United States; United States Food and Drug Administration | 2011 |
[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
Topics: Abciximab; Adenosine; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].
Topics: Adenosine; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Theoretical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticagrelor; Ticlopidine | 2012 |
Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Resistance; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Ticagrelor; Ticlopidine | 2012 |
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients?
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Topics: Adenosine; Adenosine Monophosphate; Animals; Blood Platelets; Clopidogrel; Dogs; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2012 |
Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction?
Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Clopidogrel; Drug Interactions; Dyspnea; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Diseases; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Young Adult | 2013 |
Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2013 |
The power of more than one.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2013 |
Exploring the ticagrelor-statin interplay in the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Simvastatin; Ticagrelor; Ticlopidine | 2013 |
High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Topics: Adenosine; Animals; Arachidonic Acid; Aspirin; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine; Vascular Resistance | 2013 |
[Gastrointestinal bleeding after treatment with ticagrelor].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Female; Gastrointestinal Hemorrhage; Humans; Pulmonary Disease, Chronic Obstructive; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Drug Costs; Humans; Markov Chains; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Republic of Korea; Singapore; Ticagrelor; Ticlopidine | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Markov Chains; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports.
Topics: Adenosine; Clopidogrel; Drug-Eluting Stents; Humans; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2013 |
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Industry; Drugs, Generic; Forecasting; Germany; Humans; National Health Programs; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
Is clopidogrel adequate in 2013?
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cerebrovascular Disorders; Clopidogrel; Endovascular Procedures; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Retrospective Studies; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
P2Y12 Receptor Blockade and Myocardial Perfusion.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2013 |
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Australia; Clopidogrel; Coronary Artery Bypass; Cost-Benefit Analysis; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Incidence; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2013 |
Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel.
Topics: Adenosine; Advisory Committees; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Approval; Follow-Up Studies; Humans; Mortality; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticagrelor; Ticlopidine; Treatment Outcome; Vital Statistics | 2013 |
Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Ticagrelor; Ticlopidine | 2014 |
Value of high-sensitivity troponin in assessing the extent of benefit provided by ticagrelor versus clopidogrel in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Revascularization; Ticagrelor; Ticlopidine | 2014 |
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Design; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
US lawyers investigate trial that secured license for AstraZeneca's antiplatelet drug.
Topics: Adenosine; Clopidogrel; Consumer Product Safety; Drug Approval; Drug Industry; Drug Therapy, Combination; Female; Humans; Licensure; Male; Public Health; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2013 |
Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Australia; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Markov Chains; Ticagrelor; Ticlopidine | 2013 |
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Ticagrelor as an alternative in clopidogrel-associated neutropenia.
Topics: Acute Coronary Syndrome; Adenosine; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution; Humans; Male; Neutropenia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Discrepancies in the primary PLATO trial publication and the FDA reviews.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Congresses as Topic; Humans; Information Dissemination; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2014 |
Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Reproducibility of Results; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2014 |
Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Endovascular Procedures; Female; Follow-Up Studies; Humans; Leg; Limb Salvage; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Vessel wall, not platelet, P2Y12 potentiates early atherogenesis.
Topics: Adenosine; Animals; Apolipoproteins E; Atherosclerosis; Blood Platelets; Blood Vessels; Clopidogrel; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2014 |
High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Adenosine; Clopidogrel; Female; Flow Cytometry; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Controversies in acute cardiovascular care.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.
Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Is it appropriate to compare the results from two clinical trials with one drug in common?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics".
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Japan; Marketing; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Economic Competition; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Drug Utilization; Evidence-Based Medicine; Humans; International Cooperation; Marketing; Patient Satisfaction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Models, Economic; Poland; Secondary Prevention; State Medicine; Ticagrelor; Ticlopidine | 2014 |
Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Administration Schedule; Humans; Medication Adherence; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Ethnicity; Europe; Female; Georgia (Republic); Heart Failure; Humans; Internationality; Male; Metoprolol; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Russia; Sample Size; Spironolactone; Ticagrelor; Ticlopidine; Tolvaptan | 2014 |
Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Clopidogrel; Drug Hypersensitivity; Female; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine | 2014 |
Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2014 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
Ticagrelor and the prevention of cardiovascular mortality: more than just platelet inhibition?
Topics: Acute Coronary Syndrome; Adenosine; Cause of Death; Clopidogrel; Female; Humans; Male; Ticagrelor; Ticlopidine | 2014 |
Short bowel syndrome and clopidogrel non-responsiveness: a new indication for platelet aggregometry?
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Short Bowel Syndrome; Ticagrelor; Ticlopidine | 2014 |
First report of stent thrombosis after a switch therapy resulting from ticagrelor-related dyspnea.
Topics: Adenosine; Aged; Clopidogrel; Drug Substitution; Dyspnea; Humans; Male; Purinergic P2Y Receptor Antagonists; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
[Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality of Life; Spain; Ticagrelor; Ticlopidine; Time Factors | 2014 |
Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
Topics: Adenosine; Adult; Asian People; Blood Platelets; Clopidogrel; Female; Healthy Volunteers; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Ticlopidine; Young Adult | 2015 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Tirofiban; Tissue Scaffolds; Tyrosine | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance.
Topics: Adenosine; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purpura, Thrombocytopenic, Idiopathic; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome; Warfarin | 2015 |
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
Topics: Adenosine; Aged; Clopidogrel; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Societies, Medical; Thiophenes; Ticagrelor; Ticlopidine; World Health Organization | 2014 |
A delicate balance: the cost effectiveness of new antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
Topics: Adenosine; Adult; Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Rivaroxaban; Thrombin; Ticagrelor; Ticlopidine | 2015 |
Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Drug Design; Female; Humans; Male; Middle Aged; Patient Admission; Percutaneous Coronary Intervention; Platelet Count; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor-induced acute generalized exanthematous pustulosis.
Topics: Acute Coronary Syndrome; Acute Generalized Exanthematous Pustulosis; Adenosine; Aged; Biopsy; Clopidogrel; Drug Eruptions; Female; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.
Topics: Adenosine; Administration, Oral; Animals; Apoptosis; Cardiotonic Agents; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Injections, Intraperitoneal; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Purinergic P2Y Receptor Antagonists; Rats, Sprague-Dawley; Signal Transduction; Ticagrelor; Ticlopidine; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Body Mass Index; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Genetic Testing; Genotype; Humans; Managed Care Programs; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic?
Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Conflict of Interest; Humans; Peer Review; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Selection Bias; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mortality; Neoplasms; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Sepsis; Ticagrelor; Ticlopidine | 2015 |
Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study.
Topics: Adenosine; Aged; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Registries; Reoperation; Retrospective Studies; Sweden; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Dual antiplatelet therapy use by Canadian cardiac surgeons.
Topics: Adenosine; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Ticagrelor; Ticlopidine | 2015 |
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Blood Platelets; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Genotype; Health Care Costs; Heterozygote; Humans; Middle Aged; Pharmacogenetics; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2015 |
Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
PHILO -- ensuring trial results are not lost in translation.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Odds Ratio; Patient Discharge; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2016 |
Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polypharmacy; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Bradycardia; Clopidogrel; Comorbidity; Electrocardiography; Female; Germany; Humans; Male; Non-ST Elevated Myocardial Infarction; Prevalence; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Current Antiplatelet Agents in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel?
Topics: Adenosine; Aspirin; Clopidogrel; Coma; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
Topics: Adenosine; Aged; Aged, 80 and over; Asian People; Biotransformation; Chi-Square Distribution; China; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Genotype; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Phenotype; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Topics: Adenosine; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Drug Dosage Calculations; Humans; Platelet Activation; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy.
Topics: Abciximab; Adenosine; Aged; Antibodies, Monoclonal; Catheterization, Peripheral; Clopidogrel; Female; Hematoma; Hemorrhage; Hemostatic Techniques; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Punctures; Purinergic P2Y Receptor Antagonists; Radial Artery; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrinogen; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Triglycerides; Uric Acid | 2016 |
Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Sex Characteristics; Ticagrelor; Ticlopidine | 2016 |
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs.
Topics: Abciximab; Adenosine; Adenosine Monophosphate; Animals; Antibodies, Monoclonal; Cattle; Clopidogrel; Dimethylpolysiloxanes; Equipment Design; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Lab-On-A-Chip Devices; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Powders; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Serum Albumin, Bovine; Ticagrelor; Ticlopidine | 2016 |
[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine | 2016 |
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2016 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: comment.
Topics: Adenosine; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2016 |
Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Greece; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice.
Topics: Adenosine; Adult; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Percutaneous Coronary Intervention; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Retrospective Studies; Ticagrelor; Ticlopidine; United States | 2016 |
Another side effect of ticagrelor: Atrial fibrillation.
Topics: Adenosine; Aged; Angina, Unstable; Atrial Fibrillation; Clopidogrel; Humans; Male; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angiography; Cause of Death; Clopidogrel; Comorbidity; Drug Substitution; Female; Health Care Surveys; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Registries; Risk Factors; Ticagrelor; Ticlopidine | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Homeodomain Proteins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation | 2016 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: reply.
Topics: Adenosine; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2016 |
Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.
Topics: Adenosine; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Propensity Score; Registries; Republic of Korea; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2016 |
Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Humans; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine | 2016 |
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2016 |
Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment.
Topics: Adenosine; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Preoperative Care; Retrospective Studies; Ticagrelor; Ticlopidine | 2016 |
Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Activation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Switching from clopidogrel to prasugrel or ticagrelor: tips and tricks.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Survival Analysis; Ticagrelor; Ticlopidine | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ticagrelor; Ticlopidine | 2016 |
Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine | 2016 |
Ticagrelor for left ventricular assist device thrombosis: A new therapeutic option to be evaluated with caution.
Topics: Adenosine; Aged; Aspirin; Blood Coagulation; Cardiomyopathies; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Fibrinolytic Agents; Heart-Assist Devices; Humans; Male; Medication Therapy Management; Postoperative Complications; Risk Adjustment; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Treating Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Ticagrelor; Ticlopidine; Ureteroscopy | 2016 |
Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine-dependent mechanism.
Topics: Adenosine; Animals; Blood Platelets; Bone Regeneration; Clopidogrel; Dipyridamole; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteogenesis; Platelet Activation; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine | 2016 |
Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Vitamin D | 2016 |
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial.
Topics: Adenosine; Adult; China; Clopidogrel; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Humans; Male; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Young Adult | 2016 |
Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Medication Therapy Management; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2016 |
In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
Topics: Adenosine; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Protective Effects of Ticagrelor on Myocardial Injury After Infarction.
Topics: Adenosine; Animals; Blood Platelets; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Myocardial Infarction; Platelet Aggregation Inhibitors; Random Allocation; Swine; Ticagrelor; Ticlopidine | 2016 |
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical Services; Emergency Service, Hospital; Female; Hemorrhage; Hospitalization; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Young Adult | 2016 |
Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy.
Topics: Adenosine; Aged; Canada; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Vascular disease: Ticagrelor not superior to clopidogrel for PAD.
Topics: Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Patient Preference; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Epidemiologic Studies; Female; Humans; Latin America; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Switching from ticagrelor to clopidogrel: New answers and further questions.
Topics: Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Outcome Assessment; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2017 |
Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Topics: Adenosine; Animals; Blood Coagulation; Blood Platelets; Carotid Artery Injuries; Cells, Cultured; Clopidogrel; Disease Models, Animal; Down-Regulation; Endothelial Cells; Equilibrative Nucleoside Transporter 1; Fibrinolytic Agents; Humans; Male; Mice, Inbred C57BL; Platelet Aggregation Inhibitors; Proteasome Endopeptidase Complex; Proteolysis; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thromboplastin; Thrombosis; Ticagrelor; Ticlopidine; Time Factors; Tumor Necrosis Factor-alpha | 2017 |
Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; Clopidogrel; Cyclic AMP; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine | 2017 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium.
Topics: Adenosine; Antithrombins; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Endocardium; Heart Atria; Humans; Plasminogen Activator Inhibitor 1; Purinergic P2Y Receptor Antagonists; Thromboplastin; Ticagrelor; Ticlopidine; Tumor Necrosis Factor-alpha | 2017 |
Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Asian People; Cell Adhesion Molecules; Clopidogrel; Cryopreservation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Vasodilator Agents | 2018 |
Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Asian People; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticagrelor | 2018 |
Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Belgium; Cardiologists; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Black People; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; White People | 2017 |
Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia.
Topics: Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Humans; Hypothermia, Induced; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stents; Ticagrelor; Ticlopidine | 2017 |
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Medication Therapy Management; Patient Discharge; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Survival Analysis; Ticagrelor; Ticlopidine | 2017 |
Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI.
Topics: Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Comorbidity; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Troponin | 2017 |
GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiopulmonary Resuscitation; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Shock, Cardiogenic; Slovenia; Survival Rate; Ticagrelor; Ticlopidine; Time Factors | 2018 |
Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Hospital Mortality; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; ST Elevation Myocardial Infarction; Survival Rate; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™.
Topics: Adenosine; Aged; Aspirin; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2017 |
Use of Platelet Function Testing Before Pipeline Embolization Device Placement: A Multicenter Cohort Study.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Intracranial Embolism; Intracranial Thrombosis; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Young Adult | 2017 |
Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Topics: Adenosine; Aged; Blue Cross Blue Shield Insurance Plans; Clopidogrel; Drug Utilization Review; Ethnicity; Female; Graft Occlusion, Vascular; Hemorrhage; Hospital Mortality; Humans; Male; Michigan; Middle Aged; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Preoperative Period; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Reproducibility of Results; Signal Transduction; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Ticagrelor Versus Clopidogrel on Myocardial Infarct Size in Patients Undergoing Primary Percutaneous Coronary Intervention.
Topics: Clopidogrel; Dose-Response Relationship, Drug; Humans; Magnetic Resonance Imaging, Cine; Myocardial Infarction; Myocardium; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Period; Severity of Illness Index; Ticagrelor | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Heterozygote; Homozygote; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome; Vitamin D Deficiency; Vitamin D-Binding Protein | 2017 |
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Delivery of Health Care, Integrated; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Retrospective Studies; Safety; Ticagrelor; Ticlopidine | 2017 |
Effect of Ticagrelor Versus Clopidogrel on Vascular Reactivity.
Topics: Cardiovascular Diseases; Clopidogrel; Endothelium, Vascular; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Vasodilation | 2017 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Streptokinase; Stroke; Ticagrelor; Ticlopidine; Tissue Plasminogen Activator | 2017 |
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy?
Topics: Aspirin; Belgium; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2017 |
A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Drug Costs; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2017 |
Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model.
Topics: Adenosine; Animals; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Endothelium, Vascular; Hyperplasia; Male; Neointima; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Random Allocation; Swine; Ticagrelor; Ticlopidine; Tomography, Optical Coherence; Treatment Outcome | 2017 |
Topics: Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticagrelor | 2017 |
Clopidogrel instead of prasugrel or ticagrelor after 1 month in stabilized ACS patients: back to square one for DAPT?
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2017 |
Critical Role of P2Y
Topics: Adenosine; Animals; Autoimmune Diseases; Cell Differentiation; Cells, Cultured; Clopidogrel; Colitis; Diabetes Mellitus, Experimental; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Gene Expression Regulation; Interleukin-17; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Knockout; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Th17 Cells; Ticagrelor; Ticlopidine; Trinitrobenzenesulfonic Acid | 2017 |
Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Clopidogrel; Cohort Studies; Databases, Factual; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2017 |
Letter by Moris et al Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease".
Topics: Clopidogrel; Humans; Lower Extremity; Peripheral Arterial Disease; Ticagrelor; Ticlopidine | 2017 |
Letter by Siasos et al Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease".
Topics: Clopidogrel; Humans; Lower Extremity; Peripheral Arterial Disease; Ticagrelor; Vascular Surgical Procedures | 2017 |
Response by Jones et al to Letter Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease".
Topics: Clopidogrel; Humans; Lower Extremity; Peripheral Arterial Disease; Ticagrelor; Vascular Surgical Procedures | 2017 |
Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Disease Management; Female; Hospitalization; Humans; Hyperglycemia; Italy; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2017 |
The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy.
Topics: Adenosine; Aged; Clopidogrel; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescription Drugs; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2017 |
Reversal of the platelet inhibitory effect of the P2Y
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI).
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Mutation; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
The impact of CYP2C19*2, CYP4F2*3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P450 Family 4; Female; Humans; Hydroxyeicosatetraenoic Acids; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cohort Studies; Diabetes Mellitus; Drug Utilization Review; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2017 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Greece; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Stroke; Ticagrelor; Ticlopidine | 2018 |
Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Retrospective Studies; Secondary Prevention; Ticagrelor; Ticlopidine | 2017 |
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Withholding Treatment | 2017 |
Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover.
Topics: Adenosine; Brain Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polycythemia Vera; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thrombocytosis; Ticagrelor; Ticlopidine | 2017 |
Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Italy; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Registries; Retrospective Studies; Ticagrelor; Ticlopidine | 2017 |
Contemporary use of P2Y
Topics: Adenosine; Adult; Aged; Clopidogrel; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Poland; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan.
Topics: Aged; Asian People; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Ischemia; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Taiwan; Ticagrelor; Treatment Outcome | 2018 |
Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Ticagrelor | 2018 |
Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin.
Topics: Atorvastatin; Cardiac Catheterization; Clopidogrel; Creatine Kinase; Drug Interactions; Drug-Eluting Stents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor | 2019 |
Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization Review; Female; Hemorrhage; Hospital Mortality; Humans; Italy; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-ST Elevated Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
Topics: Adenosine; Adenosine Diphosphate; Aged; Anemia; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine | 2018 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Hemorrhage; Heterozygote; Homozygote; Humans; Hypertension; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; United States; United States Food and Drug Administration | 2018 |
The paradox of clopidogrel use in patients with acute coronary syndromes and diabetes: insight from the Diabetes and Acute Coronary Syndrome Registry.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Humans; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Prospective Studies; Registries; Ticagrelor | 2018 |
Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Female; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Postoperative Hemorrhage; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Time Factors; Treatment Outcome; Withholding Treatment | 2019 |
Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
Topics: Anticoagulants; Clopidogrel; Coronary Thrombosis; Hemorrhage; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Databases, Factual; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Factors; Saphenous Vein; Ticagrelor; Time Factors; Treatment Outcome; United Kingdom | 2018 |
An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Community Pharmacy Services; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Delivery of Health Care, Integrated; Drug Costs; Female; Genetic Testing; Humans; Male; Markov Chains; Medication Therapy Management; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Point-of-Care Testing; Precision Medicine; Predictive Value of Tests; Program Evaluation; Quality of Life; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; United States | 2018 |
Bleeding frequency of patients taking ticagrelor, aspirin, clopidogrel, and dual antiplatelet therapy after tooth extraction and minor oral surgery.
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Tooth Extraction | 2018 |
Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2018 |
Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Survival Rate; Ticagrelor; United Kingdom | 2018 |
Dyspnea or Cheyne-Stokes respiration associated with Ticagrelor?
Topics: Aged; Cheyne-Stokes Respiration; Clopidogrel; Dyspnea; Humans; Male; Myocardial Infarction; Polysomnography; Ticagrelor | 2018 |
Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Platelet Function Tests; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2019 |
The TREAT Trial-Moving ST-Elevation Myocardial Infarction Care Forward, With More to Do.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor | 2018 |
Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Topics: Aged; Belgium; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Survival Analysis; Thrombosis; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
[Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Fibrinolytic Agents; Humans; Italy; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
Topics: Aged; Asia; Aspirin; Clopidogrel; Drug Administration Schedule; Female; Humans; Incidence; Inpatients; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2018 |
Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; France; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Registries; Risk Factors; Secondary Prevention; Sex Factors; Ticagrelor | 2018 |
Dual antiplatelet therapy in the 'real world'.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2018 |
Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function.
Topics: Aged; Clopidogrel; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Stroke; Sweden; Ticagrelor | 2018 |
Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
Topics: Blood Platelets; Clinical Decision-Making; Clopidogrel; Female; Humans; Male; Patient Selection; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Platelet-Rich Plasma; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor | 2018 |
In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Corona
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality Improvement; Registries; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Prediction of Post-Discharge Bleeding in Elderly Patients with Acute Coronary Syndromes: Insights from the BleeMACS Registry.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Asia; Brazil; Canada; Clopidogrel; Decision Support Techniques; Erythrocyte Transfusion; Europe; Female; Humans; Incidence; Intracranial Hemorrhages; Male; Middle Aged; Patient Discharge; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Registries; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Clinical Outcomes and Sustainability of Using
Topics: Aged; Clinical Decision-Making; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Feasibility Studies; Female; Humans; Male; Middle Aged; North Carolina; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Risk Factors; Stents; Ticagrelor; Treatment Outcome | 2018 |
Effect of Low-Dose Versus Standard-Dose Ticagrelor and Clopidogrel on Platelet Inhibition in Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asia; China; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Female; Health Care Costs; Hong Kong; Humans; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Republic of Korea; Taiwan; Ticagrelor; Ticlopidine | 2018 |
Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Drug Administration Schedule; Drug Substitution; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Switzerland; Tertiary Care Centers; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Utility of GRACE and ACUITY-HORIZONS risk scores to guide dual antiplatelet therapy in Korean patients with acute myocardial infarction undergoing drug-eluting stenting.
Topics: Aged; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Registries; Republic of Korea; Risk Assessment; Ticagrelor | 2018 |
Prasugrel or Ticagrelor for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Does it Matter?
Topics: Acute Coronary Syndrome; Biomarkers; Clopidogrel; Cross-Over Studies; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2018 |
Comparison of Ticagrelor with Clopidogrel in Reducing Interleukin-17 and Myeloperoxidase Expression in Thrombus and Improving Postprocedural Coronary Flow in ST-segment Elevation Myocardial Infarction Patients.
Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Circulation; Female; Humans; Interleukin-17; Middle Aged; Peroxidase; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Young Adult | 2018 |
There seems to be a low risk of experiencing postoperative bleeding in patients undergoing dental extractions or minor oral surgery who continue using antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticagrelor; Tooth Extraction | 2018 |
Prescribing patterns of oral antiplatelets in Wales: evolving trends from 2005 to 2016.
Topics: Administration, Oral; Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Wales | 2018 |
CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel.
Topics: Activation, Metabolic; Adult; Area Under Curve; Clopidogrel; Cytochrome P-450 CYP3A; Female; Genetic Variation; Genotype; Healthy Volunteers; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Ticagrelor; Young Adult | 2019 |
Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervent
Topics: Adenosine; Adult; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Endothelium, Vascular; Female; Humans; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Neoplasm Proteins; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prognosis; Proteoglycans; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Costs and Cost Analysis; Female; Health Care Costs; Humans; Length of Stay; Male; Middle Aged; Patient Acceptance of Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Ticlopidine | 2018 |
P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs.
Topics: AMP-Activated Protein Kinases; Animals; Clopidogrel; Disease Models, Animal; Echocardiography; Fibrosis; Heart Ventricles; Magnetic Resonance Imaging, Cine; Myocardial Infarction; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Signal Transduction; Stroke Volume; Sus scrofa; Ticagrelor; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Massive stent thrombosis during active ulcerative colitis: the tricky balance between manifest hemorrhagic and concealed thrombotic risk.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Colitis, Ulcerative; Coronary Thrombosis; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticagrelor | 2018 |
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Reply: Pleiotropic Effects of Ticagrelor Beyond Its Potent Antiplatelet Effects Contributing to Additional Clinical Benefits.
Topics: Biomarkers; Clopidogrel; Cross-Over Studies; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Pleiotropic Effects of Ticagrelor Beyond its Potent Antiplatelet Effects Contributing to Additional Clinical Benefits.
Topics: Biomarkers; Clopidogrel; Cross-Over Studies; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Late stent thrombosis in a patient with CYP2C19*3/*17 genotype and clopidogrel high on-treatment platelet reactivity.
Topics: Adult; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Genotype; Humans; Male; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor | 2018 |
The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects.
Topics: Acute Coronary Syndrome; Aftercare; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hospitalization; Humans; Italy; Male; Medication Adherence; Middle Aged; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor | 2019 |
Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
Topics: Acute Coronary Syndrome; Cause of Death; Clopidogrel; Drug Prescriptions; Follow-Up Studies; Hemorrhage; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Survival Rate; Ticagrelor | 2019 |
Ticagrelor not superior to DAPT after PCI.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2018 |
Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention: Finding the Balance for Patients With Stable Coronary Artery Disease.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Steel; Ticagrelor | 2018 |
Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Comorbidity; Comparative Effectiveness Research; Diabetes Mellitus; Female; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Ticagrelor; Treatment Outcome; United States | 2018 |
Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
The role of purinergic P2Y
Topics: Cell Line; Cell Movement; Cell Survival; Clopidogrel; Endothelial Cells; Humans; Neovascularization, Physiologic; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Wound Healing | 2018 |
The Role of OCT Guidance for Antiplatelet Therapy.
Topics: Aspirin; Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Tomography, Optical Coherence | 2018 |
Commentary: Dual antiplatelet therapy after coronary artery bypass graft surgery: Fewer stones remain unturned.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Platelet Aggregation Inhibitors; Ticagrelor | 2019 |
Effect of P2Y
Topics: Adenosine Monophosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2019 |
Commentary: Better late than never!
Topics: Clopidogrel; Coronary Artery Bypass; Ticagrelor | 2019 |
Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction.
Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Stroke; Ticagrelor | 2019 |
Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Topics: Biomarkers; C-Reactive Protein; Clopidogrel; Female; Humans; Interleukin-1beta; Interleukins; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2018 |
Discontinuation of dual antiplatelet therapy and bleeding in intensive care in patients undergoing urgent coronary artery bypass grafting: a retrospective analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Female; Humans; Inpatients; Intensive Care Units; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Ticagrelor | 2019 |
Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Treatment Outcome | 2018 |
Increased Use of Ticagrelor After Myocardial Infarction Is Not Associated With Intracranial Hemorrhage.
Topics: Age Factors; Aged; Clopidogrel; Cohort Studies; Female; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proportional Hazards Models; Secondary Prevention; Sweden; Ticagrelor | 2018 |
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug-Eluting Stents; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; United States | 2019 |
Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016.
Topics: Clopidogrel; Cross-Sectional Studies; Databases, Factual; Drug Utilization; Humans; Myocardial Ischemia; Off-Label Use; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome; United States | 2019 |
Switching of Oral P2Y
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Topics: Acute Coronary Syndrome; Administrative Claims, Healthcare; Aged; Clopidogrel; Comparative Effectiveness Research; Databases, Factual; France; Hemorrhage; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Risk Factors; Secondary Prevention; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Ticagrelor versus clopidogrel in high bleeding risk patients with acute coronary syndromes treated with drug-eluting stents.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2019 |
New opportunities to optimize antithrombotic therapy for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2019 |
Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: A matched-cohort study comparing clopidogrel with ticagrelor.
Topics: Adult; Aneurysm, Ruptured; Clopidogrel; Cohort Studies; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2019 |
Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2019 |
One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: From Korean Health Insurance Review and Assessment Data.
Topics: Aged; Cause of Death; Clopidogrel; Combined Modality Therapy; Drug Substitution; Female; Hemorrhage; Humans; Incidence; Insurance, Health; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2019 |
Increase in ticagrelor use over time is associated with lower rates of ischemic stroke following myocardial infarction.
Topics: Aged; Brain Ischemia; Clopidogrel; Comorbidity; Humans; Incidence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Risk Factors; Stroke; Sweden; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Drug interaction: Opioids and oral P2Y12 platelet inhibitors.
Topics: Analgesics, Opioid; Clopidogrel; Drug Interactions; Drug Labeling; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2019 |
Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
Topics: Aged; Aged, 80 and over; Angioplasty; Clopidogrel; Coronary Angiography; Female; Hemorrhage; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Stents; Survival Rate; Sweden; Thrombosis; Ticagrelor | 2019 |
Letter by Long et al Regarding Article, "Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease".
Topics: Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Steel; Ticagrelor | 2019 |
Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Period; Prasugrel Hydrochloride; Republic of Korea; Thromboembolism; Ticagrelor | 2019 |
Invited Commentary.
Topics: Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Ticagrelor | 2019 |
Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Preoperative Period; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2019 |
Ticagrelor induced neutrophilic eccrine hidradenitis: a unique adverse effect of a new antiplatelet drug.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Eruptions; Hand; Hidradenitis; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2019 |
Derivation and Evaluation of the Ischemic Risk Model in High-Risk Chinese Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; China; Clopidogrel; Female; Humans; Ischemia; Male; Middle Aged; Models, Biological; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Risk; Ticagrelor | 2019 |
Atrial fibrillation, with ACS and PCI: walking a tightrope.
Topics: Acute Coronary Syndrome; Atrial Fibrillation; Clopidogrel; Dabigatran; Humans; Percutaneous Coronary Intervention; Ticagrelor | 2019 |
The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction.
Topics: Aged; Anterior Wall Myocardial Infarction; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Echocardiography; Female; Follow-Up Studies; Heart Diseases; Heart Ventricles; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Treatment Outcome; Turkey | 2019 |
Dual platelet antiaggregation therapy after myocardial revascularization surgery.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Graft Occlusion, Vascular; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome; Vascular Patency | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Retrospective Studies; Stroke; Ticagrelor | 2019 |
Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Drug Substitution; Electrocardiography; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Magnetic Resonance Angiography; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor | 2019 |
Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease.
Topics: Acute Coronary Syndrome; Aftercare; Clopidogrel; Comorbidity; Coronary Disease; Drug Utilization; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Smoking; Spain; Stroke; Tertiary Care Centers; Ticagrelor | 2019 |
Discontinuation of Ticagrelor or Clopidogrel on Bleeding: Essential Role of Antifibrinolytic Agents.
Topics: Antifibrinolytic Agents; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Ticagrelor | 2020 |
The impact of
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P450 Family 4; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticagrelor | 2019 |
Replacement of ticagrelor with clopidogrel complicated with acute in‑stent thrombosis.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stents; Thrombosis; Ticagrelor | 2019 |
Comparison of Routine Versus Selective Glycoprotein IIb/IIIa Inhibitors Usage in Primary Percutaneous Coronary Intervention (from the British Cardiovascular Interventional Society).
Topics: Abciximab; Clopidogrel; Combined Modality Therapy; Drug Utilization; Eptifibatide; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Ticagrelor; United Kingdom | 2019 |
Shedding Light on Long-Term Effects of Early Antiplatelet Strategies After Fibrinolytic Treatment in STEMI.
Topics: Clopidogrel; Fibrinolysis; Humans; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor | 2019 |
Course of platelet miRNAs after cessation of P2Y12 antagonists.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; MicroRNAs; Middle Aged; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2019 |
Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2019 |
Lower Copays Sweeten Outcomes-based Deal for Brilinta.
Topics: Clopidogrel; Drugs, Generic; Humans; Insurance; Ticagrelor | 2019 |
Dyspnoea in the GLOBAL LEADERS trial - Authors' reply.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Dyspnea; Humans; Ticagrelor | 2019 |
Dyspnoea in the GLOBAL LEADERS trial.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Dyspnea; Humans; Ticagrelor | 2019 |
[Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2019 |
Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel.
Topics: Acute Coronary Syndrome; Animals; Aryldialkylphosphatase; Atherosclerosis; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, LDL; Ticagrelor | 2019 |
Contemporary audit of antiplatelet therapy prescribing patterns following coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Humans; Length of Stay; Male; New Zealand; Platelet Aggregation Inhibitors; Postoperative Care; Practice Patterns, Physicians'; Ticagrelor | 2019 |
Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights From a Single Institution Registry.
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Survival Rate; Ticagrelor; Treatment Outcome; United States | 2019 |
Safety and Effectiveness of Contemporary P2Y
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Asian People; Cardiovascular Diseases; Cause of Death; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Recurrence; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2019 |
DT-678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y
Topics: Animals; Bleeding Time; Clopidogrel; Disulfides; Dose-Response Relationship, Drug; Platelet Activation; Purinergic P2Y Receptor Antagonists; Rabbits; Random Allocation; Ticagrelor | 2019 |
A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Labeling; Drug Monitoring; Dual Anti-Platelet Therapy; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Platelet Function Tests; Practice Guidelines as Topic; Prasugrel Hydrochloride; Ticagrelor | 2019 |
Therapy with ticagrelor for ST-elevated acute coronary syndrome accompanied by diabetes mellitus.
Topics: Acute Coronary Syndrome; Aged; Atrial Function, Left; Clopidogrel; Diabetes Mellitus; Electrocardiography; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Random Allocation; Ticagrelor; Treatment Outcome | 2019 |
The association of P2Y
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Extracellular Vesicles; Female; Humans; Male; MicroRNAs; Middle Aged; Phosphatidylserines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Refining percutaneous coronary intervention: intracoronary imaging, haemodynamics, P2Y12 antagonists, and public outcomes reporting.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Restenosis; Coronary Vessels; Hemodynamics; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Spectroscopy, Near-Infrared; Switzerland; Ticagrelor; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional | 2019 |
"Ticagrelor or Prasugrel, Doctor?" The Basis for Decision in Clinical Practice.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial.
Topics: Aged; Clopidogrel; Combined Modality Therapy; Female; Humans; Male; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2019 |
Efficacy and Safety of Different Antiplatelet Strategies in Survivors of Myocardial Infarction With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Survivors; Ticagrelor; Treatment Outcome | 2019 |
Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Making; Drug Interactions; Humans; Models, Economic; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Proton Pump Inhibitors; Quality-Adjusted Life Years; Risk Assessment; Technology Assessment, Biomedical; Ticagrelor; Uncertainty | 2019 |
Tailoring P2Y
Topics: Aged; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2019 |
Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel
Topics: Acute Coronary Syndrome; Atrial Fibrillation; Clopidogrel; Cross-Sectional Studies; Echocardiography, Doppler; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Therapeutic Window of Clopidogrel and Ticagrelor in Patients With Critical Limb-Threatening Ischemia.
Topics: Aged; Clopidogrel; Critical Illness; Drug Administration Schedule; Drug Monitoring; Female; Humans; Ischemia; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Global Trial or Local One?
Topics: Acute Coronary Syndrome; Clopidogrel; Fibrinolytic Agents; Humans; Republic of Korea; Thrombolytic Therapy; Ticagrelor | 2019 |
Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients.
Topics: Acute Coronary Syndrome; Aged; Asian People; China; Clopidogrel; Coronary Thrombosis; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Assessment; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
Topics: Acute Coronary Syndrome; Clopidogrel; Europe; Female; Hemorrhage; Humans; Male; Medication Therapy Management; Middle Aged; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Risk Adjustment; Therapeutic Equivalency; Ticagrelor | 2020 |
Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; Deprescriptions; Drug Substitution; Dual Anti-Platelet Therapy; Dyspnea; Factor Xa Inhibitors; Female; Humans; Male; Non-ST Elevated Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry).
Topics: Aged; Bayes Theorem; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Angiography; Coronary Stenosis; Drug Utilization; Drug-Eluting Stents; Female; Humans; Logistic Models; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescriptions; Registries; Retrospective Studies; Severity of Illness Index; Survival Analysis; Ticagrelor; Treatment Outcome; United States | 2019 |
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndrome and Stable Coronary Artery Disease.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticagrelor; Ticlopidine | 2019 |
Safe and Effective Management of Antiplatelet Therapy in a Clopidogrel-Naive Patient Undergoing "Ad Hoc" Complex Coronary Intervention: A Case Report.
Topics: Aged; Clopidogrel; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
Trends for and Clinical Factors Associated with Choice of Oral P2Y
Topics: Administration, Oral; Adolescent; Adult; Aged; Cardiovascular Diseases; Clinical Decision-Making; Clopidogrel; Drug Prescriptions; Drug Utilization; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Patient Selection; Peritoneal Dialysis; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Prevalence; Purinergic P2Y Receptor Antagonists; Registries; Renal Dialysis; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; United States; Young Adult | 2019 |
Mind the Gap: Platelet Inhibition in Low-Risk Acute Coronary Syndrome Undergoing Percutaneous Revascularization.
Topics: Acute Coronary Syndrome; Clopidogrel; Eptifibatide; Humans; Percutaneous Coronary Intervention; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Troponin | 2019 |
Concomitant use of drugs known to cause interactions with oral antiplatelets-polypharmacy in acute coronary syndrome outpatients in Finland.
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Clopidogrel; Cohort Studies; Drug Interactions; Female; Finland; Hemorrhage; Humans; Male; Middle Aged; Outpatients; Platelet Aggregation Inhibitors; Polypharmacy; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2020 |
Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Recurrence; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors | 2020 |
Sex-specific differences in antithrombotic therapy and prognosis in patients with acute coronary syndrome treated with stent.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns, Physicians'; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Sex Factors; Stents; Ticagrelor; Ticlopidine | 2019 |
Reply.
Topics: Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Ticagrelor | 2020 |
Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Republic of Korea; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2020 |
Outcomes Related to Antiplatelet Therapy in a High-Risk ST-Segment Elevation Myocardial Infarction Population: A Retrospective Real-World Analysis of an Italian ECMO Center.
Topics: Aged; Aged, 80 and over; Clopidogrel; Extracorporeal Membrane Oxygenation; Female; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Ticagrelor and clopidogrel suppress NF-κB signaling pathway to alleviate LPS-induced dysfunction in vein endothelial cells.
Topics: Anti-Inflammatory Agents; Apoptosis; Cell Cycle; Cell Movement; Cells, Cultured; Clopidogrel; Cytokines; Human Umbilical Vein Endothelial Cells; Humans; I-kappa B Kinase; Lipopolysaccharides; Neovascularization, Physiologic; NF-kappa B; Phosphorylation; Purinergic P2Y Receptor Antagonists; Signal Transduction; Ticagrelor; Transcription Factor RelA | 2019 |
Ticagrelor or Prasugrel for Prevention of Stent Thrombosis?
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prescriptions; Purinergic P2Y Receptor Antagonists; Registries; Stents; Thrombosis; Ticagrelor | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Thromboembolism; Ticagrelor; Treatment Outcome; Warfarin | 2020 |
Mechanistic insights into the superior clinical efficacy of prasugrel over ticagrelor.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Vessels; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Treatment Outcome | 2020 |
Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries.
Topics: Clopidogrel; Europe; Humans; Prasugrel Hydrochloride; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor | 2021 |
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Dual Anti-Platelet Therapy; Humans; Molecular Diagnostic Techniques; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Predictive Value of Tests; Quality-Adjusted Life Years; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Clinical Implications of "Tailored" Antiplatelet Therapy in Patients With Chronic Total Occlusion.
Topics: Aged; Clopidogrel; Coronary Occlusion; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Survival Rate; Ticagrelor | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Gastrointestinal Hemorrhage; Hemorrhage; Heparin; Hirudins; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Stents; Ticagrelor; Urologic Diseases | 2020 |
Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR).
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor | 2021 |
[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?]
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clinical Trials, Phase IV as Topic; Clopidogrel; Hemorrhage; Humans; Multicenter Studies as Topic; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study.
Topics: Aged; Asian People; China; Chronic Disease; Clopidogrel; Coronary Occlusion; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI.
Topics: Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Drug Substitution; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Retrospective Studies; Thrombosis; Ticagrelor | 2020 |
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
Topics: Aged; Cardiologists; Cardiology Service, Hospital; Clopidogrel; Drug Utilization; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome; United States | 2020 |
A Reconciliation Attempt of the Acute Coronary Syndrome Clinical Trials on Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Exploring Medication Adherence with P2Y
Topics: Clopidogrel; Comorbidity; Drugs, Generic; Female; Humans; Insurance Claim Review; Logistic Models; Male; Medication Adherence; Middle Aged; Patient Acceptance of Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Residence Characteristics; Retrospective Studies; Risk Factors; Ticagrelor | 2021 |
Letter by Kim et al Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Ticlopidine | 2020 |
Letter by Chen et al Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Ticlopidine | 2020 |
Response by Park and Park to Letter Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Ticlopidine | 2020 |
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
The Effect of Ticagrelor on Platelet Reactivity in Patients with Clopidogrel Resistance Undergoing Neuroendovascular Procedures.
Topics: Aged; Blood Platelets; Clopidogrel; Endovascular Procedures; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Treatment Outcome | 2020 |
Efficacy of clopidogrel and ticagrelor under NT-proBNP in hospitalized ST-elevation acute coronary syndrome patients on percutaneous coronary intervention: CCC-ACS Project Analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Treatment Outcome; Ventricular Function, Left | 2020 |
Antiplatelet strategies in ageing patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aging; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2020 |
Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients.
Topics: Aged; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2020 |
Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Intensive Care Units; Male; Middle Aged; Patient Discharge; Propensity Score; Risk Factors; Ticagrelor; Treatment Outcome | 2020 |
Comparison between ticagrelor versus clopidogrel in long term outcomes of Taiwanese diabetic subjects with acute coronary syndrome undergoing successful revascularization: From TSOC ACS-DM registry.
Topics: Acute Coronary Syndrome; Clopidogrel; Comorbidity; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Mortality; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Registries; Secondary Prevention; Taiwan; Ticagrelor; Treatment Outcome | 2020 |
Infarct size following loading with Ticagrelor/Prasugrel versus Clopidogrel in ST-segment elevation myocardial infarction.
Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
Prasugrel in the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Clopidogrel is a favourable alternative to ticagrelor in older patients with NSTE-ACS.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2020 |
Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Clopidogrel; Endovascular Procedures; Female; Humans; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Self Expandable Metallic Stents; Stroke; Subarachnoid Hemorrhage; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Stroke; Survival Rate; Ticagrelor | 2020 |
Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Treatment Outcome | 2020 |
Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Measuring preferences for
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cause of Death; Clopidogrel; Female; Hemorrhage; Humans; Italy; Male; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk; Ticagrelor | 2021 |
Ticagrelor versus clopidogrel in patients with ST-elevation myocardial infarction: postdischarge mild bleeding and its clinical impacts.
Topics: Aged; China; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Prospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2021 |
Reduction in Osteoarthritis Risk After Treatment With Ticagrelor Compared to Clopidogrel: A Propensity Score-Matching Analysis.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Middle Aged; Osteoarthritis; Platelet Aggregation Inhibitors; Propensity Score; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Treatment Outcome | 2020 |
How Do Type of Preoperative P2Y
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Preoperative Period; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Withholding Treatment | 2021 |
Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Major Bleeding after Surgical Revascularization with Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Databases, Factual; Dual Anti-Platelet Therapy; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reoperation; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Time-dependent impact of Ticagrelor and Prasugrel on infarct size: Looking beyond antiplatelet effect.
Topics: Clopidogrel; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2020 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Therapy; Endarterectomy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2020 |
Evaluation of a Novel Antiplatelet Therapy Strategy in Patients Undergoing Elective Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
Topics: Acute Coronary Syndrome; Aged; Algorithms; Asian People; Clopidogrel; Data Mining; Decision Trees; Female; Hemorrhage; Hospitalization; Humans; Machine Learning; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor | 2020 |
Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Retrospective Studies; Thromboembolism; Ticagrelor; Treatment Outcome; United States | 2020 |
Real-World Comparison of Ticagrelor and Clopidogrel: Rosetta Stone or Lost in Translation?
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Coronary Angiography; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Sweden; Ticagrelor | 2020 |
Ticagrelor is Not Superior to Clopidogrel in Patients With Acute Coronary Syndromes Undergoing PCI: A Report from Swedish Coronary Angiography and Angioplasty Registry.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Registries; Sweden; Ticagrelor | 2020 |
Effect of Ticagrelor on Reducing the Risk of Gram-Positive Infections in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Ticagrelor | 2020 |
Does the level of myocardial injury differ in primary angioplasty patients loaded first with clopidogrel and the ones with ticagrelor?
Topics: Angioplasty; Clopidogrel; Echocardiography; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Severity of Illness Index; ST Elevation Myocardial Infarction; Ticagrelor; Troponin | 2020 |
Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study.
Topics: Aged; Asian People; Clopidogrel; Cohort Studies; Data Management; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Stroke; Taiwan; Ticagrelor; Treatment Outcome | 2021 |
Risk of Pneumonia with Ticagrelor Versus Clopidogrel: a Population-Based Cohort Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Humans; Platelet Aggregation Inhibitors; Pneumonia; Ticagrelor; Treatment Outcome | 2021 |
Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C9; Female; Genotype; Humans; Hyperuricemia; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stents; Thienopyridines; Ticagrelor; Ticlopidine; Uric Acid | 2021 |
Editorial - out with the old and in with the new? Gastrointestinal bleeding risk of P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Ticagrelor | 2020 |
Early usage of antiplatelet in ST-segment elevation myocardial infarction.
Topics: Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2021 |
Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome: Insights From the SWEDEHEART Registry.
Topics: Acute Coronary Syndrome; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clopidogrel; Female; Humans; Male; Prognosis; Registries; Ticagrelor; Treatment Outcome | 2020 |
Ticagrelor or Clopidogrel in Elderly Patients With Myocardial Infarction: When the Choice Makes the Difference.
Topics: Aged; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Ticagrelor; Treatment Outcome | 2021 |
Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine Deaminase; Aftercare; Clopidogrel; Drug Therapy, Combination; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2020 |
In ACS, prasugrel reduces 30-day MACE and mortality vs. ticagrelor or clopidogrel; no differences for major bleeding.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
In older patients with NSTE-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Patients; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2020 |
Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.
Topics: Aged; Asian People; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Ischemic Stroke; Loss of Function Mutation; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticagrelor | 2020 |
Ticagrelor in the management of coronary artery disease.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Efficacy and safety of potent P2Y12 inhibitors vs. clopidogrel in elderly patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Letter: the risk of gastrointestinal bleeding in patients taking third-generation P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2020 |
In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Network Meta-Analysis; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2020 |
Factors Influencing Provider and Patient Choice of P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Preference; Patient Selection; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; Cause of Death; Clopidogrel; Databases, Factual; Dyspnea; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Propensity Score; Purinergic P2Y Receptor Antagonists; Recurrence; Republic of Korea; Retrospective Studies; Stroke; Ticagrelor; United States | 2020 |
Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor | 2020 |
Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Topics: Aged; Cause of Death; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Risk of infectious events in acute myocardial infarction patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Differences in thromboembolism after stent-assisted coiling for unruptured aneurysms between aspirin plus clopidogrel and ticagrelor.
Topics: Adult; Aged; Aspirin; Clopidogrel; Diffusion Magnetic Resonance Imaging; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Thromboembolism; Ticagrelor | 2020 |
A rare case of late-onset ticagrelor-induced sinus arrest.
Topics: Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Sinus Arrest, Cardiac; Ticagrelor | 2021 |
Comparison of therapeutic effects of ticagrelor and clopidogrel on patients with acute myocardial infarction and influence of lncRNA BANCR.
Topics: Acute Disease; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; RNA, Long Noncoding; Ticagrelor | 2020 |
Acute coronary syndromes: summary of updated NICE guidance.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Cardiac Rehabilitation; Clopidogrel; Combined Modality Therapy; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Secondary Prevention; ST Elevation Myocardial Infarction; Ticagrelor; United Kingdom | 2021 |
Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis.
Topics: Acute Disease; Adult; Aftercare; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Occlusion; Coronary Restenosis; Cytochrome P-450 CYP2C19; Dual Anti-Platelet Therapy; Female; Fibrinolytic Agents; Humans; Integrin alpha2; Mutation; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stents; Thrombectomy; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2021 |
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Drug Costs; Genotype; Humans; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Singapore; Ticagrelor; Ticlopidine | 2021 |
The effect of de-escalation of P2Y12 receptor inhibitor therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: A nationwide cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Dual Anti-Platelet Therapy; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Young Adult | 2021 |
Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke.
Topics: Animals; Aspirin; Brain Ischemia; Clopidogrel; Inflammasomes; Ischemic Stroke; Isoindoles; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Phenylbutyrates; Pyroptosis; Rats; Reperfusion Injury; Stroke; Ticagrelor | 2021 |
Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Qatar; Ticagrelor | 2021 |
When less is more: dual antiplatelet therapy in elective percutaneous coronary intervention.
Topics: Clopidogrel; Dual Anti-Platelet Therapy; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
The effect of ticagrelor on microarterial thrombosis in an experimental model.
Topics: Adenosine; Animals; Clopidogrel; Models, Theoretical; Platelet Aggregation Inhibitors; Rats; Thrombosis; Ticagrelor; Ticlopidine | 2021 |
Comparison of the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome after risk stratification.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Assessment; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention-Reply.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Treatment Outcome | 2021 |
Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stroke; Sweden; Ticagrelor; Treatment Outcome | 2021 |
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2021 |
Successful Therapy With Ticagrelor in Three-Vessel Stent Thrombosis Related to Clopidogrel Resistance.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Dual Anti-Platelet Therapy; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticagrelor | 2021 |
Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Hospitals; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure.
Topics: Aged; Clopidogrel; Cohort Studies; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency; Retrospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI.
Topics: Acute Coronary Syndrome; Adenosine; Arachidonic Acid; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2021 |
Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cause of Death; Clopidogrel; England; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Survival Rate; Ticagrelor | 2021 |
Hide and seek. Ticagrelor and central apneas after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Sleep Apnea, Central; Ticagrelor | 2021 |
Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Antiplatelet therapy in ACS elderly patients: Another piece of this intriguing puzzle.
Topics: Acute Coronary Syndrome; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Ticagrelor use and practice patterns among Canadian cardiac surgeons.
Topics: Acute Coronary Syndrome; Canada; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Surgeons; Ticagrelor | 2021 |
Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Hong Kong; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor and CABG for acute coronary syndrome?-It is complicated.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID.
Topics: Age Factors; Aged; Clopidogrel; Comorbidity; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2021 |
Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Retrospective Studies; Taiwan; Ticagrelor; Treatment Outcome | 2022 |
Prehospital Adenosine Diphosphate Receptor Blocker Use, Culprit Artery Flow, and Mortality in STEMI: The MADDEC Study.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Vessels; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Survival Rate; Ticagrelor | 2021 |
Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective.
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2021 |
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y
Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity.
Topics: Blood Platelets; Clopidogrel; Humans; Lipoprotein(a); Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2022 |
Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Registries; Retrospective Studies; Ticagrelor | 2021 |
Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Topics: Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Massachusetts; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Stroke; Ticagrelor | 2021 |
Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan.
Topics: Aged; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Propensity Score; Taiwan; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Intracranial Stenting or Flow-Diverter Treatment for Unruptured Cerebral Aneurysms: A Single-Center Cohort Study.
Topics: Clopidogrel; Dual Anti-Platelet Therapy; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticagrelor; Treatment Outcome | 2021 |
Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction.
Topics: Aftercare; Aged; Clopidogrel; Female; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2021 |
Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up.
Topics: Aged; Angina, Unstable; Biomarkers; C-Reactive Protein; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Kaplan-Meier Estimate; Male; Matrix Metalloproteinase 9; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Ticagrelor; Tirofiban; Tumor Necrosis Factor-alpha | 2021 |
Ticagrelor or clopidogrel dual antiplatelet therapy following a pharmacoinvasive strategy in ST-segment elevation myocardial infarction.
Topics: Clopidogrel; Drug Substitution; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2021 |
Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Clopidogrel; Cytochrome P-450 CYP2C19; Hemorrhage; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Inflammation; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Impact of psoriasis on ticagrelor platelet activity versus clopidogrel in patients with chronic coronary syndromes treated via percutaneous coronary intervention.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Psoriasis; Ticagrelor; Treatment Outcome | 2021 |
Addressing Posttreatment Selection Bias in Comparative Effectiveness Research, Using Real-World Data and Simulation.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Comparative Effectiveness Research; Computer Simulation; Female; Hospitalization; Humans; Intention to Treat Analysis; Latent Class Analysis; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Selection Bias; Stroke; Ticagrelor; Treatment Outcome; Treatment Switching | 2022 |
Safety and efficacy of clopidogrel versus ticagrelor in acute coronary syndrome in the prehospital setting.
Topics: Acute Coronary Syndrome; Clopidogrel; Emergency Medical Services; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China.
Topics: Aged; Algorithms; Asian People; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Health Behavior; Hemorrhage; Humans; Male; Middle Aged; Pharmacogenetics; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Sociodemographic Factors; Ticagrelor; Ticlopidine | 2022 |
Use of ticagrelor and the risks of pneumonia and pneumonia-specific death in patients with non-acute coronary syndrome conditions: a population-based cohort study.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Clopidogrel; Cohort Studies; Female; Hong Kong; Hospitals, Public; Humans; Male; Platelet Aggregation Inhibitors; Pneumonia; Propensity Score; Retrospective Studies; Ticagrelor | 2021 |
Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting.
Topics: Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endovascular Procedures; Femoral Artery; Humans; Platelet Aggregation Inhibitors; Protamines; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quality of Life; Ticagrelor; Treatment Outcome | 2021 |
Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study.
Topics: Aged; Clopidogrel; Cohort Studies; Female; Humans; Kidney Failure, Chronic; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Renal Dialysis; Ticagrelor; Treatment Outcome | 2021 |
Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk.
Topics: Acute Disease; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Risk; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Thromboembolism; Ticagrelor; Treatment Outcome | 2022 |
Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel-An observational cohort study in Sweden.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sweden; Ticagrelor; Treatment Outcome | 2022 |
Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Clopidogrel versus ticagrelor for antiplatelet therapy in transcarotid artery revascularization in the Society for Vascular Surgery Vascular Quality Initiative.
Topics: Clopidogrel; Endovascular Procedures; Femoral Artery; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2022 |
Bilateral multifocal muscular hemorrhage in the triceps surae during antiplatelet therapy: a case report.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Leg; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Predictors and long-term outcomes of in-hospital switching from clopidogrel to ticagrelor among patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Diabetes Mellitus, Type 2; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Ticagrelor; Treatment Outcome | 2022 |
Clopidogrel or ticagrelor in elderly patients with acute coronary syndromes - Nihil nocere!
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2022 |
Predictors of In-Hospital De-Escalation of P2Y12 Inhibitors to Clopidogrel in Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Hospitals; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Humans; Obesity; Overweight; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2023 |
In patients with stroke or TIA and CYP2C19 loss-of-function alleles, ticagrelor vs. clopidogrel reduced 90-d stroke.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2022 |
DAPT de-escalation from ticagrelor to clopidogrel 1 mo after PCI for acute MI reduced net clinical events at 1 y.
Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel.
Topics: Acute Coronary Syndrome; Brain Ischemia; China; Clopidogrel; Hemorrhage; Hemorrhagic Stroke; Humans; Intracranial Hemorrhages; Ischemic Stroke; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stroke; Ticagrelor | 2022 |
P2Y12 inhibitor adherence trajectories in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prognostic implications.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
How do type of preoperative P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Systematic Reviews as Topic; Ticagrelor | 2022 |
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Cyclooxygenase 1; Fibrinolytic Agents; Humans; Peptides; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Thrombin; Rivaroxaban; Thrombin; Thromboplastin; Ticagrelor | 2022 |
Does thromboelastography predict bleeding in patients treated with clopidogrel or ticagrelor in off-pump coronary artery bypass grafting?
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Thrombelastography; Ticagrelor | 2022 |
Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
An alternative reduced dose regimen of ticagrelor for neuroendovascular patients.
Topics: Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2023 |
Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Practice of antiplatelet therapy in acute myocardial infarction
Topics: Clopidogrel; Humans; Hungary; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Pre-Percutaneous Coronary Intervention TIMI Flow Grade in STEMI Patients Treated with Pre-Hospital Ticagrelor Loading.
Topics: Clopidogrel; Hospitals; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Topics: Acute Coronary Syndrome; Aspirin; Australia; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Cangrelor Use Patterns and Transition to Oral P2Y
Topics: Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Treatment Outcome | 2022 |
Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; China; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Veterans | 2023 |
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cost-Benefit Analysis; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2022 |
Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
Topics: Aspirin; Canada; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Quality of Life; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine | 2023 |
In-Hospital Bleeding and Mortality in Acute Coronary Syndrome Patients Treated with Tirofiban and Potent P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Prescribing Trends and Health Care Expenditure of P2Y
Topics: Acute Coronary Syndrome; Australia; Clopidogrel; Health Expenditures; Humans; Percutaneous Coronary Intervention; Pharmaceutical Preparations; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescriptions; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Impact of Ticagrelor Versus Clopidogrel on Bleeding Outcomes of Isolated Coronary Artery Bypass Grafting.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Renal Insufficiency; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Cholesterol; Clopidogrel; Cohort Studies; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dimaprit; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Ticagrelor; Treatment Outcome | 2022 |
Preoperative treatment with clopidogrel and ticagrelor on bleeding complications in off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Inhibiting P2Y12 receptor relieves LPS-induced inflammation and endothelial dysfunction.
Topics: Acute Lung Injury; Claudin-5; Clopidogrel; Endothelial Cells; Humans; Inflammation; Inflammation Mediators; Interleukin-6; Lipopolysaccharides; NF-kappa B; NF-KappaB Inhibitor alpha; Occludin; Proto-Oncogene Proteins c-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Tumor Necrosis Factor-alpha | 2022 |
Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y
Topics: Aged; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Kidney Failure, Chronic; Middle Aged; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Retrospective Studies; Ticagrelor | 2022 |
Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
Topics: Anticoagulants; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Real-World Data on Potent P2Y12 Inhibition in Patients with Suspected Chronic Coronary Syndrome, Referred for Coronary Angiography.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2023 |
Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina.
Topics: Angina, Unstable; Clopidogrel; Fatty Acid Binding Protein 3; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Ticagrelor; Treatment Outcome | 2022 |
Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy.
Topics: Adenosine; Adenosine Diphosphate; Clopidogrel; Complement C1q; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Ticlopidine | 2022 |
Clopidogrel Resistance and Ticagrelor Replacement in Dual Antiplatelet Therapy for Carotid Artery Stenting.
Topics: Carotid Arteries; Carotid Stenosis; Clopidogrel; Female; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Ticagrelor; Treatment Outcome | 2023 |
Are there other factors that influence the assessment of bleeding risk comparing potent P2Y12 inhibitors with clopidogrel?
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2023 |
Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention.
Topics: Anticoagulants; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke Volume; Ticagrelor; Ventricular Function, Left | 2022 |
Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score-Matched Cohort Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Female; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome; United States | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Unruptured Intracranial Aneurysm Treated with Stent-Assisted Coil Embolization: A Single-Center Cohort Study.
Topics: Adenosine Diphosphate; Clopidogrel; Cohort Studies; Embolization, Therapeutic; Fibrinogen; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Stents; Ticagrelor; Treatment Outcome | 2023 |
Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adolescent; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor Aspirin vs Clopidogrel Aspirin in
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Neoplasm Recurrence, Local; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study.
Topics: Adenosine; Aspirin; Clopidogrel; Fibrinogen; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Ticagrelor versus clopidogrel dual antiplatelet therapy for unruptured intracranial aneurysms treated with flowdiverter.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Retrospective Studies; Thromboembolism; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; COVID-19; Drug Therapy, Combination; Humans; Male; Pandemics; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2022 |
Staphylococcus aureus bacteraemia treatment outcomes in patients receiving ticagrelor vs a propensity-matched cohort receiving clopidogrel.
Topics: Bacteremia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Ticagrelor; Treatment Outcome | 2023 |
Cardiovascular disease in asthma patients: From mechanisms to therapeutic implications.
Topics: Asthma; Cardiovascular Diseases; Clopidogrel; Comorbidity; Humans; Ticagrelor | 2023 |
Propensity-matched analysis of the protective effect of ticagrelor versus clopidogrel on the risk of developing Staphylococcus aureus bacteremia.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Ticagrelor; Treatment Outcome | 2023 |
Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Stroke; Ticagrelor | 2023 |
Genotype-Guided Selection of Antiplatelet Therapy: The Evidence Moves East.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2023 |
Prasugrel-related hepatotoxicity.
Topics: Acute Coronary Syndrome; Chemical and Drug Induced Liver Injury; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2022 |
A Comparative Study on Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome Treated With Primary Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2023 |
[Debate on antiplatelet monotherapy: Why not leaving out good old aspirin for clopidogrel or ticagrelor in monotherapy in chronic coronary syndromes after a percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor as Compared to Clopidogrel Following Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Canada; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2023 |
P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2023 |
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk.
Topics: Clopidogrel; Hemorrhage; Humans; Ischemia; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2023 |
Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Cytochrome P-450 CYP2C19; East Asian People; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor and primidone interaction masquerading as dual antiplatelet therapy noncompliance.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Primidone; Ticagrelor; Treatment Outcome | 2023 |
Removal of an Epidural Catheter in a Patient Receiving Ticagrelor: A Case Report.
Topics: Anesthesia, Epidural; Catheterization; Catheters; Clopidogrel; Humans; Ticagrelor | 2023 |
Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study.
Topics: Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2023 |
A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Contemporary Use of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A GRACE Risk Score Stratification-Based Analysis in a Large-Scale, Real-World Study From China.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Risk Factors; Ticagrelor; Treatment Outcome | 2023 |
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cohort Studies; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2023 |
Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013-2018.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prescriptions; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome; United States | 2023 |
Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Streptokinase; Ticagrelor; Treatment Outcome | 2023 |
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Comparison of clopidogrel vs. ticagrelor medication adherence in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Medication Adherence; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Arachidonic Acid; Aspirin; Clopidogrel; Gelsolin; Humans; Mean Platelet Volume; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke Volume; Ticagrelor; Ventricular Function, Left | 2023 |
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Sex-Specific Differences in Potent P2Y
Topics: Clopidogrel; Female; Humans; Male; Prasugrel Hydrochloride; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2023 |
Age- and Sex-Specific Disparities in Outcomes After Ticagrelor Versus Clopidogrel in East Asian Patients.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; East Asian People; Female; Hemorrhage; Humans; Ischemia; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Utilization of P2Y
Topics: Aged; Clopidogrel; Female; Frailty; Humans; Male; Medicare; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome; United States | 2023 |
Ticagrelor vs Clopidogrel in Acute Myocardial Infarction Patients With a History of Ischemic Stroke.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor | 2023 |